Spenser Lin No Comments

Healthcare News, Deals, and Investments Update August 3rd, 2026

LECO_Weekly-Healthcare-News_8-3-2026Download
  1. Lawrence, Evans & Co. Closes $30M Cross-Border Refinance and Growth Acquisition Financing for Expanding Healthcare RCM Platform Lawrence, Evans & Co. (LECO) announced the closing of a refinance and growth acquisition financing for a fast-growing healthcare revenue cycle management platform. LECO led the transaction while coordinating multiple acquisitions across several countries and managing the related overseas legal and regulatory requirements. The $30M financing supported the owner’s non-dilutive refinancing and acquisition line of credit needs, letting the company fund growth without giving up equity. Neil Johnson, Managing Partner at Lawrence, Evans & Co., LLC, led the transaction. The deal reflects LECO’s work advising healthcare and technology companies on complex, cross-border capital solutions tied to acquisition strategies. (Link)
  2. Clearview Capital agreed to exit Advantage Behavioral Health in a $610 million municipal-bond-financed sale to nonprofit QCF/I, Inc. Connecticut-based private equity firm Clearview Capital agreed to sell New Jersey-headquartered Advantage Behavioral Health, an operator of mental health centers and sober-living facilities, to nonprofit QCF/I, Inc., which is funding the purchase through a planned $610 million unrated municipal bond issuance. Clearview, together with ABH’s founders and management, is expected to receive roughly $415 million at closing, with up to $100 million more tied to performance milestones. The sale comes just over a year after Clearview recapitalized the company. ABH expects to treat more than 500,000 patients annually and generate about $170 million in revenue and $78 million of EBITDA this year. This is QCF’s fourth and largest acquisition. (Link)
  3. Blue Sea Capital closed an oversubscribed continuation vehicle for One Physics, led by Apogem Capital, Churchill Asset Management, Dextra Partners and Future Standard. Blue Sea Capital, a West Palm Beach private equity firm with over $1.5 billion in assets under management focused on middle-market healthcare companies valued up to $500 million, closed its first continuation vehicle to extend its partnership with One Physics. The meaningfully oversubscribed transaction was led by Apogem Capital, Churchill Asset Management, Dextra Partners and Future Standard, with participation from Abbott Capital and Twin Bridge Capital Partners. Both Blue Sea and One Physics management reinvested significantly. Towson, Maryland-based One Physics is North America’s leading outsourced medical physics provider, with more than 210 physicists delivering regulatory-mandated testing and compliance services to hospitals, imaging centers and cancer facilities. (Link)
  4. Kettering Health signed a non-binding letter of intent for Knox Community Hospital to join its nonprofit system. Knox Community Hospital, a 99-bed nonprofit hospital in Mount Vernon, Ohio, signed a non-binding letter of intent to join Kettering Health, a nonprofit system headquartered in Kettering, Ohio. The two Ohio organizations entered exclusive negotiations toward a definitive agreement by early fall, with closing targeted by the end of 2026 pending regulatory review. As a nonprofit combination, no purchase price applies. Kettering Health committed to significant capital investment in Knox’s service area over the 10 years after closing, including a new EHR system and workforce support. Kettering operates 14 medical centers and more than 100 outpatient locations across western Ohio; Knox would be its farthest medical center beyond southwest Ohio. (Link)
  5. Health Catalyst Capital acquired a leading Midwest provider of psychiatric medical care for elderly and disabled adults to fund regional expansion. New York-based private equity firm Health Catalyst Capital acquired a clinician-led Midwest psychiatric medical care provider serving elderly and disabled adults across long-term care facilities and hospitals. Financial terms were not disclosed, and the target remains unnamed. Both parties are private. Health Catalyst Capital invests in healthcare services and technology businesses and leverages relationships with over 250 healthcare and technology enterprises, driving value by helping portfolio companies integrate AI and build commercial relationships. With the backing, the practice plans to expand its regional footprint into additional long-term care and hospital settings, a segment seeing rising demand as the population ages. (Link)
  6. LiveWell Partners, backed by Encore Management Group, acquired Michigan Community VNA Home Health and Hospice. LiveWell Partners, a St. Louis-based home health and hospice platform backed by private equity firm Encore Management Group, acquired Detroit-based Michigan Community VNA Home Health and Hospice. Financial terms were undisclosed. Founded in 2023, LiveWell has grown largely through Midwest acquisitions and now operates across Illinois, Kansas, Michigan, Missouri and Ohio; this is its third Michigan deal. Under LiveWell’s operating model, acquired organizations keep their community identities and leadership while gaining shared clinical, operational and technology resources. Michigan Community VNA, which traces its roots to 1898, provides skilled home health, therapies, palliative care and hospice across metropolitan Detroit and complements LiveWell’s existing regional density strategy. (Link)
  7. Nexus acquired Telemetrix RPM to extend its clinical care operating system from the hospital to the home. Nexus, formerly Nexus Bedside, acquired Telemetrix RPM, a remote patient monitoring and chronic care management company operating inside native Epic workflows. Financial terms were undisclosed, and both companies are private. The deal, which closed July 23 in Cleveland, unifies inpatient coordination, remote monitoring, chronic care management and cardiac AI into a single workflow. Akram Boutros, MD, serves as CEO of both entities; former Telemetrix CEO Burley Wright becomes COO of Nexus, and founder Bret Shillingstad, MD, stays on as chief medical officer of both. The combination reflects a broader push among health tech providers toward integrated platforms connecting inpatient and post-acute care. (Link)
  8. ARC Health partnered with Old Greenwich, Connecticut-based The Waverly Group to expand collaborative pediatric care. ARC Health, a national network of mental healthcare providers, partnered with The Waverly Group, a multidisciplinary pediatric practice in Old Greenwich, Connecticut. Financial terms were undisclosed, and both organizations are private. Waverly becomes ARC Health’s second Connecticut partner and fourth in the greater New York metro area, offering ABA and behavior therapy, occupational and physical therapy, psychotherapy, psychological testing, speech therapy and related services. The practice keeps its identity and clinical leadership while gaining ARC Health’s operational resources and national provider network. CEO Vince Morra emphasized the coordinated, multidisciplinary model. ARC Health operates a provider-centric structure in which partners become equity-owning members. (Link)
  9. Included Health signed a definitive agreement to acquire Firefly Health to build a clinically integrated health plan alternative for employers. Included Health, an AI-native virtual care and navigation company, agreed to acquire Firefly Health, a clinically integrated health plan and advanced primary care provider serving more than 20,000 members through a network of over 2,300 providers. Financial terms were not disclosed, and the deal is expected to close in the third quarter of 2026 subject to regulatory review. Both companies are privately held. The combination pairs Included Health’s clinician-in-the-loop platform with Firefly’s plan design and near- and in-home network, targeting employers facing steep medical cost trends. Firefly reported 15%+ total cost of care savings and 90% member satisfaction in 2025. (Link)
  10. Graham Partners acquires TechData Service Company to form Quantive Intelligence platform Private equity firm Graham Partners acquired TechData Service Company and combined it with LLX Solutions and R Square Technology to form Quantive Intelligence, a decision-sciences platform focused on biostatistics, statistical programming, and clinical data services. The platform serves pharmaceutical and biotechnology sponsors with submission-stage clinical development support. Headquartered in King of Prussia, Pennsylvania, with operations in Massachusetts, Greater China, and India, the combined organization employs more than 700 people. Financial terms were not disclosed. The transaction closed July 1, 2026. (Link)
  11. Vital Infrastructure Property Trust acquired an EmblemHealth-leased Brooklyn medical office building for approximately $89 million. Toronto-based healthcare infrastructure REIT Vital Infrastructure Property Trust acquired the roughly 140,000-square-foot East New York Health Hub at 101 Pennsylvania Avenue in Brooklyn for about $89 million (C$126.7 million), or more than $635 per square foot, from developer Dominion Management Company. (The linked headline labels the buyer “Global Healthcare REIT,” but the acquirer is Vital Infrastructure Property Trust.) The trophy-quality building is leased long-term to nonprofit insurer EmblemHealth, with additional tenants including AdvantageCare Physicians, New York Cancer & Blood Specialists and Quest Diagnostics. CEO Zach Vaughan called it a step in Vital’s strategy to re-enter the large, fragmented U.S. healthcare real estate market. (Link)
  12. Novanta Inc. (NASD: NOVT) completed its ~$1.2 billion acquisition of Riverpoint Medical from Arlington Capital Partners. Novanta (NASD: NOVT) completed the acquisition of Riverpoint Medical from Washington, D.C.-area private investment firm Arlington Capital Partners, paying approximately $1.2 billion in cash at closing plus a potential $250 million milestone payment due by early January 2027. Riverpoint is a category leader in minimally invasive surgical consumables, including surgical fibers for sports medicine, trauma and cardiovascular applications, with facilities in Portland, Oregon and San Jose, Costa Rica. A Novanta subsidiary borrowed $616 million under its credit facilities, funding the rest with cash on hand and a recent $300 million equity raise. The deal roughly doubles Novanta’s recurring medical consumables revenue to about $300 million. (Link)
  13. Serelora, Inc. acquired the clinical risk-stratification software of ACTIN Care Groups to extend its agentic EHR into population-level analysis. Serelora, a company building an AI-native agentic electronic health record, acquired the clinical risk-stratification software of ACTIN Care Groups. Financial terms were undisclosed, and both companies are privately held. The acquired technology includes WellCheck, a 27-instrument preventive risk battery assessing clinical, behavioral and social risk factors, which becomes a native capability of Serelora’s record. Co-founder and CTO Spencer Wozniak framed the deal as extending the system’s intelligence from the individual chart to whole populations, letting organizations identify who is trending toward risk. The acquisition moves Serelora beyond documentation into population health analytics inside the same agentic system clinicians already use. (Link)
  14. Quasar Medical acquired Medres International’s Nitinol Design and Development Center in San Diego to expand its minimally invasive device manufacturing platform. Quasar Medical, a global contract development and manufacturing organization specializing in minimally invasive devices, acquired the Medres Nitinol Design and Development Center in Carlsbad, California. Financial terms were undisclosed. The transaction covers the 10,000-square-foot facility established in 2024, its engineering talent, manufacturing capabilities and customer relationships. Both parties are private. The site becomes Quasar’s dedicated nitinol center under SVP of Technology Christine Trepanier, complementing hubs in Israel and Galway and sitting an hour from Quasar’s Tecate, Mexico production facility. Medres International retains its remaining business. The deal deepens Quasar’s exposure to nitinol, a widely used enabling material for implantable and disposable devices. (Link)
  15. Transform Health Partners completed an acquisition of Sound Surgeons to expand its platform. Transform Health Partners acquired Sound Surgeons, a bariatric and weight-loss surgery practice, along with Sound Weight & Wellness in Washington state. The deal extends the buyer’s strategy of adding medical facility assets to its portfolio, with a focus on outpatient weight-loss and bariatric services. (Link)
  16. Timshel Health, LLC added Texas-based MyMD Select to its national direct primary care holding company to open new clinics across Texas. MyMD Select, an East Texas direct primary care practice founded in 2014 by Jeremy Smith, MD, joined Timshel Health, a national holding company of direct primary care practices. Financial terms were undisclosed, and both companies are private. MyMD Select guarantees members all-hours access and same- or next-day appointments through functional-medicine-trained providers, and partners with employers to lower spending on labs, imaging and downstream care. With Timshel’s backing, MyMD Select plans to open new clinics throughout Texas. Timshel CEO Mac Findlay framed the deal as helping the practice scale while preserving its culture; Smith becomes MyMD Select’s chief medical officer. (Link)
  17. Private investor acquires Lampert’s Home Therapy A private investor acquired Lampert’s Home Therapy, Inc., a therapist-owned provider of pediatric occupational, physical, and speech therapy services based in Largo, Florida. The company serves children and adults with developmental disabilities across West Central Florida through clinic, home, school, and community settings. Founded in 2000, Lampert’s delivers specialized programs including the TheraSuit Method. Financial terms were not disclosed. The transaction closed June 22, 2026. (Link)
  18. Processa Pharmaceuticals, Inc. (NASD: PCSA) acquired Vidya Therapeutics, Inc. in a stock-for-stock transaction alongside an oversubscribed ~$200 million private placement from a syndicate led by Bain Capital Life Sciences, RA Capital Management and Janus Henderson Investors. Processa (NASD: PCSA) acquired Vidya Therapeutics, adding BTK inhibitor VT-7208, and simultaneously secured approximately $200 million in gross proceeds through Series A preferred stock priced at $1,221.19 per share. The oversubscribed placement drew Bain Capital Life Sciences, Janus Henderson Investors, RA Capital Management, SilverArc Capital, ADAR1 Capital Management, Cormorant Asset Management, Integral Health Asset Management, Marshall Wace, Octagon Capital and Soleus Capital. Proceeds fund operations into the second half of 2029 and three parallel Phase 2 programs. Existing Processa holders are left owning roughly 0.9% on a fully diluted basis, reflecting heavy dilution driven by the incoming investor syndicate. (Link)
  19. Waldencast plc (NASD: WALD) completed the sale of its Obagi Medical dermatological skincare and aesthetics business to mid-market investor Bridgepoint in a transaction valued at up to $460 million. Waldencast (NASD: WALD) closed the divestiture of Obagi Medical to Bridgepoint on July 30, 2026, in a deal valued at up to $460 million. Consideration includes roughly $366 million in cash, $30 million in vendor notes ($10 million fixed, $20 million adjustable) and up to $64 million of earnout tied to 2026 non-injectables and 2027 injectables revenue. Preliminary pro forma total consideration is about $380 million, with net cash proceeds near $334 million. Waldencast used about $178 million at closing to repay its senior term loan, eliminating $135.8 million of long-term debt. The Jersey-incorporated company now focuses on growing Milk Makeup, which generated $110.4 million of 2025 net revenue. (Link)
  20. MiMedx Group, Inc. (NASD: MDXG) agreed to acquire Sanara MedTech Inc. (NASD: SMTI) in a cash-and-stock deal valued at about $350 million. MiMedx (NASD: MDXG) entered a definitive merger agreement to acquire Sanara MedTech (NASD: SMTI) at $35 per share, a total enterprise value of approximately $350 million. Sanara holders receive $33.00 in cash plus 0.4735 MiMedx shares each, a 46% premium to Sanara’s 30-day volume-weighted average price. MiMedx will fund the cash portion with cash on hand and a committed $300 million first lien senior secured term loan from Hayfin Capital Management. The deal combines MiMedx’s surgical portfolio with Sanara’s regenerative surgical technologies, targeting 2027 combined revenue above $400 million, adjusted EBITDA margins over 20% and $20 million-plus in synergies. Closing is expected by year-end, pending Sanara shareholder and regulatory approval. (Link)
  21. Scribe Therapeutics Inc. (NASD: SCTX) closed a $155.5 million IPO at $15.00 per share, with a concurrent private placement to Sanofi. Scribe Therapeutics (NASD: SCTX) completed its IPO, selling 9,867,000 shares at $15.00, including full exercise of the underwriters’ 1,287,000-share option. Aggregate gross proceeds reached about $155.51 million, a figure that includes a concurrent private placement in which strategic partner Sanofi bought 500,000 shares at the IPO price. The shares began trading on the Nasdaq Global Market under ticker SCTX. Scribe is a clinical-stage biotech developing CRISPR-based genetic medicines, with lead candidate STX-1150 targeting PCSK9 to reduce LDL-C. The company, co-founded by Nobel laureate Jennifer Doudna, holds strategic collaborations with Sanofi and Eli Lilly. (Link)
  22. Synlogic and Caldera Therapeutics announce merger agreement and concurrent private placement Synlogic, Inc. (OTC: SYBX) and privately held Caldera Therapeutics entered a definitive all-stock merger agreement. The combined company will operate as Caldera Therapeutics and intends to list on the Nasdaq Capital Market under the ticker CALD. Concurrently, Caldera secured commitments for an approximately $278 million private placement from a syndicate of healthcare institutional investors. Proceeds are expected to fund Phase 2 trials of CLD-423, a TL1A x IL-23p19 bispecific antibody for inflammatory bowel disease, with cash runway projected into 2029. (Link)
  23. Thoma Bravo completed its majority-stake acquisition of French occupational health software leader padoa, with existing investors Five Arrows and Kamet Ventures reinvesting. Thoma Bravo, the world’s largest software-focused investment firm with more than $172 billion in assets under management, completed its investment in padoa, the European leader in occupational health, safety and prevention software. The investment was made through Thoma Bravo’s Europe Fund, with significant participation from padoa’s co-founders and existing shareholders Five Arrows (Rothschild & Co’s alternative assets arm) and Kamet Ventures. Thoma Bravo assumes majority control while CEO Cédric Mathorel and the executive team retain a substantial stake. The capital funds AI development, customer service expansion, product innovation and international growth, particularly across the DACH region. padoa had previously raised roughly €105 million pre-buyout. (Link)
  24. PetIQ acquires MYOS muscle health portfolio PetIQ, a leading pet health and wellness company and portfolio company of Bansk Group, acquired MYOS Corp and its Fortetropin-based portfolio of muscle health products for pets. The products support muscle preservation, injury recovery, and healthy aging in companion animals. Terms of the transaction were not disclosed. The acquisition expands PetIQ’s science-backed brand portfolio and strengthens its position in the growing pet health and wellness category. (Link)
  25. Latigo Biotherapeutics files for IPO Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing non-opioid pain medicines, filed an amended S-1 registration statement for its initial public offering. The company plans to offer 16 million shares of common stock, with an additional 2.4 million shares available to underwriters. The expected price range is $16.00 to $18.00 per share. Latigo has applied to list on the Nasdaq Global Select Market under the ticker LTGO. Its lead candidates are oral Nav1.8 inhibitors designed to stop pain transmission without addiction risk. (Link)
  26. Attovia Therapeutics files for IPO Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases, filed an amended S-1 registration statement for its initial public offering. The company plans to offer 12.5 million shares of common stock, with an additional 1.875 million shares available to underwriters for overallotments. The expected price range is $15.00 to $17.00 per share. Attovia has applied to list on the Nasdaq Global Market under the ticker ATTO. Proceeds will support clinical development of its ATTOBODY platform candidates. (Link)

Venture Deals and Other

  1. Function secured $450 million in non-dilutive growth financing from General Catalyst’s Customer Value Fund to scale its preventive health platform. Function, an Austin-based whole-body health company, closed $450 million in growth financing from General Catalyst’s Customer Value Fund, the firm’s non-dilutive vehicle that ties capital to customer growth rather than equity. General Catalyst manages a portfolio of 800-plus businesses. The financing follows Function’s $298 million Series B in November and its Q2 acquisitions of Getlabs’ nationwide blood-draw network and supplement platform SuppCo. Function offers 160-plus lab tests starting at $365 per year plus MRI and CT scanning across 200-plus locations, and reports 500,000-plus members. (Link)
  2. Healia, an Ohio-based healthcare benefits platform, raised a $14 million Series A led by 111° West Capital with participation from Y Combinator, First Round Capital, Pioneer Fund, GoAhead Ventures and Ohio-based North Coast Ventures. Healia, a Columbus, Ohio provider of a healthcare benefits platform for dual-income families and employers, raised $14 million in Series A funding led by 111° West Capital, bringing total funding to $18 million. Participating investors included Y Combinator, First Round Capital, Pioneer Fund, GoAhead Ventures and North Coast Ventures, a Cleveland, Ohio venture firm. Led by founder and CEO Priyang Shah, Healia builds health reimbursement arrangements that let employers cover employee healthcare costs and premiums when workers enroll in a spouse’s plan. Its platform compares plan options on total cost of ownership, facilitates spousal-plan enrollment and automates claims to reimburse expenses within hours. Proceeds fund operations and product development. (Link)
  3. Flourish Health raised $46 million, with a $26 million Series A led by B Capital, F-Prime and Cherryrock Capital, to scale intensive youth mental health care. Flourish Health, a Richmond, Virginia mental health provider for young people with serious, complex needs, announced $26 million in Series A funding led by B Capital, F-Prime and Cherryrock Capital, which combined with $20 million in previously undisclosed funding brings total capital raised to $46 million. The Series A investors are backing a psychiatrist-led, in-home model delivered through four-person Care Pods and a proprietary AI workflow platform. Studies with major health plans showed 70–96% reductions in hospitalizations and 69–90% reductions in residential treatment. The new capital funds national expansion in partnership with large health plans, platform investment and clinician hiring. (Link)
  4. Doctronic acquired pediatric telehealth company Summer Health, building on its $40 million Series B round backed capital base. Doctronic, an AI-enabled doctor consultation platform, acquired Summer Health, a text-based pediatric telehealth company, to extend primary care to children from birth. Deal terms were undisclosed; both companies are private. Doctronic raised $40 million in Series B funding in March, bringing total funding to $65 million, part of which was earmarked for pediatric expansion. Summer Health, founded in 2022, had raised $11.65 million in Series A funding in 2024 after an earlier $7.5 million round, and has supported more than 100,000 pediatric encounters. Doctronic plans to use Summer Health’s repository of 100,000-plus pediatric conversations to develop pediatric-specific AI models; founder Ellen DaSilva joins to lead B2B growth. (Link)
  5. Epitel, Inc. secured a $26 million Series B co-led by Catalyst Health Ventures and Genoa Ventures to expand its wireless remote EEG monitoring system. Epitel, a Salt Lake City AI-driven wireless brain health company, closed a $26 million Series B co-led by Catalyst Health Ventures and Genoa Ventures, with new and existing investors participating. The capital funds commercial expansion of its REMI Remote EEG Monitoring System, a fully wireless FDA-cleared platform that pairs wearable sensors with AI-driven seizure detection for at-home monitoring over several weeks. The REMI portfolio holds five FDA 510(k) clearances and is cleared for patients as young as one year old. Proceeds scale sales, marketing and customer teams, streamline provider deployment and grow ambulatory market access. Joshua Phillips of Catalyst Health Ventures chairs Epitel’s board. (Link)
  6. Dopl Technologies raised a $6.3 million seed round led by SpringTide Ventures, with participation from WRF Capital, Tacoma Venture Fund, HeartX, Transform Health Ventures and Precursor Ventures. Dopl Technologies, a Bothell, Washington medical technology company developing a robotic ultrasound platform, raised $6.3 million in seed funding led by SpringTide Ventures, bringing total funding above $8 million. WRF Capital, Tacoma Venture Fund, HeartX, Transform Health Ventures, Precursor Ventures and others participated. Led by CEO and co-founder Ryan James, PhD, Dopl combines robotics, AI and remote clinical expertise across its Traverse robotic ultrasound system, Dopl Connect data platform and SonoFlex distributed sonographer workforce tool. The company currently serves critical access hospitals across Washington State. Proceeds fund FDA clearance work, including product verification and validation, submission activities, clinical evaluation and initial market release. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Lawrence Evans & Co is pleased to announce the successful closing of a $30M Refinance / Growth Capital facility for a Healthcare Revenue Cycle Management (RCM) Platform

Lawrence, Evans & Co., LLC is pleased to announce the successful closing of a refinance and growth acquisition financing for a rapidly expanding healthcare revenue cycle management (RCM) platform.

LECO successfully led the transaction while simultaneously navigating multiple acquisitions across several countries—and the associated overseas legal and regulatory requirements—to support the owner’s non-dilutive refinancing and acquisition line of credit needs.

The transaction was led by Neil Johnson, Managing Partner at Lawrence, Evans & Co., LLC.

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update July 27th, 2026

LECO_Weekly-Healthcare-News_7-27-2026Download
  1. Longshore Capital Partners entered a strategic growth partnership with revenue cycle management provider Prochant. Chicago-based Longshore Capital Partners, a lower middle-market private equity firm that takes control positions in North American services businesses with $5 million to $15 million of EBITDA, invested in Prochant, a Charlotte, North Carolina technology-enabled RCM provider serving home medical equipment, DME, infusion and specialty pharmacy operators. Terms were undisclosed. Capital will fund technology, analytics, AI and automation investment, service capacity expansion, new revenue cycle product development and talent acquisition, alongside acquisitions in core markets. Longshore is backing an existing management team under CEO Joey Graham, preserving leadership and culture while accelerating investment in a recurring-revenue outsourced services model. (Link)
  2. SkyKnight Capital, L.P. agreed to acquire a controlling position in Apex Infusion from FFL Partners, which retains a minority stake alongside the clinician-led management team. SkyKnight Capital, a San Francisco private equity firm, signed a definitive agreement to partner with Apex Infusion, a Signal Hill, California omnichannel infusion services provider founded in 2006. FFL Partners, which completed its investment in 2024, remains a minority shareholder, and Apex’s clinician-led management retains significant ownership and continues to lead the business. Apex delivers therapy through a home infusion nursing network and roughly 40 ambulatory infusion suites. SkyKnight intends to fund new market entry, health system and payor partnerships, and technology-enabled access initiatives across a site-of-care shift thesis. (Link)
  3. Winterbird Partners made a growth investment in Minneapolis-based Microsoft services partner Emergent Software. Winterbird Partners invested in Emergent Software, a Minneapolis, Minnesota Microsoft services partner specializing in data modernization, AI deployment, cloud transformation, application development and managed services. Deal value was not disclosed. Led by CEO Jamie Anderson, Emergent manages solutions across the Microsoft ecosystem including Fabric, Azure, Copilot, Foundry and modern data platforms. Proceeds will fund headcount expansion, additional service capabilities and entry into new geographies. For Winterbird, the transaction is a bet on the durability of enterprise AI and data-platform implementation, backing a founder-led services firm against a single hyperscaler ecosystem rather than horizontal consultancy model. (Link)
  4. Healthcare technology platform Focus entered a definitive agreement to acquire Plano, Texas-based managed technology services company GuideIT. Focus, a Chicago-headquartered healthcare technology services company, agreed to acquire GuideIT, a nationally recognized managed technology services provider offering managed IT, cybersecurity, cloud integration, IT and clinical service desk, and medical data services. Terms were undisclosed; GuideIT will operate as GuideIT, A Focus Company. Focus supports more than 100 electronic health record and practice management systems and is consolidating fragmented healthcare vendor relationships into a single accountable partner. GuideIT CEO and board member Russell Freeman described a deliberate partner selection process. The acquisition scales Focus’s Unified Healthcare Platform thesis through capability breadth rather than geographic density. (Link)
  5. Knox Lane completed its $437 million take-private acquisition of Cross Country Healthcare, Inc. (formerly NASD: CCRN), concurrently selling the locums division to portfolio company All Star Healthcare Solutions. Growth-oriented investment firm Knox Lane closed its all-cash acquisition of Cross Country Healthcare at $13.25 per share, valuing the technology-enabled workforce solutions company at roughly $437 million and ending its NASD listing. The deal follows a terminated agreement with Aya Healthcare. Knox Lane simultaneously moved Cross Country’s locum tenens division into All Star Healthcare Solutions, an existing portfolio company, creating immediate platform consolidation. Managing Partner John Bailey and Partner Shamik Patel cited the company’s position at the intersection of workforce services and technology. Joel Tremblay, formerly of Medical Solutions, was installed as CEO, succeeding co-founder Kevin Clark. (Link)
  6. Care Career acquired MAS Medical Staffing, completing its first acquisition phase and lifting consolidated annual revenue beyond $150 million. Woodbridge, New Jersey-based Care Career, a healthcare workforce technology organization led by CEO Siva Konatham, acquired Manchester, New Hampshire-based MAS Medical Staffing, including its travel, allied and per diem operations and technology assets. Financial terms were undisclosed. This is Care Career’s seventh acquisition in 24 months, following IDR Healthcare in February 2026, Source Medical Staffing in October 2025, and four firms in May 2025. The completed first round now exceeds $150 million of annual revenue, with signed LOIs expected to close in Q3 2026 pushing consolidated revenue past a quarter billion by year-end, aided by MAS’s Maestra workforce platform. (Link)
  7. Equality Asset Management-backed Mindoula acquired Valera Health and Janus Healthcare Partners in a double transaction expanding its whole-person care enablement platform. Mindoula, the Silver Spring, Maryland behavioral health company backed by Equality Asset Management, simultaneously acquired New York-based virtual mental health provider Valera Health and Duxbury, Massachusetts psychiatric collaborative care provider Janus Healthcare Partners. Terms were undisclosed. These are Mindoula’s third and fourth acquisitions since its 2013 founding, following Care at Hand and 180 Health Partners. Valera contributes more than 300 multi-state behavioral providers and specialization in suicide risk reduction, DBT and serious mental illness; Valera had itself raised $74.3 million and acquired Vita Health in 2025. Janus adds psychiatry CoCM capability, positioning Mindoula for value-based contracts with payers and health systems. (Link)
  8. Beacon Behavioral Partners entered Ohio and Michigan through a partnership with Ohio- and Michigan-based Pure Psychiatry, adding a 17-location outpatient platform. Plano, Texas-based Beacon Behavioral Partners, a growing network of independent psychiatric practices, acquired Pure Psychiatry, establishing its first presence in Ohio and Michigan and marking one of its largest expansions to date. Financial terms were undisclosed. Pure Psychiatry, led by founders Taylor Hennrick, PA-C, Sarang Patel, PA-C and Dr. Rakesh Amin, provides psychiatric care across all age groups including medication management for anxiety, depression, ADHD and bipolar disorder. Beacon will supply operational, administrative and strategic support to fund de novo clinic openings and provider recruitment. The deal follows Beacon’s appointment of Rob Jardeleza as CEO roughly a week earlier. (Link)
  9. Truehelm-backed Wildflower Health acquired digital pelvic floor platform Every Mother, marking its entry into direct-to-consumer women’s health. Wildflower Health, the San Francisco tech-enabled women’s health company backed by Truehelm, acquired Every Mother, a clinically validated core and pelvic floor therapy platform founded by Allison Rapaport. Terms were undisclosed. Wildflower operates enterprise infrastructure connecting commercial health plans, risk-bearing provider groups and patients across all 50 states, supporting thousands of women’s health providers. Every Mother contributes HSA/FSA-eligible on-demand exercise programs addressing diastasis recti, urinary incontinence, pelvic organ prolapse and pelvic pain. Strategically, the acquisition adds a consumer subscription revenue channel to an enterprise contracting model and extends patient relationships beyond the traditional six-to-twelve-week postpartum drop-off. (Link)
  10. DuneGlass Capital-backed Aviva Aesthetics expanded into Ohio through a partnership with Avon, Ohio-based Vitality Health. Aviva Aesthetics, the Chicago-based entrepreneur-owned medical aesthetics platform launched in 2024 with healthcare services independent sponsor DuneGlass Capital, partnered with Vitality Health, a medical aesthetics and wellness practice in Avon, Ohio founded in 2014 by Alana Mercer, PA-C. Terms were undisclosed. This is Aviva’s eighth partnership of 2026 and its first Ohio location, deepening Midwest presence. Vitality Health provides injectables, laser treatments, skin rejuvenation, weight management and hormone optimization. Aviva’s Entrepreneur Equity structure explicitly positions against traditional private equity roll-ups, allowing founders to retain full equity and control while accessing scale economics and back-office support. (Link)
  11. PE-backed Premier Care Dental Management acquired cosmetic dentistry practice Brookline Smile Artists in Massachusetts. Premier Care Dental Management, the New Hyde Park, New York dental clinical organization operating under the Dental365 brand and backed by The Jordan Company, added Brookline, Massachusetts-based Brookline Smile Artists to its network. Terms were undisclosed. PCDM supports practices across New York, Connecticut, New Jersey, Pennsylvania, Ohio, New Hampshire, Massachusetts and Rhode Island, and has pursued an acquisition-led growth cadence including multiple Ohio additions earlier in 2026. The tuck-in extends the sponsor-backed platform further into higher-margin cosmetic dentistry, a service line with meaningful cash-pay mix, while continuing the roll-up strategy aimed at retiring and scaling-back owner-dentists across the Northeast. (Link)
  12. Shore Capital Partners-backed Innovate 32 partnered with Houston-based Post Oak Dental, expanding its Texas dental support organization footprint. Innovate 32, the Nashville-based dental services organization formed by Chicago lower middle-market private equity firm Shore Capital Partners, closed a partnership with Post Oak Dental, an established Houston, Texas practice. Terms were undisclosed. Under CEO Josh Johnson and a board combining dentists, multi-site healthcare operators and private equity executives, Innovate 32 has assembled a network across Texas, Tennessee, Florida and the Mid-Atlantic since its 2024 founding. Post Oak Dental retains its clinical focus while gaining management infrastructure. For Shore, the affiliation continues a disciplined buy-and-build in general dentistry, prioritizing clinician alignment and local leadership over transactional roll-up. (Link)
  13. Dentalcorp entered the U.S. market with the acquisition of Florida-based Northstar Dental Partners. Toronto-based Dentalcorp, one of the largest dental support organizations in North America, acquired Northstar Dental Partners, a Boca Raton-headquartered group supporting 21 dental practices across South Florida, the Treasure Coast, Southwest Florida and Central Florida. Founder and CEO Dr. Jordan Tomalty retains an ownership stake and will remain instrumental to continued growth. Combined with Dentalcorp’s Canadian network, the partnership brings the total to over 650 supported practices. (Link)
  14. vybe urgent care acquired Liberty Urgent Care’s Horsham and Hatfield centers, supported by growth-oriented debt financing from Live Oak Bank. vybe urgent care, the leading independent urgent care operator in greater Philadelphia, acquired Liberty Urgent Care’s two Montgomery County, Pennsylvania centers, expanding its network from 16 to 18 sites. Terms were undisclosed. The transaction was funded through a recent growth-oriented refinancing completed with Live Oak Bank, which vybe intends to draw on for further acquisitions and de novo development. Liberty founder Erik Soiferman, D.O. joins as Vice President of Occupational Medicine Services, strengthening vybe’s occupational health and workers’ compensation capabilities. The debt-funded structure allows the independent operator to consolidate a fragmented regional market without an equity sponsor. (Link)
  15. Ares Management Corporation (NYSE: ARES) and Rubicon Founders-backed US Heart & Vascular acquired Tennessee physician-owned practice Apex Vascular and its outpatient center. US Heart & Vascular, the Nashville-area cardiovascular support services platform backed by funds managed by the Private Equity Group of Ares Management (NYSE: ARES) alongside Rubicon Founders, acquired Apex Vascular and Apex Vascular Outpatient Center. Terms were undisclosed. Headquartered in Lenoir City, Tennessee, Apex has served East Tennessee for nearly two decades across Knoxville, Crossville, Harrogate, Decatur, Sevierville and Oak Ridge, treating peripheral artery disease, varicose veins, carotid artery disease and dialysis access. Founder Christopher Pollock, MD cited access to resources for regional expansion. The tuck-in deepens USHV’s density in a specialty prized for recurring outpatient procedure volume. (Link)
  16. Paradigm Oral Health bought back BlackRock, Inc.’s (NYSE: BLK) Long Term Private Capital stake in a surgeon-led transaction backed by a Warburg Pincus-led group including Goldman Sachs (NYSE: GS) Alternatives and Sixth Street. Lincoln, Nebraska-based Paradigm Oral Health repurchased BlackRock Long Term Private Capital’s ownership stake, returning majority control to its surgeons and management. The buyback is funded by a significant investment led by Warburg Pincus, a private partnership since 1966, in partnership with Goldman Sachs (NYSE: GS) Alternatives and Sixth Street. Terms were undisclosed. Founded in 2018 by David Rallis, DDS, MD, Paradigm operates an oral surgery and digital dentistry platform built to attract and retain surgeons. The structure is notable for reversing conventional sponsor control: incoming capital supports clinician majority ownership, technology investment, advanced training and de novo clinic expansion. (Link)
  17. Groups Recover Together acquired Better Life Partners in its first-ever acquisition, doubling its New England patient volume.Burlington, Massachusetts-based Groups Recover Together, the value-based opioid use disorder treatment provider backed by Oak HC/FT, Bessemer Venture Partners, Transformation Capital, RRE Ventures, Optum Ventures and Kaiser Permanente Ventures, acquired Better Life Partners in a transaction that closed March 31. Financial terms were undisclosed. Better Life Partners, founded in Vermont in 2018 and backed by aMoon, Alumni Ventures, F-Prime Capital, Maverick Ventures and .406 Ventures, had raised $26.5 million in a 2023 Series B but experienced financial distress. CEO Cooper Zelnick highlighted mental health and virtual primary care capabilities the company intends to scale nationally beyond New England. (Link)
  18. Ohio-based Cardinal Health (NYSE: CAH) agreed to acquire the Diabetes Health business of AdaptHealth Corp. (NASD: AHCO) and, in its entirety, NMS Capital-backed Strive Medical for approximately $360 million in cash. Cardinal Health (NYSE: CAH), headquartered in Dublin, Ohio, deployed roughly $360 million of cash across two definitive agreements to scale its at-Home Solutions platform, subject to working capital adjustments. The AdaptHealth (NASD: AHCO) unit serves over 225,000 patients annually through a centralized mail-order CGM model, while NMS Capital portfolio company Strive Medical adds urology, wound care, ostomy and incontinence supply distribution to 20,000-plus patients. Both transactions build on Cardinal’s Advanced lDiabetes Supply acquisition and are expected to be accretive to non-GAAP EPS within twelve months of close, extending the Ohio distributor’s consolidation of fragmented direct-to-patient supply channels. (Link)
  19. Surgery Partners, Inc. (NASD: SGRY) agreed to sell its ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health for approximately $795 million. Surgery Partners (NASD: SGRY), the Brentwood, Tennessee short-stay surgical facility operator, placed into escrow signature pages to sell its Idaho Falls hospital interests to existing partner Intermountain Health, a Utah-based nonprofit system of 34 hospitals and roughly 400 clinics. The transaction values the combined facilities at approximately $1.15 billion, with total consideration to Surgery Partners of about $795 million before purchase price adjustments. Physician ownership of Mountain View Hospital is unchanged. CEO Eric Evans framed the divestiture as portfolio optimization, refocusing capital toward ambulatory surgery centers. The company reaffirmed 2026 revenue guidance of $3.35–$3.45 billion excluding transaction impact. (Link)
  20. Gentherm Incorporated (NASD: THRM) acquired Ohio-based Innovative Medical Equipment, LLC, maker of the ThermaZone thermal therapy device. Gentherm (NASD: THRM), the Novi, Michigan thermal management and pneumatic comfort technology leader, acquired Innovative Medical Equipment, a Cleveland-area, Ohio provider of the ThermaZone non-opioid hot-and-cold thermal therapy system. Terms were undisclosed. Founder and President Brad Pulver framed Gentherm’s scale and global operating footprint as the growth enabler for the Ohio business. Management expects revenue synergies from cross-selling ThermaZone through Gentherm’s expanded healthcare customer channels. Announced alongside record Q2 2026 revenue of $416 million, raised full-year guidance and a new $400 million repurchase authorization, the deal advances Gentherm’s strategic pivot toward higher-margin medical adjacencies. (Link)
  21. RS2 Healthcare Partners, the Boston-based private equity firm formerly known as Riverside Partners, completed an investment in KMM Group, a Hatboro, Pennsylvania-based vertically integrated precision contract manufacturer serving the medical device industry. RS2 Healthcare Partners, founded in 1989 and rebranded from Riverside Partners in May 2026 to formalize an exclusive lower-middle-market healthcare strategy, closed an investment in KMM Group. Terms and stake size were undisclosed. The firm has raised $1.6 billion in total capital commitments since inception and concentrates on pharma services, medical device contract manufacturing and technology-enabled healthcare, supported by healthcare, clinical and AI advisory boards. KMM produces complex, tight-tolerance components for failure-intolerant end markets. J. Mark King joins as President and CEO, while co-founders John Shegda and Eric Wilhelm move to Chief Technology Officer and Executive Vice President, Business Transformation, preserving customer and employee continuity under sponsor ownership. (Link)
  22. Eurofins Scientific (EUFI.PA) agreed to acquire Element Materials Technology’s Life Sciences Testing Services business in North America for an enterprise value of $400 million. Eurofins Scientific, a global leader in bioanalytical testing, reached agreement with Element Materials Technology to acquire its North America Life Sciences Testing Services business, encompassing biopharma product testing, environmental testing and food testing across a network of 27 laboratories and facilities employing approximately 750 FTEs. The business is expected to generate over $150 million in 2026 revenues with profitability in line with the Eurofins Group average. The transaction expands Eurofins’ geographic footprint in key U.S. and Canadian regions where it has been underrepresented and is expected to close in Q4 2026 subject to customary regulatory approvals. (Link)
  23. Repligen Corporation (NASD: RGEN) agreed to acquire BioLife Solutions, Inc. (NASD: BLFS) for a total enterprise value of approximately $1.5 billion. Repligen will acquire BioLife in a cash-and-stock transaction valued at $31.00 per BioLife share ($11.25 cash plus 0.1442 shares of Repligen common stock), representing a 24% premium to the 90-day VWAP. The deal adds BioLife’s market-leading biopreservation media platform (including CryoStor) and cell-processing tools that support 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based trials. The transaction is expected to be accretive to growth, margins and adjusted EPS (at least 5 cents in year one and 25 cents in year two) with $20–30 million of synergies; closing is targeted for Q4 2026. (Link)
  24. Nordic Capital agreed to sell life sciences software platform ArisGlobal to Dassault Systèmes (Euronext Paris: DSY) for up to $2 billion, marking a full exit for the Swedish sponsor. Nordic Capital, which manages approximately €39 billion, is exiting ArisGlobal entirely in a sale to Dassault Systèmes (Euronext Paris: DSY) reported at $1.8 billion cash plus a $200 million earnout. Nordic first invested in 2019 via its ninth fund at a reported $700 million enterprise value and added to its stake in 2021. Under Nordic’s ownership the Waltham, Massachusetts company converted to SaaS, completed two bolt-ons and is expected to generate roughly $175 million of 2026 revenue, processing 12 million safety cases annually for 200-plus customers. Closing is expected in the second half of 2026. (Link)
  25. Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) entered a definitive agreement to acquire certain cannabis cultivation, manufacturing and retail assets of The Cannabist Company Holdings Inc. across five markets for up to $35 million. Vireo Growth, through subsidiary Vireo Health of Arcadia, agreed to acquire selected operations from Cannabist subsidiaries in Colorado, Illinois, Massachusetts, New Jersey and West Virginia for total consideration of up to US$35 million (up to US$18.75 million cash at closing plus up to US$16.25 million in seller notes), subject to adjustments and regulatory approvals. The staged transaction is expected to add up to 25 dispensaries plus cultivation and production assets, deepening Vireo’s Colorado presence and adding four new states. Closing is targeted through 2026 into 2027 amid Cannabist’s CCAA and Chapter 15 proceedings. (Link)
  26. Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) agreed to acquire Planet 13 Holdings Inc. (CSE: PLTH; OTCQX: PLNH) in an all-share merger. Vireo Growth entered a definitive merger agreement to acquire all outstanding equity of Planet 13, with each Planet 13 share converting into 0.015383618 of a Vireo subordinate voting share (16.6% premium to the 20-day VWAP and 24% premium to the closing price as of July 24, 2026). The transaction deepens Vireo’s Nevada and Florida footprints (adding the flagship Las Vegas superstore, additional dispensaries, cultivation/production capacity and licenses) and adds a Waukegan, Illinois dispensary. On a pro forma basis with prior announced deals, Vireo expects to operate approximately 265 dispensaries across 15 states. Closing is subject to stockholder, regulatory and listing approvals. (Link)
  27. First Choice Healthcare Solutions, Inc. (OTCQB: FCHS) and Westin Acquisition Corp. (NASD: WSTN) announced a definitive business combination agreement to create a publicly traded healthcare and wellness company. The transaction values First Choice at a pro forma enterprise value of approximately $650 million and is expected to accelerate its strategic rebrand to Wellgevity 360, a platform focused on longevity, preventative care and personalized biology-driven solutions. Westin will domesticate and the combined company is expected to trade on NASD. Closing is targeted for Q4 2026 subject to customary approvals and conditions. (Link)
  28. Avanos Medical, Inc. (NYSE: AVNS) stockholders approved the company’s $25.00-per-share take-private by American Industrial Partners, valuing the medtech at roughly $1.272 billion. Avanos Medical (NYSE: AVNS) shareholders voted overwhelmingly in favor of the acquisition by affiliates of funds advised by American Industrial Partners, with approximately 99.75% of shares voted supporting the merger, representing about 74.96% of shares outstanding as of the June 18 record date. Holders receive $25.00 per share in cash, an enterprise value near $1.272 billion and a 72.1% premium to the pre-announcement close, plus an 82.8% premium to the 30-day VWAP. All regulatory approvals had been obtained, with closing expected no later than July 27, 2026. The operationally focused industrials investor takes Avanos private, delisting from the NYSE. (Link)
  29. Royalty Pharma plc (NASD: RPRX) acquired a portion of Neurimmune’s royalty interest in cliramitug for up to $425 million. Royalty Pharma (NASD: RPRX) committed up to $425 million to Zurich-based Neurimmune in exchange for a 3% to 4% royalty on worldwide net sales of cliramitug, an investigational anti-amyloid antibody for ATTR cardiomyopathy. The structure front-loads $125 million upfront, with a further $125 million payable in Q1 2027 and $175 million tied to clinical and regulatory milestones. Cliramitug is licensed globally to Alexion, AstraZeneca Rare Disease, which is running the Phase 3 DepleTTR-CM trial. For Royalty Pharma, the transaction buys exposure to the rapidly growing ATTR-CM market; for Neurimmune, it is non-dilutive capital funding its internal pipeline. (Link)
  30. Aurobindo Pharma Limited (NSE: AUROPHARMA; BSE: 524804), through wholly owned subsidiary Apitoria Pharma Private Limited, agreed to acquire 80% ownership control of A1 Biochem Labs (India) Private Limited and A1 Biochem Labs LLC, USA at a $17 million enterprise value. Aurobindo Pharma (NSE: AUROPHARMA; BSE: 524804) is deploying $13.6 million in cash through Apitoria Pharma for an 80% interest in A1 Biochem Group’s contract research business, struck at a $17 million enterprise value on a debt-free, cash-free basis, subject to closing adjustments. The existing promoter retains 20%, and A1 Biochem Labs (India) will absorb A1 Biochem Labs LLC and the CRO business of A1 Biochem Research (India). The target posted FY26 turnover of ₹1,024.42 million and EBITDA of ₹465.46 million — a 45% margin — across Wilmington and Hyderabad labs with 90-plus scientists. Aurobindo is building an integrated CRDMO platform across the API value chain; closing is expected in 90 to 120 days. (Link)
  31. Scancell Holdings plc (AIM: SCLP) and Neuphoria Therapeutics Inc. (NASD: NEUP) announced an all-share merger agreement and associated financing. Scancell will acquire Neuphoria in an all-share transaction; the combined company will operate as Scancell, list on NASD (in addition to AIM) and advance a pipeline of targeted, off-the-shelf active immunotherapies, led by iSCIB1+ in advanced melanoma. Existing Scancell shareholders are expected to own approximately 85.5% and Neuphoria shareholders 14.5% on a pro forma basis (before financing). Concurrent financing of up to $89 million (equity and debt) is intended to fund the global registrational Phase 3 trial. Closing is targeted for late Q4 2026 subject to shareholder and regulatory approvals. (Link)
  32. Footbridge Partners and ALZA Capital Partners sold Ohio-, Pennsylvania- and Michigan-based medical spa platform The Skin Center to an undisclosed middle-market healthcare private equity fund. Footbridge Partners and ALZA Capital Partners exited The Skin Center, a medical spa and cosmetic surgery platform operating 14 locations across Pennsylvania, Ohio and Michigan, selling to an unnamed middle-market healthcare private equity fund in a recapitalization. Terms were undisclosed. Founded in 1981 by Jerry and Dominic Brandy, the company delivers neurotoxins, dermal fillers, laser skin resurfacing, laser hair removal and cosmetic surgery under CEO Eric Warden. Footbridge co-founder and Managing Partner David Rosner credited management and providers for the outcome. The incoming sponsor inherits a platform positioned for de novo openings and further M&A across the consolidating medical aesthetics market. (Link)

Venture Deals and Other

  1. MannKind Corporation (NASD: MNKD) raised approximately $50 million in a private placement led by Frazier Life Sciences. MannKind (NASD: MNKD) closed a roughly $50 million private placement with institutional investors, led by longstanding biotech investor Frazier Life Sciences. The company sold 10,440,838 common shares at $3.89 and pre-funded warrants for 2,412,632 shares at $3.88, with a $0.01 exercise price and no expiry. Proceeds fund general corporate purposes including a $45 million contingent value rights payment triggered by the FDA’s July 23, 2026 approval of Furoscix ReadyFlow for edema in heart failure and chronic kidney disease patients. (Link)
  2. Insight Partners led a $19 million Series A in AI-native provider credentialing platform Assured, with participation from First Round Capital and Kindred Ventures. Insight Partners led Assured’s $19 million Series A, joined by existing backers First Round Capital and Kindred Ventures, bringing total capital raised to $25 million following a $6 million seed in September 2025. Insight Managing Director Teddie Wardi articulated the thesis directly: incumbent credentialing tools function as systems of record while Assured’s agents perform the work itself, verifying data against more than 2,000 primary sources and cutting credentialing time by 30%. Launched in 2024, the NCQA-certified CVO serves over 100 organizations including Houston Methodist. Proceeds expand R&D and go-to-market teams ahead of a privileging product in early 2027. (Link)
  3. Brevy Care raised $4.77 million with participation from GreyMatter Capital to expand Medicaid reimbursement software for family caregivers. Brevy Care, a developer of software helping family caregivers access Medicaid reimbursements, raised $4.77 million in a round including San Francisco-based GreyMatter Capital, a mental and behavioral health-focused venture firm founded in 2021 that typically writes first checks of $250,000 to $1.2 million. The financing brings Brevy’s total capital raised to $4.92 million. GreyMatter’s thesis centers on early-stage innovation in behavioral healthcare delivery and adjacent care-navigation infrastructure. For investors, Brevy addresses a reimbursement-access gap in self-directed Medicaid programs, a payer-funded and demographically supported category as aging populations shift care burden toward unpaid family members. (Link)
  4. Sixth Street Growth led a $120 million Series D in autonomous revenue cycle management platform Candid Health, with participation from Oak HC/FT, 8VC and Y Combinator. Candid Health raised $120 million led by Sixth Street Growth, the dedicated growth platform of Sixth Street, which manages over $135 billion and has invested more than $13 billion across 90-plus companies. Oak HC/FT, 8VC and Y Combinator participated. The round marks a 3x valuation increase over the February 2025 Series C led by Oak HC/FT. Managing Director Alex Katz cited diligence calls with nearly 40 customers and proof points applying agentic AI at scale. Candid reported 190% year-over-year annual contracted run-rate growth and 180% net dollar retention in 2025, targeting the $280 billion US RCM spend. (Link)
  5. Innovation Endeavors and Xora co-led a $21 million Series A in sensor developer Elio, with participation from Kevin Weil, Scribble VC, UpWest and Resolute Ventures. Elio, a Silicon Valley and Israel-based company building sensors designed for artificial intelligence rather than human vision, raised $21 million co-led by Innovation Endeavors and Xora. Kevin Weil and Scribble VC participated, alongside existing investors UpWest and Resolute Ventures, who led the prior round. Total funding reaches $29 million. Founded by former Meta AR/VR executives, Elio embeds computation directly into optics using dynamic micromirror layers that behave like a neural network, letting AI decide what to capture in real time. Investors are backing applications spanning microscopy, semiconductor inspection, robotics and defense drone detection. (Link)
  6. 7wire Ventures and Allumia Ventures co-led an oversubscribed $16.2 million Series A in Karoo Health, joined by First Trust Capital Partners, SpringRock Ventures and Hyde Park Angels. Karoo Health, an Albuquerque, New Mexico cardiovascular technology company led by CEO Ian Koons, closed a $16.2 million oversubscribed Series A co-led by 7wire Ventures and Allumia Ventures, with First Trust Capital Partners, SpringRock Ventures and Hyde Park Angels participating. Managing Partners Lee Shapiro of 7wire and Jeff Stolte of Allumia join the board. Deployed programs have produced independently analyzed reductions exceeding 40% in emergency department visits and inpatient admissions, plus a greater than 10% total cost of care reduction. Karoo supports 600-plus cardiology providers across 11 states; proceeds fund predictive models and health plan expansion. (Link)
  7. FUSE led a $16 million financing in AI-powered concierge primary care platform Prosper Medical, with participation from Aurum Partners, Better.vc, Cal Innovation Fund, Fluent, Latitude Capital, Knoll Ventures and WTI. Prosper Medical, a San Francisco company founded in 2026 by CEO Ryan McQuaid and CMO James Wantuck, MD, raised $16 million led by FUSE alongside Aurum Partners, Better.vc, Cal Innovation Fund, Fluent, Latitude Capital, Knoll Ventures and Western Technology Investment. Investors are backing repeat founders who previously built PlushCare and sold it to Accolade for $450 million. Unlike cash-pay concierge peers, Prosper is in-network with major insurance plans across all 50 states at a $69 monthly membership, using an AI care layer for longitudinal data aggregation and referral coordination. Proceeds expand the physician network and enter new markets. (Link)
  8. Decathlon Capital Partners provided a non-dilutive growth-debt investment to value-based care technology company Health Endeavors. Decathlon Capital Partners, a growth-debt provider with offices in Palo Alto and Park City, made a strategic investment in Health Endeavors, a Farmington, Utah technology partner to Accountable Care Organizations. Deal size was undisclosed, but the structure requires no dilution of existing shareholders. Managing Director Matt Hoffman framed the investment as conviction in value-based care economics. Health Endeavors serves over 2 million patients with 16-plus years of ACO experience and partnerships with Novant Health and Providence. Decathlon targets companies with $4 million to $100 million revenue, 10%-plus growth and near-term visibility to cash-flow-positive status, avoiding equity dilution and loss of control. (Link)
  9. Vensana Capital and Ohio-based Mutual Capital Partners co-led a $30 million Series A in TYBR Health, with participation from Neovate Capital Partners and existing investors. TYBR Health, a Houston, Texas orthopedic biologics company co-founded and led by CEO Tim Keane, PhD, raised $30 million in Series A financing co-led by Vensana Capital and Mutual Capital Partners, the Cleveland, Ohio venture firm managed by Bill Trainor and Wayne Wallace that invests exclusively in Midwest healthcare IT and medical device companies. Proceeds expand commercial access to the FDA-cleared B3 GEL System, a flowable extracellular matrix hydrogel, broaden indications and fund clinical studies on tissue protection during orthopedic surgery. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update July 20th, 2026

LECO_Weekly-Healthcare-News_7-20-2026Download

Healthcare Weekly News and Deals – 20 July, 2026

  1. PE-backed Ridgemont Equity Partners and Coogee Bay Partners Acquire Ohio-based Caring Transitions. Ridgemont Equity Partners, a Charlotte-based middle-market private equity firm, and Coogee Bay Partners (digital-marketplace operators Joshua Ellstein and Michael Felman) acquired Caring Transitions, a Cincinnati, Ohio-based nationwide franchise network providing senior move management, downsizing, estate-sale and home-cleanout services through its CTBids digital marketplace. Terms were undisclosed. Ellstein and Felman become Co-Executive Chairmen alongside President Joe Lewandowski. Founded in 2006, the Ohio company operates more than 300 franchise locations. The sponsors plan to scale and modernize the CTBids platform to capture liquidity from an aging population downsizing its households, blending Ridgemont’s buyout capital with Coogee Bay’s marketplace-operating expertise. (Link)
  2. Great Point Partners-backed VetnCare acquired Holistic Veterinary Care. VetnCare, a Northern California veterinary hospital group backed by Greenwich-based healthcare private equity firm Great Point Partners, acquired Holistic Veterinary Care, an Oakland practice specializing in integrative and rehabilitative animal medicine founded in 2009. Terms were undisclosed. The deal is VetnCare’s sixth add-on since Great Point’s investment and the first under CEO Matt Kirchner; founder Dr. Gary Richter stays on as Clinical Director. Great Point Partners, founded in 2003 with roughly 30 professionals, backs a buy-and-build strategy that has more than doubled VetnCare over three years while preserving local clinical leadership. The tuck-in extends the platform into alternative and rehabilitative care rather than simply adding locations. (Link)
  3. HCAP Partners / Hamilton Lane (Nasdaq: HLNE)-backed PAX Health acquired independent medical examination provider MAKRAF IME. PAX Health, a behavioral health company backed by HCAP Partners and funds managed by Hamilton Lane (Nasdaq: HLNE), acquired MAKRAF IME, a New Jersey statewide psychology and neuropsychology independent medical examination group serving 17 counties. Terms were undisclosed. The deal is PAX Health’s fourth acquisition since its March 2024 founding and expands its medical-legal evaluation platform for insurers, employers, attorneys and state agencies. MAKRAF’s licensed examiners deliver opinions on causality, permanency and fitness-for-duty. For its sponsors, the tuck-in advances a buy-and-build strategy in behavioral health, adding a complementary IME capability with an established statewide referral network to the Red Bank-based platform. (Link)
  4. Morgan Stanley/TPG-backed Guardian Dentistry Partners acquires Majority Stake in Select Dental Management. Guardian Dentistry Partners (GDP), a dental partnership organization capitalized by Morgan Stanley Private Credit, TPG Twin Brook and Prudential, agreed to a majority acquisition of Select Dental Management (SDM), adding 38 locations, 130 dentists and 720 team members across eight Northeastern states and Washington, D.C. SDM grew EBITDA 115% between 2022 and 2024 at roughly 20% practice-level margins. The deal, expected to close before the end of Q3 2026, significantly expands GDP’s geographic reach and reinforces its equity-ownership, dentist-partnership model. For its sponsors, the transaction scales a differentiated DPO platform through affiliation rather than transactional roll-up, prioritizing clinician retention and alignment. (Link)
  5. Family Capital Kaltroco acquired school-based mobile dental provider Smile America Partners from private equity firm Beach Point Capital Management. Kaltroco, a family-owned private investment company with offices in Nashville, Zurich and Cape Town, acquired Smile America Partners, the largest U.S. school-based mobile dental program, from seller Beach Point Capital Management. Terms were undisclosed, though the Farmington Hills, Michigan-based DSO generates roughly $20 million EBITDA on about $100 million revenue. Beach Point had bought majority control in January 2023 from Morgan Stanley Capital Partners. Smile America served over 370,000 children across 8,000-plus schools in 20 states in 2025. Kaltroco, which invests family capital with no outside LPs, backs continued expansion of pediatric dental access under existing CEO Steve Higginbotham. (Link)
  6. Hidden Harbor Capital Partners’ portfolio company Inspire Aesthetics partnered with Colorado-based Millard Plastic Surgery. Inspire Aesthetics, the plastic-surgery management services organization backed by lower-middle-market private equity firm Hidden Harbor Capital Partners, formed a strategic partnership with Millard Plastic Surgery, a Denver/Englewood, Colorado provider founded by Dr. John Millard and supported by four plastic surgeons. Terms were undisclosed. The affiliation extends Inspire’s national roll-up of premium aesthetic practices while preserving physician-led clinical decision-making. For Hidden Harbor, adding a well-regarded Colorado platform advances its buy-and-build thesis in high-end plastic surgery, layering operational resources onto a two-decade-old brand. The deal deepens Inspire’s geographic footprint in the Mountain West as sponsors continue consolidating the fragmented medical-aesthetics market. (Link)
  7. Macquarie Asset Management-backed Health Wave Partners acquired Alamar Senior Living from sellers Walton Street and Scarp Ridge Capital Partners. Health Wave Partners, a Chicago-based senior-housing investment platform backed by a strategic partnership with Macquarie Asset Management, acquired Alamar Senior Living, a 134-unit Class A assisted living and memory care community in Wellington, Florida. The seller was a partnership between Walton Street and Scarp Ridge Capital Partners. Terms were undisclosed. Built in 2018 and 96% occupied after a 2025 renovation, Alamar will continue under operator AgeWell Senior Living. The acquisition expands Health Wave’s presence in South Florida’s demographically favorable senior-housing market, reflecting its strategy of pairing high-quality communities with best-in-class operators to capture demand from an aging population. (Link)
  8. Ascension-owned AMSURG, acquired five North Carolina gastroenterology and endoscopy centers to expand its ambulatory surgery platform. AMSURG, one of the largest U.S. ambulatory surgery center operators with more than 250 centers and now part of Ascension following its roughly $3.9 billion take-private, added five North Carolina centers spanning the state’s eastern and central regions. Terms were undisclosed. The acquired centers bring 15 board-certified gastroenterologists and hepatologists offering colonoscopy, endoscopy and capsule imaging. The tuck-in reflects AMSURG’s continued buy-and-build consolidation of physician-aligned GI assets, deepening regional density in a specialty prized for recurring, outpatient procedure volume. The deal underscores how scaled ASC platforms keep absorbing community practices to strengthen payer positioning and geographic coverage. (Link)
  9. Brookdale Senior Living Inc. (NYSE: BKD) acquired the previously managed Brookdale Galleria community in Houston for $23.4 million. Brookdale Senior Living (NYSE: BKD), the largest U.S. senior-living operator with 541 communities, completed the $23.4 million acquisition of the 244-unit Brookdale Galleria independent and assisted living community in Houston’s affluent Galleria district. Management framed the price as a substantial discount to replacement cost, funding the deal with cash on hand and an expanded line of credit rather than equity issuance. With occupancy below Brookdale’s consolidated average, the company plans a repositioning through modest development capex to capture upside that accrues directly to shareholders. The purchase converts a managed asset into owned real estate in a strategically important market. (Link)
  10. Family-owned Family Hospice acquired North Georgia Community Hospice, LLC to complete its northwest Georgia footprint. Family Hospice, a family-owned, locally operated palliative and hospice provider founded in January 2022 and serving 13 locations across Georgia and South Carolina, completed its acquisition of North Georgia Community Hospice, a Dalton-based provider serving northwest Georgia. Terms were undisclosed. Backed by the nonprofit Family Hospice Foundation, the buyer positioned the deal as extending its full continuum of hospice and palliative services—including additional clinical and bereavement resources—into the region. The transaction reflects steady consolidation among community hospice operators pursuing regional density in a market shaped by favorable senior demographics and rising home-based, end-of-life care utilization across the Southeast. (Link)
  11. Physician-led Summit Spine & Joint Centers acquired Southeast Neurology & Pain Management (SNPM), its third acquisition in three years. Summit Spine & Joint Centers, a physician-led minimally invasive spine and interventional pain platform led by founder-CEO Dr. Amit Patel, acquired Southeast Neurology & Pain Management, adding clinics in Thomasville, Georgia and Tallahassee and Panama City, Florida. Terms were undisclosed. The deal—Summit’s third practice acquisition in three years—lifts its network to 55 clinics and 21 ambulatory surgery centers across Georgia, Florida, North Carolina, South Carolina and Tennessee. The acquisition advances Summit’s strategy of partnering with established physician-led pain practices while preserving local clinical leadership, building regional density in interventional pain as demand for minimally invasive treatment grows across the Southeast. (Link)
  12. Tempus AI, Inc. (NASDAQ: TEM) agreed to acquire Personalis, Inc. (Nasdaq: PSNL) for $16.25 per share, an enterprise value of roughly $1.5 billion. o prTempus AI (NASDAQ: TEM) agreed to acquire Personalis (Nasdaq: PSNL) at $16.25 per share—about $1.5 billion enterprise value net of Tempus’ existing stake—a 6% premium to Friday’s close and 28% to the unaffected 30-day VWAP. The primarily all-stock deal uses a floating exchange ratio capped at 0.3356, with Tempus able to elect up to 50% cash. It builds on a November 2023 partnership in which Tempus invested in Personalis and commercializes its ultrasensitive NeXT Personal MRD test. Tempus is buying deeper into the roughly $20 billion molecular residual disease market, integrating tumor-informed cancer monitoring across its AI-enabled precision-oncology platform; closing is expected late 2026 or early 2027. (Link)
  13. BrainsWay Ltd. (NASDAQ/TASE: BWAoY) made a $500,000 minority preferred-equity investment in outpatient behavioral health platform Sound Minds Behavioral. BrainsWay (NASDAQ/TASE: BWAY), a neurostimulation medtech company, took a minority position in Sound Minds Behavioral through a preferred, annually compounding security, deploying $500,000 as part of a strategic equity financing round. The structure mirrors BrainsWay’s playbook of supplying growth capital to expanding interventional-psychiatry providers while retaining focus on its core Deep TMS technology. Sound Minds operates outpatient mental-health clinics across Connecticut, Pennsylvania, New Jersey and New York, offering therapy, medication management, PHP/IOP and interventional psychiatry. For BrainsWay, the minority-stake model expands its distribution reach and aligns a growth-oriented partner with its device platform without diluting its clinical and scientific priorities. (Link)ot
  14. IPG Photonics Corporation (NASDAQ: IPGP) entered a binding offer to acquire Lumibird Medical from Lumibird SA for €300 million plus a €50 million earn-out. IPG Photonics (NASDAQ: IPGP) agreed to acquire Lumibird Medical for €300 million on a cash-free, debt-free basis, plus up to €50 million contingent on 2026–2027 performance, funding the purchase with cash on hand. France-based Lumibird Medical, whose brands include Quantel Medical, Ellex and Optotek Medical, posted FY2025 revenue of €112.2 million and EBITDA of €24.1 million (21.5% margin). IPG expects the high-margin ophthalmology-and-urology laser business to be accretive to gross margin, EBITDA and adjusted EPS in year one, lifting Advanced Solutions to roughly 26% of sales and adding about $1 billion of addressable market to its medical-laser growth platform. (Link)
  15. PE-backed Raintree acquired agentic-AI voice developer Spike Technologies to advance autonomous revenue-cycle management. Raintree, the leading EHR and practice-management platform for rehabilitation and physical-therapy organizations, acquired San Francisco-based Spike Technologies, a developer of agentic AI voice technology founded in 2022. Terms were undisclosed. The acquisition embeds AI voice agents natively into Raintree’s EMR to automate payer calls, claim follow-ups, eligibility, prior authorization and patient outreach—work that consumes front-desk staff amid roughly 13% claim-denial rates. Management framed the deal as a foundational step toward fully autonomous RCM. Strategically, Raintree is betting that native, context-aware automation—rather than bolted-on chatbots—will compress administrative cost and differentiate its platform in a large, labor-intensive workflow market. (Link)
  16. JLL Partners recapitalized life-sciences services firm CAI. JLL Partners, a New York-based middle-market private equity firm focused on healthcare, industrials and business services, closed a recapitalization of CAI, an Indianapolis-based professional services firm providing commissioning, qualification and validation (CQV) and operational-readiness services to life-sciences and mission-critical customers. Terms were undisclosed; the transaction closed July 1. CAI’s 700-plus professionals operate across North America, Europe, Australia and Asia. JLL Partners, which has deployed roughly $9 billion of equity across 61 platform investments since 1988, aims to accelerate CAI’s global expansion, technology investment and service-line growth—another example of a specialist sponsor backing scaled pharma-services platforms serving highly regulated environments. (Link)
  17. Lyric acquired precision payment-accuracy company Concert to expand its Lyric42 healthcare decision-intelligence platform. Lyric, a Philadelphia-based leader in healthcare decision intelligence for payment accuracy, acquired Concert, a precision-health payment-accuracy company whose proprietary technology translates machine-readable clinical policies into real-time claims decisions. Terms were undisclosed. The acquisition builds on a commercial partnership begun in 2023, during which the pair’s shared diagnostics solution grew nearly tenfold. Lyric, which supports roughly 200 million lives and nine of the top ten U.S. health plans, will embed Concert’s policy intelligence into its AI-powered Lyric42 platform. Strategically, the deal shifts payment integrity toward shared, machine-readable policy standards as genetic testing and specialty therapies reshape plan cost management. (Link)
  18. Warburg Pincus acquired Indian pharmaceuticals company Integrace Private Limited from sellers True North and Temasek. Warburg Pincus, the global growth-investing firm, acquired Integrace Private Limited, an India-based orthopedics- and gynecology-focused pharmaceutical formulations company, from exiting investors True North and Temasek in a deal reported at around ₹1,200 crore (terms officially undisclosed). Integrace holds 20-plus brands—including Lizolid, Stiloz, Mifegest and Cytolog—and relationships with over 45,000 healthcare professionals through science-led marketing. Industry veteran Rehan Khan, formerly of MSD and Abbott India, joins as CEO. Warburg Pincus, active in Indian healthcare for three decades, is betting on building a scaled, therapy-focused branded formulations platform via consolidation in women’s health and orthopedics, backed by predictable chronic-care demand. (Link)
  19. Verdane acquired stakes in four Trifork Labs technology businesses—Axoniq, Dawn Health, Frameo and XCI—from publicly listed Trifork Group (Nasdaq Copenhagen: TRIFOR). Verdane, the Oslo-based specialist growth investor, acquired ownership stakes in four Trifork Labs companies—event-sourcing pioneer Axoniq, patient-centric digital-health business Dawn Health, WiFi photo-frame software provider Frameo, and cybersecurity firm XCI—from Trifork Group (Nasdaq Copenhagen: TRIFOR). Investing via its Freya funds, Verdane acquired 52% of the four companies’ combined €43.6 million book value, paying Trifork €22.8 million cash plus uncapped earnouts; three stakes will be co-owned with Trifork while XCI was fully acquired. Verdane will deploy operational advisors across go-to-market, data, finance and talent, with the digital-health asset Dawn Health anchoring the healthcare relevance of this growth-stage portfolio transaction. (Link)
  20. Avathon Capital-backed Summit Professional Education acquired pediatric pelvic-health educator Kids Bowel & Bladder. Summit Professional Education, a Franklin, Tennessee continuing-education provider backed by Avathon Capital, acquired Kids Bowel & Bladder (KBB), the leading U.S. continuing-education organization for pediatric pelvic health, founded by Dawn Sandalcidi. Terms were undisclosed. The deal extends Summit’s already-strong pelvic-health franchise into pediatric specialty care, adding on-demand and live courses plus a Certificate in Pediatric Pelvic Health. Summit—whose portfolio includes Herman & Wallace Pelvic Rehabilitation Institute, PT Final Exam, the National Federation of Personal Trainers and The Knowledge Tree—has educated over 400,000 clinicians. (Link)
  21. Avera Health (Non Profit Health System) acquired physician-owned multispecialty group The Center for Neurosciences, Orthopaedics & Spine (CNOS). Avera Health, a Sioux Falls-based nonprofit health system, acquired The Center for Neurosciences, Orthopaedics & Spine (CNOS), a physician-owned multispecialty group headquartered in Dakota Dunes, South Dakota. Terms were undisclosed. The deal brings more than 100 physicians and advanced-practice providers plus over 350 staff across nine specialties—including orthopedics, neurosurgery, neurology and gastroenterology—and eight clinic locations into Avera, effective January 1, 2027, when the group becomes Avera CNOS. Building on an existing referral relationship across the South Dakota–Iowa–Nebraska Siouxland region, the acquisition reflects continued health-system consolidation of independent specialty groups to strengthen regional care continuity, employed-physician scale and integrated delivery across a tri-state footprint. (Link)
  22. Zoetis Inc. (NYSE: ZTS) agreed to acquire veterinary teleradiology platform VitalRADS. Zoetis (NYSE: ZTS), the world’s largest animal-health company, agreed to acquire VitalRADS, a veterinary teleradiology services platform, building on a partnership the two announced in August 2025. Terms were undisclosed; closing is expected in Q3 2026. VitalRADS provides cloud-based teleradiology, mobile ultrasound, outpatient imaging and cloud image storage, giving practices around-the-clock access to board-certified specialists across 25-plus species with two-hour STAT reads. Folding VitalRADS into its Global Diagnostics portfolio advances Zoetis’ build-out of an end-to-end Virtual Reference Lab with AI-assisted reporting. Strategically, the deal deepens the animal-health leader’s higher-growth diagnostics and imaging franchise, layering recurring specialist services onto its reference-laboratory network. (Link)
  23. Lōkahi Therapeutics completed a strategic business combination with Glucotrack, Inc. (Nasdaq: GCTK), taking control of the public company. Glucotrack (Nasdaq: GCTK) completed a strategic business combination with Lōkahi Therapeutics, a capital-efficient biopharmaceutical platform that acquires and advances overlooked therapeutic assets via its ai² sourcing model. Lōkahi becomes the operating and controlling business, using Glucotrack’s public listing as a capital-efficient platform; upon stockholder approvals and preferred-stock conversion, Lōkahi securityholders will hold roughly 90% of the combined company on a fully diluted basis. A planned private placement is intended to strengthen the capital structure. Glucotrack’s legacy continuous blood glucose monitoring business will operate as a wholly owned subsidiary. The reverse-merger structure gives Lōkahi public-market access to pursue a repeatable, acquisitive pipeline strategy. (Link)
  24. Johnson & Johnson’s (NYSE: JNJ) DePuy Synthes acquired spine-implant maker Expanding Innovations, Inc. DePuy Synthes, the orthopedics business of Johnson & Johnson (NYSE: JNJ), acquired Expanding Innovations, a Mountain View, California commercial-stage medtech company specializing in expandable interbody cage technology for spine surgery. Terms were undisclosed. Expanding Innovations’ non-screw-based X-PAC portfolio—covering TLIF and LLIF expandable cages and a lumbar plate system—will complement DePuy Synthes’ TriALTIS Spine System and integrate into its VELYS enabling-tech platform. The deal strengthens J&J’s position in the fast-growing expandable interbody cage segment of the lumbar-fusion market. Strategically, it deepens the medtech giant’s spine portfolio and innovation pipeline as it competes for surgeon adoption in higher-growth orthopedic categories. (Link)
  25. Eli Lilly and Company (NYSE: LLY) agreed to acquire psychedelics developer AtaiBeckley Inc. (Nasdaq: ATAI) for up to $3.8 billion. Eli Lilly (NYSE: LLY) agreed to acquire AtaiBeckley (Nasdaq: ATAI), a New York clinical-stage biotech developing psychedelic-based mental-health therapies, for $6.75 per share in cash—about $2.8 billion upfront and a 26% premium—plus contingent value rights worth up to $2.50 per share (roughly $1 billion), for total potential value near $3.8 billion. AtaiBeckley’s lead candidate, BPL-003, is an intranasal 5-MeO-DMT formulation for treatment-resistant depression. Expected to close in Q3 2026 pending stockholder and regulatory approval, the deal extends Lilly’s cash-fueled acquisition spree beyond obesity and diabetes, bolstering its neuroscience pipeline and validating big pharma’s growing conviction in psychedelic medicine. (Link)

Venture Deals and Other

  1. Index Ventures-led (VC-backed) Chai Discovery Raises $400M Series C. Chai Discovery raised a $400 million Series C led by Index Ventures alongside Kleiner Perkins, Sequoia Capital and Dimension, with new investors including Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD and Sapphire Ventures, plus returning backers Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures and General Catalyst. The round values the AI molecular-design company at $3.8 billion. Investors cited Chai’s rapid product velocity and commercial traction—its models are already deployed at large pharmaceutical partners—as the thesis. The capital accelerates development of Chai’s generative models for de novo antibody and molecule design targeting historically “undruggable” biology. (Link)
  2. Oak HC/FT-led (VC-backed) Corner Health Raises $32.5M Seed + Series A. Corner Health raised $32.5 million across Seed and Series A financing, with its Series A led by Oak HC/FT and participation from First Round Capital and Zigg Capital, alongside earlier backers Homebrew, Pathlight Ventures, Wischoff Ventures and Go Global Ventures. Oak HC/FT, a fintech-and-healthcare specialist managing over $7 billion, framed the primary-care shortage as an infrastructure problem its AI-native operating system, Cora, is built to solve. Corner Health equips nurse practitioners to launch independent practices, having scaled to 70-plus provider-owned clinics and 35,000 patient visits. The capital funds team growth, platform development and multi-state expansion of its clinician-ownership model. (Link)
  3. Lux Capital/VC-backed SONATA Launches Doctor-led Preventive-Health Membership. SONATA launched its physician-led, prevention-focused healthcare membership in New York, San Francisco and Los Angeles, backed by Lux Capital, Box Group, Sunflower Capital and operators from companies including Linear and Ramp. Round size was not disclosed. Co-founded by Sagan Schultz (ex-Linear, McKinsey) and David Deng (ex-Ramp, Flatiron Health), the $2,500-a-year membership combines whole-genome sequencing, 140-plus biomarkers, in-home testing and in-house clinical AI with ongoing board-certified physician care. For its venture backers, SONATA represents a bet on AI-enabled, longitudinal preventive care that synthesizes genomics and biomarkers into personalized, physician-directed plans—positioning the company in the fast-growing consumer preventive-health and longevity market. (Link)
  4. Arteria/VC-backed Provect AI Raises $7M. Provect AI, a Palo Alto medical-imaging software company, raised $7 million led by Arteria Capital and ValueStream Ventures, with participation from Newfund Capital and Sand Hill Angels, alongside FDA 510(k) clearance for its platform. The software reconstructs volumetric 3D images from standard 2D C-arm x-ray data without a CT scanner or added hardware, targeting spine and orthopedic image-guided procedures. Investors are backing a capital-light approach to intraoperative 3D imaging that integrates with existing PACS and navigation systems. The proceeds fund commercial expansion, customer deployments and continued product development as Provect commercializes its cleared technology into surgical workflows. (Link)
  5. Game Changers Ventures-led (VC-backed) Cognify Health Raises Seed. Cognify Health raised a seed round led by Game Changers Ventures to build a healthcare platform for youth athletics, starting with concussion care. Round size was undisclosed. Founded and led by Christian Juzang, Cognify connects families with a concussion specialist via telehealth within 24 hours and provides return-to-learn and return-to-play plans, drawing on clinicians tied to organizations including USA Basketball and UCLA BrainSPORT. For its lead investor, the thesis is building the “default healthcare layer” for youth sports—using concussion care as an entry point into a broader, nationwide integrated pediatric-athletics platform addressing an underserved, geographically fragmented care gap. (Link)
  6. Symbiotic Capital (Growth debt) Provides up to $65M to THINK Surgical. THINK Surgical, a Fremont, California orthopedic surgical-robot maker, secured a debt facility from healthcare-credit firm Symbiotic Capital providing up to $65 million of growth capital—an initial $25 million funded tranche, an additional $15 million milestone tranche, and up to $25 million discretionary. Combined with recent investments from existing backers, management expects the facility to fully finance the company to profitability. Proceeds advance the dual-channel commercial strategy for its TMINI Miniature Robotic System, compatible with roughly 70% of total-knee implants. For Symbiotic, the deal reflects private-credit appetite to fund scaled, commercial-stage medtech growth without dilutive equity at a critical inflection. (Link)
  7. Orlando Health Ventures-led (Health-system/VC) 410 Medical Raises $12M. 410 Medical, a Durham, North Carolina critical-care device company, closed an oversubscribed $12 million financing led by Orlando Health Ventures, with participation from Hatteras Venture Partners, Ballad Health, OSF Healthcare, Rex Health Ventures, CU Healthcare Innovations Fund, Sarnova, Catalyst by Wellstar, Tampa General and an undisclosed strategic investor. The heavy health-system investor syndicate reflects clinical conviction in 410’s LifeFlow rapid fluid-and-blood delivery products, used at 500-plus hospitals and EMS agencies. Orlando Health Ventures deepened an existing partnership by leading the round. Proceeds scale commercial operations and support a next-generation LifeFlow infuser planned for 2027. (Link)
  8. Capital Q Ventures (Strategic partnership investment) in Woddle. Woddle, a smart-nursery and infant-monitoring healthcare startup previously backed by Madison-based HealthX Ventures, announced a strategic partnership and investment from Capital Q Ventures, an Orlando, Florida alternative-investment firm spanning venture capital, private credit and private equity. Round size was undisclosed. Woddle builds technology-enabled tools for parents and caregivers, initially focused on the modern nursery. For Capital Q, the investment adds a consumer-health hardware-and-software company to a portfolio that emphasizes hands-on support for growth-stage businesses. The partnership provides Woddle additional capital and strategic backing as it scales its baby-focused product line and builds out its parenting-support platform. (Link)
  9. Insight Partners-led (Growth/VC-backed) TytoCare Raises $25M+ TytoCare closed an oversubscribed growth round exceeding $25 million led by Insight Partners, with participation from HOOP, OliveTree, OrbiMed, Qumra Capital and Qualcomm Ventures, alongside the appointment of Adam Pellegrini as CEO. Insight Partners, which manages over $90 billion, cited institutional conviction in TytoCare’s market position and demand for AI-enabled remote diagnostics. TytoCare, a remote physical-examination company with FDA-cleared devices and AI software-as-a-medical-device algorithms, is repositioning as an AI-first clinical-enablement platform for chronic and complex disease. Proceeds fund its AI algorithm pipeline, deeper payer and health-system partnerships, and go-to-market expansion into cardiometabolic, oncology and post-acute populations. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update July 13th, 2026

LECO_Weekly-Healthcare-News_7-13-2026Download

Healthcare Weekly News and Deals –July 13th, 2026

  1. American Industrial Partners agreed to acquire Avanos Medical (NYSE: AVNS) in an all-cash take-private valued at approximately $1.272 billion. American Industrial Partners (AIP), an operationally oriented investor with roughly $17.8 billion in assets, is acquiring Avanos Medical (NYSE: AVNS) for $25.00 per share in cash — a ~72% premium to Avanos’s pre-announcement close — valuing the medical-technology company at about $1.272 billion enterprise value. Having cleared regulatory review, the deal is expected to close by late July 2026 following a July 22 stockholder vote. Alpharetta, Georgia-based Avanos, focused on specialty nutrition and pain-management/recovery devices, will become privately held. AIP plans to leverage its operational playbook to support Avanos’s next phase of innovation and commercial execution. (Link)
  2. TCW Steel City (part of PNC Financial Services Group, NYSE: PNC), alongside co-lenders Brightwood, CIFC and CalSTRS, provided a $170 million recapitalization financing to Colorado-based Lone Peak Dental Group. TCW Steel City — the private-credit platform combining PNC Financial Services Group (NYSE: PNC) and TCW Private Credit — served as lead arranger and administrative agent on a $170 million recapitalization of Lone Peak Dental Group, a Dental Partnership Organization operating 75-plus offices across 14 states. The facility bundled a term loan, revolver and delayed-draw term loan structured to bankroll future acquisitions. Brightwood, CIFC and CalSTRS joined as additional lenders. The senior-secured package reflects private-credit appetite for scaled, mission-driven dental platforms pursuing both de novo and affiliation growth, giving Lone Peak flexible capital to expand pediatric dental access across its footprint. (Link)
  3. Surplus Solutions, a portfolio company of private equity firm NMS Capital, acquired Frederick, Maryland-based DCM BioServices to expand its laboratory-automation technical-service capabilities. NMS Capital, a private equity firm managing more than $2.0 billion across business and healthcare services, added to its Surplus Solutions platform with the acquisition of DCM BioServices, a Frederick, Maryland provider of lab-automation maintenance, repair and integration. Terms were undisclosed. The tuck-in extends Surplus Solutions’ equipment-lifecycle-management model into recurring preventive-maintenance contracts — a stream NMS partner David Peterson framed as a natural extension of existing customer relationships. DCM services 3,000-plus instruments across 200-plus labs nationwide, deepening the platform’s technical bench across leading instrument makers and reinforcing NMS’s buy-and-build thesis in life-sciences services. (Link)
  4. Orthopedic & Balance Therapy Specialists, a seven-clinic Northwest Indiana outpatient physical-therapy practice, was sold to an undisclosed national rehabilitation platform. Orthopedic & Balance Therapy Specialists (OBTS), a seven-location outpatient physical-therapy provider founded in 2003 in Northwest Indiana, completed a sale to an unnamed national rehabilitation platform. Both financial terms and the acquiring platform were left undisclosed. The transaction fits the broader private-equity-driven consolidation of outpatient rehab, where scaled platforms continue absorbing founder-owned, multi-clinic practices with strong payer relationships and regional density. OBTS’s shareholders sought a strategic partner to preserve clinical standards and culture while accessing platform resources for continued growth, positioning the practice to expand within its market under larger ownership. (Link)
  5. EQT (Nasdaq Stockholm: EQT), through its EQT X fund, agreed to acquire the Corza Biosurgery/TachoSil business from Corza Medical, which is backed by private equity firm GTCR. EQT (Nasdaq Stockholm: EQT) agreed to acquire Corza Biosurgery — built around TachoSil, a dual-action hemostat-and-sealant surgical patch — from GTCR-backed Corza Medical. Financial terms were undisclosed; closing is expected in Q4 2026. Investing through its EQT X fund, EQT plans to accelerate U.S. commercial and indication expansion, broaden adoption in underpenetrated markets, and build a wider biosurgery platform via add-on M&A. GTCR, which carved out TachoSil in 2021 and combined it with Surgical Specialties, exits the unit. TachoSil is used across cardiovascular, hepatic, neurological and thoracic procedures in more than 50 countries. (Link)
  6. Onto Health, a fertility and longevity platform backed by ARTIS Ventures and Humania, acquired U.S.-based clinical-decision-support company LEVY Health. Onto Health — a physician-led fertility and longevity provider backed by ARTIS Ventures and Humania — acquired LEVY Health, a U.S. clinical-decision-support software company for reproductive medicine. Terms were undisclosed. The purchase follows Onto’s roughly $20 million Series A and provides the technological backbone for a scalable, tech-enabled fertility-care infrastructure spanning the United States and the Gulf Cooperation Council region. LEVY’s diagnostics help clinics identify endocrine disorders and streamline fertility workups, letting practices fold low-complexity fertility care into existing models. The deal signals investor appetite for AI-enabled infrastructure plays in the multi-billion-dollar global fertility-services market. (Link)
  7. ResMed (NYSE: RMD) agreed to sell its MatrixCare software business to private equity firm Frazier Healthcare Partners for $490 million in cash. ResMed (NYSE: RMD) agreed to divest its MatrixCare post-acute-care software unit to Frazier Healthcare Partners, a healthcare-focused private equity firm, in a $490 million all-cash deal expected to close in the first quarter of ResMed’s fiscal 2027. ResMed, which paid $750 million for MatrixCare in 2018, will redeploy proceeds toward shareholder returns via an accelerated share repurchase while sharpening its sleep-and-breathing focus. MatrixCare — serving 15,000-plus skilled-nursing, senior-living and home-health providers — generated roughly $220 million revenue and $55 million adjusted operating profit in fiscal 2026. Frazier, which has raised over $11 billion, gains a scaled long-term-care software platform. (Link)
  8. Steel Partners Holdings (NYSE: SPLP), a shareholder of InMode (NASDAQ: INMD), offered to acquire the medical-aesthetics company for $16.75 per share in cash, topping a competing CEO-led bid. Steel Partners Holdings (NYSE: SPLP), which owns roughly 1.3% of InMode (NASDAQ: INMD), launched an unsolicited $16.75-per-share all-cash offer for the Israeli medical-aesthetics maker — a 20% premium to the $13.95 unaffected price and $0.55 above a rival buyout led by CEO Moshe Mizrahy. Steel argued the CEO’s $16.20 bid undervalued InMode using a low 2026 EBITDA estimate, demanded Mizrahy’s removal over governance conflicts, and urged the board to form an independent committee. Steel also offered existing holders the option to roll up to 40% of their equity into the privatized company, intensifying the contested sale process. (Link)
  9. Emergency Care Partners — backed by private equity firms Varsity Healthcare Partners, MidOcean Partners and Regal Healthcare Capital Partners — partnered with Phoenix-based Empower Emergency Physicians. Emergency Care Partners (ECP), the largest single-specialty emergency-medicine physician-services provider in the U.S. and backed by Varsity Healthcare Partners, MidOcean Partners and Regal Healthcare Capital Partners, formed a strategic partnership with Empower Emergency Physicians, a Phoenix independent group serving Dignity Health’s St. Joseph’s hospitals. Terms were undisclosed. The deal extends Pensacola-based ECP’s Southwest footprint to more than 1.7 million annual patient encounters across ten states while preserving Empower’s physician-led model. It reflects the sponsors’ buy-and-build strategy of consolidating physician-owned groups under ECP’s infrastructure, building on MidOcean’s 2025 preferred-equity investment that funds continued acquisitions. (Link)
  10. Incline Equity Partners acquired a majority stake in medical and health physics testing provider West Physics from LNC Partners, which retains a minority interest. Incline Equity Partners acquired a majority equity interest in Atlanta-based West Physics, a provider of medical and health physics testing and consulting that certifies MRI, CT and X-ray equipment against ACR, IAC and Joint Commission standards across 6,000-plus client sites in all 50 states and abroad. Terms were undisclosed. Seller LNC Partners — which first invested in May 2018 and grew revenue more than 3.7x over seven years through organic expansion and six add-on acquisitions — rolls over a minority position alongside Incline. Founder-CEO Dr. Geoffrey West continues to lead, with both sponsors backing further organic growth and M&A into adjacent services and geographies. (Link)
  11. Cygnet Group, backed by parent company Universal Health Services (NYSE: UHS), acquired Orchard Care Group in the Republic of Ireland. Cygnet Group — the UK mental-health and social-care provider owned by Universal Health Services (NYSE: UHS) — acquired Orchard Care Group, an integrated fostering, residential and disability-care provider in the Republic of Ireland. Terms were undisclosed. Orchard operates 39 residential and community homes plus two day services and employs over 550 people, with its executive team staying on. The deal marks Cygnet’s first residential-support expansion beyond the UK, extending UHS’s international social-care reach. It follows Cygnet’s recent run of UK acquisitions and hospital builds, signaling continued consolidation of specialist care assets under the publicly traded U.S. hospital operator. (Link)
  12. HCC Healthcare signed a business-combination agreement with SPAC RF Acquisition Corp III (Nasdaq: RFAM) to pursue a Nasdaq listing at a roughly $500 million equity value. Singapore-incorporated HCC Healthcare, which runs integrated medical and long-term-care services through Taiwan subsidiaries, agreed to merge with RF Acquisition Corp III (Nasdaq: RFAM), a publicly traded special-purpose acquisition company, to go public on Nasdaq. The deal reflects a pre-transaction equity value of approximately $500 million at $10.00 per share, with closing targeted for Q4 2026 subject to shareholder and regulatory approvals. On a pro forma basis, the combined Taiwan-focused network spans 120-plus long-term-care facilities and 9,000-plus beds. The SPAC route gives HCC public-market capital to scale its aging-population care model across Taiwan, Japan and Asia. (Link)
  13. Austin, Texas-based private equity firm CenterGate Capital invested in Canadian Dental Labs (CDL), Canada’s leading manufacturer of dental prosthetics and orthodontic appliances. CenterGate Capital, an Austin, Texas private equity firm, made a control investment in Canadian Dental Labs (CDL), the Toronto-headquartered platform that is Canada’s leading maker of dental prosthetics and orthodontic appliances. Terms were undisclosed. CDL — comprising labs including Shaw Lab Group, Protec Dental and Hallmark — serves 5,000-plus dental professionals and DSOs nationwide, with CEO Ali Rezaei continuing to lead. CenterGate backs the platform’s next growth phase, funding investment in people, technology and its coast-to-coast laboratory network. The deal underscores private equity’s appetite for scaled, technology-forward dental-lab consolidators with recurring, patient-specific manufacturing demand. (Link)
  14. ReFocus Eye Health, the management-services organization backed by Zenyth Partners, partnered with Connecticut’s 11-location Solinsky EyeCare. ReFocus Eye Health — a Northeast ophthalmology management-services organization backed by investment firm Zenyth Partners — affiliated with Solinsky EyeCare, an 11-location comprehensive ophthalmology and optometry practice serving Greater Hartford, Connecticut. Terms were undisclosed. Adding Solinsky’s 14 ophthalmologists and optometrists lifts ReFocus’s network to more than 250 affiliated physicians across 114 locations in nine states. The affiliation preserves physicians’ clinical autonomy while providing operational and administrative support, reflecting Zenyth-backed ReFocus’s continued regional roll-up strategy. The transaction adds to a wave of private-equity-sponsored consolidation in eye care as platforms pursue density in attractive Northeastern markets. (Link)
  15. CONMED Corporation (NYSE: CNMD) is weighing a potential sale after receiving takeover interest from unnamed private equity firms. CONMED Corporation (NYSE: CNMD), a surgical-device maker focused on orthopedic and general surgery, saw shares jump as much as 10% after Bloomberg reported the company is exploring strategic options following acquisition interest from private equity firms. No formal sale process has been confirmed and specific bidders have not been disclosed. CONMED, whose products include sports-medicine implants, electrosurgery systems and the AirSeal platform, has been sharpening its focus on higher-margin surgical segments after exiting gastroenterology lines. The reported interest highlights sustained private-equity appetite for scaled medtech assets, though any transaction remains speculative pending confirmation of a formal review. (Link)
  16. Clarivate Plc (NYSE: CLVT) agreed to sell its Life Sciences & Healthcare segment to healthcare-focused investment firm Altaris LLC for $600 million. Clarivate Plc (NYSE: CLVT) agreed to divest its Life Sciences & Healthcare segment to Altaris LLC, an investment firm focused exclusively on healthcare, for $600 million. Clarivate receives $500 million cash at closing plus $25 million deferred, using proceeds to cut debt and sharpen its subscription-first focus on Academia & Government and Intellectual Property. The company expects a $225–250 million non-cash goodwill impairment. For Altaris, the carve-out delivers a data-and-analytics platform supporting decision-making across the drug and device lifecycle. The transaction reflects the recurring theme of publicly traded information providers shedding non-core units to specialist private-equity buyers. (Link)
  17. Private equity firm Warburg Pincus, partnering with the Abu Dhabi Investment Authority, is nearing a $7 billion-plus acquisition of specialty pharmacy PANTHERx Rare from owners General Atlantic, Nautic Partners and The Vistria Group. Warburg Pincus, which manages over $100 billion, is in advanced talks to acquire Pittsburgh-based specialty pharmacy PANTHERx Rare for more than $7 billion including debt, partnering with sovereign-wealth fund the Abu Dhabi Investment Authority. PANTHERx, focused on rare and orphan-disease medicines and patient support, is owned by a consortium of General Atlantic, Nautic Partners and The Vistria Group, which bought it from Centene in 2022. Nothing is finalized and timing could slip. The deal reflects private equity’s bet on recession-resistant, high-margin orphan-drug demand and the growing pattern of buyout firms pairing with sovereign-wealth capital on large checks. (Link)
  18. Halma plc (LSE: HLMA) acquired Summit Partners-backed Dreampath Diagnostics for an initial €154 million plus an earn-out of up to €121 million. UK-listed Halma plc (LSE: HLMA) acquired Dreampath Diagnostics, a Strasbourg-based provider of automated tissue-sample management systems for pathology labs, from growth-equity firm Summit Partners. Halma is paying an initial €154 million (about $132 million) in cash, with a performance-based earn-out of up to €121 million through 2028. Summit, which made an undisclosed growth investment in 2025, exits after helping Dreampath scale to 300-plus million samples across 500-plus labs in 50 countries. Dreampath — forecasting roughly €33 million revenue for the year to March 2027 — will run standalone within Halma’s Healthcare Sector, strengthening its diagnostics traceability capabilities. (Link)
  19. Spero Health — backed by Heritage Group, Health Velocity Capital, South Central Inc. and Frist Cressey Ventures — acquired CleanSlate Centers, backed by Granite Growth Health Partners, HealthQuest Capital and CRG. Spero Health, a Nashville-area outpatient addiction-treatment provider owned by Heritage Group, Health Velocity Capital, South Central Inc. and Frist Cressey Ventures, acquired multi-state opioid-treatment operator CleanSlate Centers — backed by Granite Growth Health Partners, HealthQuest Capital and CRG — in a deal that closed July 1 and averts CleanSlate’s shutdown. Spero assumed CleanSlate’s equity interests in exchange for taking on its debt and deal costs; terms were undisclosed. The combination roughly doubles Spero’s footprint to 128 locations across ten states, with heavy overlap in Ohio, Indiana and Kentucky, reflecting Spero’s thesis that consolidation strengthens payer leverage. (Link)
  20. Private equity firm Enhanced Healthcare Partners made a growth investment in LeadingReach, healthcare’s largest connected referral network. Enhanced Healthcare Partners (EHP), a healthcare-focused private equity firm, made a growth investment in Austin-based LeadingReach, operator of healthcare’s largest verified referral network spanning 30,000-plus organizations, 60,000-plus care settings and 125,000-plus providers processing 25,000 daily referrals. Terms were undisclosed. EHP adds experienced healthcare operators to LeadingReach’s board and provides resources to accelerate AI-powered automation, deeper EHR integrations and expanded network infrastructure following the company’s recent acquisition of iNaira Healthcare Technologies. The investment reflects EHP’s focus on founder-led health-IT platforms positioned to benefit from the industry’s shift toward value-based care and referral coordination. (Link)
  21. Shore Capital Partners, a healthcare-focused private equity firm, acquired Denver-based employee-benefits technology platform ThrivePass. Shore Capital Partners, a Chicago-based private equity firm with roughly $17 billion in assets, acquired ThrivePass, a Denver employee-benefits administration technology platform founded by Wade Rosen, Andreas Deptolla and Charles Shen. Terms were undisclosed. The investment funds continued development of ThrivePass’s configurable platform — spanning lifestyle spending accounts, rewards, tuition reimbursement, COBRA and pre-tax benefits for employers, brokers and PEOs. Shore brings healthcare-focused operational resources and a consolidation playbook to scale the business as demand grows for digital-first benefits tools. The deal extends Shore’s health-tech portfolio, targeting a lower-middle-market platform with organic and acquisition-driven growth potential. (Link)
  22. Integrity, LLC acquired Stride Health, the portable-benefits technology platform powering gig-economy insurance enrollment for partners including Uber, DoorDash and Amazon Flex. Dallas-based insurance distributor Integrity, LLC acquired Stride Health, a San Francisco portable-benefits technology platform that helps independent and gig workers enroll in health, dental, vision and life coverage. Terms were undisclosed. Stride — founded in 2014 and previously Allstate-backed — connects 4.6 million-plus workers and 140-plus enterprise partners including Uber, DoorDash, Gusto and Amazon Flex. Integrity folds Stride’s consumer marketplace into its IntegrityCONNECT agent platform and roughly 600,000-strong agent network, expanding into the under-65 individual market where tens of millions lack employer coverage. The deal pairs digital enrollment with agent-assisted distribution as worker-misclassification rules reshape portable-benefits demand. (Link)
  23. Principal Financial Group (Nasdaq: PFG) agreed to acquire digitally-native ancillary employee-benefits company Beam Benefits to expand its small-business protection platform. Principal Financial Group (Nasdaq: PFG) agreed to acquire Beam Benefits, a cloud-native ancillary employee-benefits company serving over 25,000 small businesses with dental, vision, life, disability and supplemental health coverage. Terms were undisclosed. Beam — built on an AI-powered underwriting and self-service technology stack and available in 46 states plus D.C. — generated roughly $175 million in premiums in 2025. Principal, which serves 180,000 employers, expects the deal to close in the latter half of 2026 and to lift Specialty Benefits premium and fee growth to at or above the high end of its 5–9% medium-term target in 2027. The digital-first model adds scalable capabilities to Principal’s SMB strategy. (Link)

Venture Deals and Other

  1. Valspring Capital led a $28 million Series B in Pediatrica Health Group, with participation from existing investor M33 Growth. Pediatrica Health Group, a Miami-based multi-site pediatric primary-care organization, closed a $28 million Series B led by Boston growth-equity firm Valspring Capital, with existing backer M33 Growth participating. The capital funds organic growth and strategic acquisitions plus investment in clinical infrastructure, technology and value-based-care capabilities. Pediatrica — founded through its partnership with M33 — has scaled to 21 locations across Florida and Texas. Valspring, formed by Bain Capital Ventures’ former healthcare team, cited its thesis that lasting healthcare change comes from companies innovating on patient and provider experience. The round backs continued expansion of equitable pediatric primary-care access. (Link)
  2. RPS Ventures led a $19 million Series B in Handspring Health, with new investor Angelini Ventures joining returning backers Cobalt Ventures, NextView Ventures, nvp capital, Hyde Park Angels and Cornucopian Capital. Handspring Health, a virtual youth mental-health provider, raised a $19 million Series B led by RPS Ventures, with new investor Angelini Ventures joining returning backers Cobalt Ventures, NextView Ventures, nvp capital, Hyde Park Angels and Cornucopian Capital. The round — lifting total funding to $37 million — funds clinician hiring, deeper value-based-care partnerships with payers, broader geographic reach and technology investment. Handspring, which employs rather than contracts its therapists and trains them in-house in evidence-based modalities, has treated 4,000-plus patients across nine states and grown revenue more than tenfold in two years. RPS’s Nancy Hilliker joins the board. (Link)
  3. Surface Ventures led a $3 million seed round in Octozi, with participation from Remarkable Ventures and following a prior investment from Debiopharm’s venture arm. Octozi, a New York agentic-AI company automating clinical-trial data operations for pharmaceutical sponsors, raised $3 million in seed funding led by Surface Ventures, with Remarkable Ventures participating and building on an earlier stake from Swiss pharma Debiopharm’s venture arm. The capital expands Octozi’s human-in-the-loop platform, which integrates with clinical systems to automate data cleaning, reconciliation, review and reporting. A peer-reviewed study found the tool boosted data-cleaning throughput roughly sixfold and cut reviewer error rates from about 55% to 8%, with estimated savings above $5 million per Phase III oncology trial. Surface Ventures’ Gyan Kapur framed the bet on compressing drug-development timelines. (Link)
  4. Andreessen Horowitz led a $50 million equity round for Pearl Health, joined by Viking Global Investors, AlleyCorp and Ulysses Capital, alongside a $60 million debt facility led by Trinity Capital (NASDAQ: TRIN). Pearl Health, a New York health-technology company enabling providers to manage risk for Medicare patients, raised $110 million — a $50 million equity round led by Andreessen Horowitz with Viking Global Investors, AlleyCorp and Ulysses Capital, plus a $60 million debt facility led by Trinity Capital (NASDAQ: TRIN). The capital funds AI-platform expansion, new risk products, Medicare Advantage entry and enterprise health-system and payer partnerships. Pearl — profitable in 2025 — supports 10,000-plus providers across 40-plus states serving 250,000-plus beneficiaries and manages roughly $3.6 billion in annualized medical spend. a16z’s Vineeta Agarwala praised Pearl’s technology-led approach to value-based payment. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Jul 6th, 2026

LECO_Weekly-Healthcare-News_7-6-2026Download

Healthcare Weekly News and Deals –July 6th, 2026

  1. Select Medical Holdings Corporation (formerly NYSE: SEM) has completed a $3.9 billion management buyout led by Executive Chairman Robert A. Ortenzio, Senior EVP Martin F. Jackson, and private equity firm Welsh, Carson, Anderson & Stowe. Select Medical (NYSE: SEM) completed its acquisition by a consortium led by Executive Chairman Robert A. Ortenzio, Senior EVP Martin F. Jackson, and private equity firm Welsh, Carson, Anderson & Stowe at $16.50 per share, valuing the healthcare operator at approximately $3.9 billion. The price represents an 18% premium over SEM’s unaffected price as of November 24, 2025, and a 25% premium to the 90-day VWAP. WCAS, founded in 1979, focuses on healthcare and technology and has managed more than $33 billion in committed capital. The insider-led structure lets management pursue a concentrated rehabilitation strategy free of quarterly earnings pressure; SEM was delisted from the NYSE on July 1, 2026. (Link)
  2. Blue Owl Capital Inc. (NYSE: OWL) has completed the acquisition of Sila Realty Trust, Inc. (formerly NYSE: SILA) in an all-cash transaction valued at approximately $2.4 billion to expand its Real Assets platform. Blue Owl Capital (NYSE: OWL) announced its managed funds completed the acquisition of Sila Realty Trust, a net lease REIT focused on healthcare properties. The all-cash deal was valued at approximately $2.4 billion at $30.38 per share, a 19% premium to Sila’s April 17, 2026 close and a 25.6% premium to the 30-day VWAP. Sila stockholders approved the merger with more than 98% of votes cast in favor, and the stock was delisted. For Blue Owl (NYSE: OWL), which manages $315 billion in assets, the acquisition adds Sila’s 137 healthcare properties across 65 markets, deepening exposure to durable, essential real estate. (Link)
  3. BridgeBio Pharma, Inc. (NASD: BBIO) has raised up to $1 billion in convertible preferred equity led by Sixth Street with participation from HealthCare Royalty, a business of KKR (NYSE: KKR). BridgeBio Pharma (NASD: BBIO) entered an agreement with funds managed by Sixth Street and funds managed by HealthCare Royalty, a business of KKR (NYSE: KKR), to invest up to $1 billion in newly issued convertible preferred equity. Sixth Street funded $800 million as lead investor, with HealthCare Royalty funding $133.9 million at closing. The terms favor BridgeBio: a 7.00% initial dividend payable in kind or cash, an initial conversion price of $137.79 (over a 100% premium to the 30-day VWAP), stepping to $153.10 after year five, with permanent equity and no holder redemption. The capital funds Attruby’s growth and three planned launches. (Link)
  4. PACS Group, Inc. (NYSE: PACS) has agreed to acquire the operations of 34 skilled nursing facilities across six western states from Eduro Healthcare to broaden its post-acute platform. PACS Group (NYSE: PACS) entered a definitive agreement to acquire the operations of 34 skilled nursing facilities across six western states from Eduro Healthcare, a family-owned operator with nearly 20 years of history. The operations span Texas (22), Montana (six), South Dakota (three), and one each in New Mexico, North Dakota, and Utah, comprising 3,633 skilled nursing beds. The deal reflects PACS’s aggressive, acquisition-driven strategy that has propelled its market capitalization to $6.32 billion, though it also adds operational complexity and regulatory scrutiny that investors are weighing. CEO Jason Murray emphasized aligned operating models built on empowering local leadership. (Link)
  5. National HealthCare Corporation (NYSE American: NHC) has acquired 32 skilled nursing facilities and three independent living facilities from National Health Investors, Inc. (NYSE: NHI) for $560 million to convert leased assets into owned real estate. National HealthCare Corporation (NYSE American: NHC) completed the $560 million acquisition of 32 skilled nursing facilities and three independent living facilities from National Health Investors, Inc. and its affiliates, assets NHC had operated since a 1991 Master Lease. The strategic logic is ownership economics: management said the deal is expected to be accretive to earnings and cash flow, and CEO Steve Flatt framed owning versus leasing as yielding stronger long-term investor returns. NHC (NYSE American: NHC) shares have surged over 101% in the past year, trading near a 52-week high, with 12 consecutive years of dividend increases. The seven-state portfolio deepens NHC’s owned footprint across the Southeast. (Link)
  6. United Therapeutics Corporation (NASD: UTHR) has acquired Thymmune Therapeutics, Inc. for $140 million in cash plus up to $160 million in milestones to expand its regenerative medicine pipeline. United Therapeutics (NASD: UTHR) acquired preclinical biotech Thymmune Therapeutics, paying $140 million in cash subject to post-closing adjustments, with former equityholders eligible for up to $160 million in earn-outs tied to clinical and regulatory milestones through 2031. The structure ties the bulk of upside to performance, limiting UTHR’s downside on an early-stage asset. United Therapeutics reported $1.28 billion in cash as of March 31, 2026, comfortably funding the deal. Strategically, the acquisition strengthens UTHR’s regenerative medicine portfolio and supports its long-term strategy to expand transplantable organ supply, complementing its UThymoKidney program and adding lead candidate THY-100 for congenital athymia. (Link)
  7. GTCR-backed Experity has acquired Exdion Healthcare to accelerate AI-driven revenue cycle management automation for on-demand care. Experity, the on-demand healthcare technology platform used by nearly half of all U.S. urgent care clinics, acquired Exdion Healthcare, an AI-driven SaaS company specializing in the patient chart-to-cash lifecycle. The deal reflects sponsor GTCR’s vertical-integration playbook: Experity is backed by GTCR, a Chicago private equity firm, whose urgent-care strategy has been to own the EMR, practice management, billing, and analytics layers. GTCR Principal Radu Cret said the combination reflects the firm’s Leaders Strategy, scaling differentiated AI capabilities into a unified platform. Founded in 1980, GTCR has invested more than $35 billion in over 300 companies and manages approximately $45 billion in equity capital. Exdion’s insurance-focused affiliate was excluded. (Link)
  8. U.S. Physical Therapy, Inc. (NYSE: USPH) Acquires 12-Clinic Physical Therapy Practice in New State Expansion. U.S. Physical Therapy, Inc. (NYSE: USPH) announced the acquisition of a 12-clinic physical therapy practice effective July 1, 2026, acquiring a 67% equity interest (sellers retain 33%). The practice generates ~112,000 annual visits and $12 million in revenue, expanding USPH’s footprint to 45 states. The add-on aligns with USPH’s growth strategy of partnering with high-quality local operators while leveraging national scale in outpatient PT and industrial injury prevention. COO-West Graham Reeve highlighted alignment in clinical excellence and community relationships. This continues USPH’s disciplined M&A approach in a fragmented market. (Link)
  9. An affiliate of Peak Rock Capital has completed the acquisition of Asembia LLC from the Irene family to expand its healthcare portfolio through technology investment and add-on acquisitions. An affiliate of Peak Rock Capital, a middle-market private investment firm, completed the acquisition of Asembia LLC and its related entities, a specialty-pharma commercialization platform offering HUB services, specialty distribution, data services, pharmacy software, and GPO solutions. Peak Rock makes investments in the range of $50 million to $1.5 billion. The thesis is founder-partnership plus buy-and-build: Managing Director Spencer Moore said Peak Rock will invest in technology, capabilities, and marketing while pursuing complementary acquisitions to support accelerated growth. CEO Anthony DiSimone framed the deal as demonstrating Peak Rock’s commitment to founder-owned businesses with strong growth potential in resilient, technology-enabled healthcare. (Link)
  10. Gainline Capital Partners’ portfolio company M&M International has acquired KC Tech to expand its medical-grade tubing manufacturing capabilities. Gainline Capital Partners announced that its portfolio company M&M International, a manufacturer of precision-engineered stainless-steel tubing serving the medical device market, acquired KC Tech, a fellow manufacturer also focused on that market. This is a classic private-equity add-on: Gainline acquired M&M in July 2024 and installed a U.S.-based management team to support growth through organic expansion and strategic acquisitions. Gainline partner Rob Dellinger said the buy-and-build plan was in place from the outset, with KC Tech the next step. Gainline invests in U.S.-based middle-market companies, prioritizing first-institutional-capital partnerships; financial terms were not disclosed. The deal adds larger-diameter tubing to M&M’s portfolio. (Link)
  11. Martis Capital Management has acquired a majority stake in Deerfield Group from Edgewater Funds, with founders and management retaining significant ownership, to expand its healthcare marketing platform. Martis Capital Management, a middle-market healthcare private equity firm, acquired a majority equity stake in Deerfield Group, a marketing, communications, and media partner for healthcare and life sciences. Financial terms were not disclosed, and Deerfield’s founders and management team retain significant ownership. The deal marks a transition from prior investor Edgewater Funds, during which Deerfield grew revenue more than 30 percent annually since 2017. Managing Partner Mario Moreno cited Deerfield’s differentiated platform at the intersection of healthcare marketing, media, and technology. Since 2011, Martis has raised more than $2.2 billion from institutional clients for North American middle-market healthcare. (Link)
  12. Momentum Life Sciences has received a strategic growth investment from Parthenon Capital to accelerate its specialty-therapy commercialization platform and fund acquisitions. Momentum Life Sciences, a commercialization platform offering patient- and provider-facing solutions for specialty therapy initiation and adherence, announced a strategic investment from Parthenon Capital, a growth-oriented private equity firm. Financial terms were not disclosed, and Momentum’s existing leadership team will continue as significant shareholders. The structure is a management-aligned growth recapitalization: the capital will accelerate Momentum’s growth strategy and fund strategic acquisitions. Parthenon Partner Dan Killeen cited therapy adoption and adherence as acute, underserved challenges and a compelling opportunity to expand across the commercialization ecosystem. Parthenon, with offices in Boston, San Francisco, and Austin, has particular expertise in healthcare and technology services. (Link)
  13. Cathay Capital has launched and invested in Ascendia Autism Care, with Gladstone Capital Corporation (NASD: GLAD) as a capital partner, to expand access to evidence-based ABA therapy. Cathay Capital launched Ascendia Autism Care, a platform expanding access to evidence-based Applied Behavior Analysis therapy, beginning with a founding affiliate operating 20 centers across eight states. Cathay’s investment is sized to fund both the founding transaction and substantial growth capital, though financial terms were not disclosed. Crucially, Gladstone Capital Corporation (NASD: GLAD) was a capital partner in the transaction. The thesis targets an acute supply-demand gap; Cathay VP Jackson Catalano cited significant unmet need and the benefits of early intervention. Cathay Capital, founded in 2007, now manages more than $5.5 billion in assets, and plans de novo expansion plus school-based channels over 24 months. (Link)
  14. OpenLoop has acquired Y Combinator-backed Hey Revia, founded by Shaun Wei and David Zhu, to expand its AI-powered telehealth communications infrastructure. OpenLoop, an Iowa-based infrastructure telehealth platform, acquired Hey Revia, a Y Combinator-backed AI voice and communication platform automates healthcare operations such as insurance verification, prior authorizations, and pharmacy coordination. OpenLoop will integrate Hey Revia’s offerings into Launchpad, its self-serve platform for launching branded telehealth services, compressing client onboarding. Cofounders Shaun Wei and David Zhu join OpenLoop as EVP of engineering and senior director of engineering, respectively. The transaction extends OpenLoop’s acquisitive push following its earlier purchase of food-as-medicine platform Season Health. (Link)
  15. INVO Fertility, Inc. (NASD: IVF) has acquired the remaining stake in HRCFG from Karen Hammond, Lisa Ray, and Nicholas Cataldo for $175,001 to take full control of its Birmingham, Alabama fertility clinic. INVO Fertility (NASD: IVF) entered a Membership Interest Transfer Agreement to acquire 100% of HRCFG, gaining full control of its Birmingham, Alabama fertility clinic. The structuring is highly deferred and cash-flow-funded: the $175,001 consideration includes $1 at closing, $48,000 paid pro rata in equal monthly installments over nine months starting October 2026, and $127,000 drawn from HRCFG’s own free cash flow. For INVO (NASD: IVF), the appeal is consolidation—the company will consolidate the Alabama clinic’s results prospectively—converting a partial interest into a wholly owned revenue stream with minimal upfront capital outlay. Sellers will provide transition services for about four months and support for 12 months thereafter. (Link)
  16. Clarivate Plc (NYSE: CLVT) has announced the sale of its Life Sciences & Healthcare segment for $600 million to reduce leverage and refocus on its Academia & Government and Intellectual Property markets. Clarivate Plc (NYSE: CLVT) announced it has agreed to sell its Life Sciences & Healthcare segment for $600 million. The divestiture caps a process launched in February 2026, when Clarivate said a sale would allow further emphasis on its Academia & Government and Intellectual Property markets and that proceeds would strengthen its balance sheet through reduced leverage. The strategic driver is debt: Clarivate carries roughly $4.6 billion in long-term debt at a net leverage ratio of 7.7x trailing EBITDA, and the segment generated $389.8 million in 2025 revenue, its smallest at about 16% of the total. The acquirer was not identified in the sources available at the time of writing. (Link)
  17. Klick Health, backed by Linden Capital Partners and GIC, has acquired Oxford PharmaGenesis to expand its scientific-to-commercial capabilities for life sciences clients. Klick Health struck its third takeover in 18 months, acquiring UK-based Oxford PharmaGenesis to expand global reach and deepen scientific expertise. The deal follows a capital-backed roll-up strategy: months after acquiring Ward6’s Singapore operations, Klick received growth investment from Linden Capital Partners and GIC to accelerate expansion, and one year later made Oxford PharmaGenesis its biggest acquisition yet. The rationale is capability convergence—deepening Klick’s scientific expertise while expanding real-world evidence and health economics and outcomes research capabilities—positioning the combined firm against other private-equity-backed groups scaling in life sciences communications. Financial terms were not disclosed. (Link)
  18. Pacira BioSciences (NASD: PCRX) Agrees to Divest iovera° Business to Zimmer Biomet for Up to $140 Million. Pacira BioSciences, Inc. (NASD: PCRX) has agreed to divest its iovera° cryoneurolysis business to Zimmer Biomet Holdings, Inc. (NYSE: ZBH) for up to $140 million, including $70 million upfront and up to $70 million in revenue-based milestones through 2031. The move supports Pacira’s 5×30 strategy and transition to a pure-play innovative biopharmaceutical company focused on non-opioid pain therapies. Zimmer Biomet, a global medical technology leader, gains a complementary drug-free pain management device with established adoption and spasticity program upside. The transaction includes a transition services agreement and is expected to close in Q3 2026. (Link)
  19. ClearOne (NASD: CLRO) Enters Merger Agreement with Vivani Subsidiary Cortigent to Create Neurostimulation Public Platform ClearOne, Inc. (NASD: CLRO) has entered a definitive merger agreement with Cortigent, Inc., a wholly-owned subsidiary of Vivani Medical, Inc. (NASD: VANI). The deal includes a concurrent $10–15 million financing. Upon closing, the combined entity will operate as Cortigent Holdings, Inc. (expected ticker: CRGT), with Vivani owning a majority stake. Cortigent is developing precision neurostimulation implants (including the Orion cortical system with FDA Breakthrough Device Designation) for vision restoration and stroke recovery. The transaction provides Cortigent a public listing and growth capital while positioning the combined company in the high-potential neurotechnology space. Expected close in Q3 2026. (Link)
  20. Corten Capital has acquired Beacon Intelligence from the Hanson Wade Group, with Ampersand Capital Partners investing as a minority co-investor, to accelerate life sciences R&D intelligence. Corten Capital completed its acquisition of Beacon Intelligence from the Hanson Wade Group, with Ampersand Capital Partners investing alongside Corten as a minority co-investor, establishing Beacon as a fully independent company. The strategic aim is scale for a proprietary data platform: the investment gives Beacon resources to deepen coverage, expand into new therapeutic areas, and accelerate product features. Beacon is the third investment from Corten Capital II, which closed in March 2024 with €680 million in capital commitments, and Corten is partnering with management led by CEO Rob Poolman and Chair Sati S. Sian. David Anderson, General Partner at Ampersand, will join the board. (Link)
  21. Prestige Consumer Healthcare Inc. (NYSE: PBH) Completes Acquisition of LaCorium Health and Prices $400 Million Senior Notes Offering. Prestige Consumer Healthcare Inc. (NYSE: PBH) has closed its previously announced acquisition of LaCorium Health, an Australian leader in therapeutic skincare products (Dermal Therapy®, Flexitol®, and Crampeze® brands) for approximately $150 million in cash. LaCorium generates ~$40 million in annual revenue and is expected to contribute ~$12 million in EBITDA post-synergies, with strong growth potential through category expansion and geographic reach. The deal was financed with cash on hand and existing credit facilities. Concurrently, Prestige priced a $400 million senior notes offering (6.25% due 2034) to refinance existing debt. The transaction bolsters Prestige’s international consumer healthcare portfolio. (Link)
  22. Byggmästare Anders J Ahlström Holding AB (Nasdaq Stockholm: AJA B) reported that its portfolio company Safe Life completed four acquisitions during Q2 2026, adding roughly €20 million in annual revenue. Byggmästare Anders J Ahlström Holding’s largest portfolio company, Safe Life, added approximately €20 million in annual revenue through four acquisitions in Q2 2026, enhancing its buy-and-build strategy. The acquisitions broaden Safe Life’s presence in Europe and North America and align with its shift toward recurring, subscription-based revenue. For the listed investor Byggmästaren (Nasdaq Stockholm: AJA B), the value creation is concentrated: it owns roughly 12% of Safe Life, which represents about 34% of reported NAV. With €15 million acquired in Q1 and €20 million in Q2, Safe Life added ~€35 million of acquired revenue in H1—covering 80–115% of the assumed annual pace in the analyst valuation framework. (Link)

Venture Deals and Other

  1. Flare Therapeutics Inc. has secured $85 million in an insider-led Series C financing led by Third Rock Ventures and Nextech Invest, with participation from Pfizer Ventures, Eli Lilly, Novartis, and others. Flare Therapeutics, a clinical-stage biotech targeting transcription factors, closed an $85 million Series C led by existing investors. The round was led by Third Rock Ventures and Nextech Invest and included Pfizer Ventures, Boxer Capital, GordonMD Global Investments, Invus, Casdin Capital, Eli Lilly and Company, Novartis, Agent Capital, and Eventide Asset Management. The insider-led composition signals conviction from a syndicate that includes strategic pharma investors. Proceeds will advance Flare’s ARON degrader FX-111 to proof of concept and fund preclinical development of the ARON RIPTAC program, alongside the appointment of veteran executive Anna Protopapas as CEO to steer its prostate-cancer focus. (Link)
  2. Integral Privacy Technologies has raised $25 million in total funding from backers including Caffeinated Capital, GreatPoint Ventures, Array Ventures, LiveRamp Ventures, Haystack, and Venrex. Integral Privacy Technologies, a San Francisco-based developer of automated data privacy engineering and decentralized telemetry protection software, raised $25 million in total funding. Backers included Venrex, The General Partnership, Array Ventures, GreatPoint Ventures, LiveRamp Ventures, Haystack, Virtue Ventures, Also Capital, Caffeinated Capital, LifeX Ventures, Circle & Co, and WS Investments. The broad syndicate reflects investor appetite for privacy infrastructure tied to AI development. The company intends to use the funds to expand its privacy engineering and statistical methodology divisions, invest in continuous risk-assessment linkage infrastructure, and accelerate go-to-market operations across global AI development labs. Integral spent four years validating peer-reviewed disclosure methodologies across healthcare and life sciences. (Link)
  3. Pictor Holdings Inc. has secured a $7.5 million bridge round from existing investors to accelerate commercialization of its targeted proteomic platform. Pictor Holdings, a Carlsbad, California-based targeted proteomic platform company, closed a $7.5 million bridge round of growth capital supported by existing investors. The financing brings Pictor’s total capital raised to approximately $30 million and will fund expanded commercial partnerships, platform and manufacturing scale-up, and translational studies across human and animal health markets. The insider-only backing signals continuity of conviction ahead of a larger raise; as CFO Tim Shannon noted, existing-investor support reflects confidence in the platform and commercial model as the company advances toward a Series A. Pictor has launched seven commercial products and secured four strategic partnerships in its first U.S. year. (Link)
  4. Upside Lands $20M Series A to Solve the U.S. Housing Crisis for Healthcare. Upside, a housing stability platform purpose-built for healthcare, closed a $20 million Series A co-led by Aquiline and Flare Capital Partners with participation from 645 Ventures, Freestyle Capital, Triple Impact Capital, and Techstars. The company addresses housing instability—a major driver of healthcare costs—by pairing dedicated Care Guides with AI-supported housing orchestration and a proprietary affordable housing database. Operating across 10 states with partnerships including four of the largest national payers, Upside has achieved 90%+ enrollment, stabilization for more than half of members within 90 days, and up to 4x ROI within 12 months. Proceeds will support expansion across Medicaid, Medicare Advantage, and employer-sponsored markets. (Link)
  5. Lycia Therapeutics Raises $75 Million in Oversubscribed Series D Financing and Strengthens Leadership Team. Lycia Therapeutics, Inc., a clinical-stage biotechnology company developing LYTAC and cataLYTAC degraders targeting extracellular proteins for autoimmune, inflammatory, and allergic diseases, closed an oversubscribed $75 million Series D. The round was co-led by Janus Henderson Investors and Balyasny Asset Management with participation from Adage Capital Management, HBM Healthcare Investments, OrbiMed, and continued support from existing investors including Eli Lilly, Franklin Templeton, Invus, RTW Investments, and Venrock. Proceeds will advance lead programs LCA-0061 (IgE degrader for food allergy) and LCA-0321 (for Graves’ disease) toward early clinical proof-of-concept. The company also appointed Amy Bachrodt as Chief Financial Officer and promoted Karen Flick to General Counsel. (Link)
  6. Anodyne Nanotech Closes $12.6 Million Series A to Advance Once-Weekly GLP-1 Patch into Phase I Clinical Trials. Anodyne Nanotech Inc., a clinical-stage biotechnology company developing transdermal delivery of large molecules via its HeroPatch microneedle platform, closed a $12.6 million Series A led by Velocity Partners VC and co-led by Evercurious VC, with participation from Relativity Healthcare Partners. Proceeds will advance ANN-101, a once-weekly GLP-1 patch for obesity, into Phase I trials, support manufacturing scale-up, and expand the platform for peptides, antibodies, and nucleic acids. The company is also developing combination patches (e.g., apelin/GLP-1) to address lean mass loss associated with GLP-1 therapies. New board member Vikram Lamba (ex-Zosano Pharma, Bayer) joined as part of the round. (Link)
  7. Ladder Health Raises $7 Million Seed to Address Pediatric Therapy Waitlist Crisis. Ladder Health, a virtual-first pediatric developmental care company, closed an oversubscribed $7 million Seed round led by Nina Capital with participation from Mairs & Power Venture Capital, South Dakota First Capital, 25madison Health, Hatteras Venture Partners, Create Health Ventures, Jumpstart Capital, and others. The company delivers speech, occupational, physical, and feeding therapy through an AI-enabled platform that activates caregivers and extends care into the home. Ladder partners with health systems and pediatric practices to reduce wait times from months to days, currently operating in Massachusetts, North Carolina, and Maryland with plans for further expansion. The funding will support geographic growth and platform development. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Jun 29th, 2026

LECO_Weekly-Healthcare-News_6-29-2026Download
  1. The Doctors Company, the nation’s largest physician-owned medical malpractice insurer and parent of TDC Group, has completed its $1.3 billion all-cash acquisition of specialty insurer ProAssurance Corporation (NYSE: PRA) at $25.00 per share, creating a combined platform protecting more than 200,000 healthcare professionals nationwide. Napa, California-based The Doctors Company finalized its $1.3 billion buyout of ProAssurance (NYSE: PRA), acquiring all outstanding shares at $25.00 per share in cash — a transaction that ProAssurance shareholders had approved in June 2025. With the deal closed, PRA’s common stock has been delisted from the NYSE and deregistered with the SEC. The combined entity, operating under TDC Group, now holds $12 billion in assets and more than $2.5 billion in direct written premium, pairing The Doctors Company’s medical malpractice franchise with ProAssurance’s specialty lines spanning medical liability, medical technology and life sciences products liability, and workers’ compensation. ProAssurance will operate as a wholly owned subsidiary while an optimal structural review is conducted. (Link)
  2. Merck KGaA Agrees to Acquire Bio-Techne Corporation (NASD: TECH) for $11.3 Billion in Cash at $73 Per Share — a 36% Premium to the One-Month VWAP — in Merck KGaA’s Largest Acquisition Since the $17 Billion Sigma-Aldrich Deal in 2014 Merck KGaA, Darmstadt, Germany, entered into a definitive agreement on June 25, 2026 to acquire Minneapolis-based Bio-Techne (Nasdaq: TECH), a global provider of life science tools including 6,000 recombinant proteins, 425,000 antibodies, ProteinSimple analytical instruments, and RNAscope spatial biology technologies, for $73 per share in cash — a total enterprise value of approximately $11.3 billion. The transaction will be funded through existing cash and new debt while preserving an investment-grade rating, with Merck KGaA expecting immediate EBITDA accretion and approximately €140 million in annual cost synergies by year three; the deal is expected to close in late 2026 or early 2027 pending Bio-Techne shareholder and regulatory approvals. (Link)
  3. PsychPlus, a Houston-based psychiatric and therapeutic care provider, has acquired multinational digital mental health platform Koa Health to form what the companies describe as the world’s largest technology-enabled mental health company. PsychPlus completed its acquisition of Koa Health in an all-strategic transaction whose value was not disclosed, positioning the combined platform to serve more than 6 million patients across the US, Europe, Australia, and Asia-Pacific. The deal pairs PsychPlus’s proprietary clinical technology network — scaled to over 200 US locations in five years — with Koa Health’s digital-first delivery model, 56 patents, and 23 peer-reviewed studies. Led by CEO Dr. Faisal Tai, PsychPlus is investing to build an integrated, multi-channel care continuum; Koa Health founder Dr. Oliver Harrison joins as President. The combination targets faster patient access and a scalable global mental-health blueprint. (Link)
  4. Strata Critical Medical, Inc. (Nasdaq: SRTA) has acquired the Heart and Lung Transplant National Recovery Program (HLT-NRP) for $21.5 million to expand its national organ recovery platform. Strata Critical Medical (Nasdaq: SRTA) completed its purchase of HLT-NRP at a mid-single-digit multiple of pre-synergy Adjusted EBITDA, structured as roughly 80% cash and 20% stock subject to a multi-year lockup tied to the seller’s continued involvement. HLT-NRP is expected to generate approximately $10.0 million in revenue and $3.1 million in Adjusted EBITDA for full-year 2026. Co-CEOs Will Heyburn and Melissa Tomkiel framed the deal as adding clinical depth and geographic reach in Florida and California, deepening its fastest-growing Transplant Clinical line. CFO Mat Schneider emphasized the acquisition fits Strata’s capital allocation framework, expecting growth and operational synergies to lower the effective purchase price over time. (Link)
  5. AMR Clinical Acquires ClinOhio Research Services, Adding a Columbus, Ohio Multi-Therapeutic Clinical Research Site Specializing in Women’s Health, Dermatology, and Family Practice to Its 30+ Site National Network Knoxville, Tennessee-based AMR Clinical, a Curewell Capital-backed integrated research site organization with more than 30 U.S. locations and over 8,000 completed trials across more than 145,000 enrolled participants, announced on June 29, 2026 the acquisition of ClinOhio Research Services, a Columbus, Ohio-based multi-therapeutic clinical research facility specializing in Women’s Health, Dermatology, and Family Practice. The addition expands AMR’s geographic footprint into the Columbus market — home to The Ohio State University Wexner Medical Center and one of the most active clinical research ecosystems in the Midwest — and deepens its therapeutic capabilities across its Phase I–IV trial platform. AMR has grown to 30+ sites through a combination of acquisitions and organic site launches under Curewell Capital’s ownership. (Link)
  6. CareRite Centers has acquired the Grand Rehabilitation and Nursing at Queens from a Grand Healthcare System–linked entity (Clearview Land LLC) for $58.2 million. New Jersey–based CareRite Centers, an elder care and rehabilitation provider, deployed $58.2 million to acquire a 179-bed facility plus an adjacent parking lot in Whitestone, Queens, in a transaction recorded June 24. The deal closed April 28 and was signed for the buyer by co-founder and principal Mark Friedman. The seller, Clearview Land LLC, appears tied to Grand Healthcare System CEO Jeremy Strauss, whose New York network spans roughly 12 skilled nursing and rehab centers. The purchase price sits far above the property’s 2022 city-assessed market value of $8.1 million, marking a substantial premium as CareRite expands its regional footprint beyond its existing Brooklyn and Manhattan facilities. (Link)
  7. TELEO Capital Management has acquired pharmaceutical manufacturing intelligence platform SmartFactory Rx — now rebranded Modersys — from semiconductor-equipment maker Applied Materials, Inc. (NASDAQ: AMAT) in a corporate carve-out. Boise-based private equity firm TELEO Capital Management acquired Modersys (formerly SmartFactory Rx) from Applied Materials, Inc. (NASDAQ: AMAT) for an undisclosed sum, executing the carve-out strategy central to its lower-middle-market playbook. TELEO, which targets technology, software, and healthcare IT, will operate Modersys as an independent company to accelerate AI-driven product innovation for biopharma and life-sciences manufacturers. (Link)
  8. Incline Equity Partners has partnered with West Physics to expand its medical and health physics testing platform. Pittsburgh-based private equity firm Incline Equity Partners, which targets the middle market with enterprise values of $25–$750 million, backed Atlanta-headquartered West Physics, a market leader in accreditation and testing services for MRI, CT and X-ray imaging equipment. Financial terms were not disclosed. Managing Director Nic Meiring signaled the investment thesis: pursuing expansion into adjacent service offerings and new geographies both organically and through strategic M&A within a highly fragmented industry. Founder and CEO Dr. Geoff West will continue leading the company, planning to accelerate organic growth by investing in the services support structure, in-house residency program and broader physicist network. (Link)
  9. Chicago Pacific Founders has made a strategic growth investment in Attune, the Chicago-based Agentic Engagement Platform for Healthcare, to scale AI-driven patient coordination across value-based care. Healthcare-focused private equity firm and operator Chicago Pacific Founders (CPF) made an undisclosed strategic growth investment in Attune, an AI-powered patient-engagement platform. CPF — which manages more than 3 million lives across its value-based care network and invests exclusively in value-based care, healthcare services, and tech-enabled businesses — is deploying capital as an operator to embed Attune across its delivery models. The investment, framed by Co-Founder and Managing Partner Vance Vanier and Attune CEO Matt Coughlin, targets an estimated $430–480 billion in annual US care-coordination waste. Attune has outperformed human advocate teams, exceeding one Medicaid health-risk-assessment target by 40% within three weeks of going live. (Link)
  10. Hunterdon Health and Hackensack Meridian Health have signed a letter of intent to pursue a proposed merger of the two New Jersey nonprofit health systems. Flemington-based Hunterdon Health and Edison-based Hackensack Meridian Health signed a nonbinding letter of intent June 22 after both boards of trustees voted to advance merger exploration. The letter of intent is nonbinding and does not represent a final deal, with no immediate changes to patient care, staffing or compensation. As a nonprofit combination, no purchase price applies; the strategic rationale centers on pooling resources, technology and expertise to expand services, invest in clinical research, and compete against larger, better-resourced systems. Leaders Patrick Gavin and Robert Garrett cited mission alignment and patient-centered innovation as both parties work toward a definitive agreement. (Link)
  11. DermDox Group has acquired Modern Aesthetics Plastic Surgery, expanding its dermatology, aesthetics and specialty healthcare platform. DermDox Group, a growing platform focused on dermatology, aesthetics and specialty healthcare services, completed a strategic transaction acquiring Modern Aesthetics Plastic Surgery. The deal reflects sustained strategic-buyer and investor demand for high-quality assets in the aesthetics and elective healthcare sectors, where consolidation continues across physician practices, med spas, plastic surgery and dermatology. The acquisition expands DermDox’s capabilities within the aesthetic and surgical services market while providing Modern Aesthetics with additional resources to support future growth and patient care initiatives. (Link)
  12. New York-based investment group Black Pearl Equities has entered into a definitive agreement to acquire all outstanding shares of Selectis Health, Inc. (OTCQB: GBCS), a Denver-based skilled nursing and senior living operator, for $5.75 per share in cash in a transaction valued at an implied premium to market.Brooklyn, New York-based Black Pearl Equities has agreed to acquire Selectis Health (OTCQB: GBCS) through a cash tender offer at $5.75 per share — a deal unanimously approved by Selectis’s Board of Directors as fair and in the best interests of stockholders. The transaction, structured as a tender offer followed by a short-form merger under the Utah Revised Business Corporation Act, requires valid tender of at least 70% of outstanding shares and carries no financing contingency. The deal is expected to close in Q3 2026. Selectis currently operates eight skilled nursing, assisted living, and independent living properties across Arkansas and Oklahoma, serving Medicare, Medicaid, and private-pay residents. Black Pearl, a healthcare-focused investment and advisory firm, will take Selectis private as a wholly owned subsidiary. (Link)
  13. Standard Dental Labs Inc. has signed a letter of intent to acquire an additional dental laboratory in the Tampa Bay region. Orlando-based dental laboratory consolidator Standard Dental Labs (OTCQB: TUTH) executed a non-binding LOI to acquire an established, undisclosed dental lab in Tampa Bay, advancing its strategy of building a regional Florida network. President and CEO James D. Brooks said the firm continues identifying high-quality labs whose owners value joining a larger organization. The LOI follows the company’s acquisition of BRLIT Dental Laboratory last month and remains subject to due diligence and definitive agreements. Brooks emphasized that developing regional density creates economies of scale and long-term shareholder value, with an active acquisition pipeline across Central Florida driven by owner succession planning and consolidation pressures. (Link)
  14. Fortitude Mining Holdings, Inc., currently wholly owned by Digital Currency Group (DCG), has agreed to combine with HeartSciences Inc. (Nasdaq: HSCS) in an all-stock business combination to take its vertically integrated Zcash mining platform public. Digital Currency Group, the sole stockholder of Fortitude Mining Holdings, will hold approximately 95% of the combined company on a fully diluted basis at closing, reflecting continued conviction in the venture mining business. Fortitude and HeartSciences (Nasdaq: HSCS) entered a definitive all-stock merger agreement expected to close in the second half of 2026, with the combined entity operating under the Fortitude brand and trading on Nasdaq under the ticker “TUDE,” subject to approval. DCG founder and CEO Barry Silbert framed Zcash as one of the most compelling opportunities in digital assets, pairing Bitcoin-style scarcity and Proof-of-Work discipline with privacy properties. The public listing gives Fortitude capital-markets access to scale its mining platform. (Link)

Venture Deals and Other

  1. GRAIL, Inc. (Nasdaq: GRAL) has completed a $110 million equity financing from Samsung entities, including Samsung C&T Corporation, to fund its growth and international expansion. GRAIL (Nasdaq: GRAL) closed a $110 million equity investment from Samsung affiliates. The Samsung entities purchased GRAIL common stock at $70.05 per share, representing a long-term investment supporting GRAIL’s growth and international expansion. The strategic capital strengthens GRAIL’s balance sheet and extends its cash runway as it pursues U.S. regulatory approval and reimbursement for its Galleri multi-cancer early detection test. GRAIL and Samsung C&T intend to collaborate to commercialize Galleri in South Korea, with potential expansion into Japan and Singapore. Samsung C&T, which has invested in Samsung Biologics, continues building its biopharmaceutical and life sciences portfolio through this milestone deal. (Link)
  2. Assort Health has raised a $120 million Series C led by Menlo Ventures, with backing from Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Joe Montana, Tau Ventures and Quiet Capital, reaching unicorn status. Assort Health secured $120 million in Series C funding, hitting unicorn status, to scale its voice AI agent platform for healthcare. Menlo Ventures led the round, joined by Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Joe Montana, Tau Ventures and Quiet Capital. Menlo partner Matt Murphy cited Assort’s category leadership, strong ROI and proven specialty-care execution. The company has raised $222 million to date and hit a $1.2 billion valuation, with revenue jumping 20x in 15 months. Investors are betting on Assort’s proprietary specialty dataset and Synapse AI model as defensible moats in a rapidly consolidating, capital-intensive market. (Link)
  3. xCures has raised a $46 million Series B led by Innovius Capital, with participation from iGrow, GKCC and Spring Mountain Capital, to scale its clinical data structuring platform. xCures completed a $46 million Series B financing led by Innovius Capital, with heavy participation from iGrow, GKCC, Spring Mountain Capital and existing institutional investors. The round pushes the company’s total institutional funding past $76 million to scale its Clinical Clarity Engine, which turns unstructured medical records into decision-ready data. Innovius Capital partner Stu Posluns emphasized that the future of healthcare AI depends on the accuracy, completeness and trust profile of underlying clinical data. xCures has processed more than 300 million medical records from over 550,000 healthcare locations, a defensive moat investors view as difficult for lightweight entrants to replicate. (Link)
  4. Prosper AI has raised a $30 million Series A led by Andreessen Horowitz (a16z), with participation from Base10, Emergence Capital, Y Combinator and Company Ventures, to build an AI workforce for healthcare operations. Prosper AI banked $30 million to scale its agentic AI platform powering administrative tasks from patient scheduling to insurance verification and patient billing. Andreessen Horowitz led the Series A round, with participation from Base10 and continued support from Emergence Capital, Y Combinator and Company Ventures. a16z partner Jay Rughani cited the founders’ ambition and strong competitive win rates as the conviction drivers, noting the platform’s end-to-end pull-through across customers. The funding follows roughly 5x revenue growth since the September seed round; capital will expand engineering and customer teams and deepen integrations across major EHR platforms. (Link)
  5. Rapalogix Health Raises $20 Million in Series A Financing to Advance Its Pipeline of Longevity-Based Skin Health Products Targeting the mTOR Pathway, a Scientifically Validated Mechanism Linked to Cellular Aging and Skin Regeneration Carlsbad, California-based Rapalogix Health, a biotechnology company pioneering longevity-based skin health through mTOR pathway modulation, closed a $20 million Series A to advance its proprietary product pipeline and expand commercial operations. Rapalogix is developing prescription and consumer products using rapamycin analogs targeting mTOR — a cellular pathway linked to aging, inflammation, and skin regeneration — in a category positioned at the intersection of dermatology, longevity medicine, and aesthetic health as investor and consumer interest in science-backed longevity products accelerates. (Link)
  6. Hera has raised a $27 million Series A led by Bain Capital Ventures, with participation from Accel and IA Ventures, to expand its AI-powered senior care coordination platform. Hera raised $27 million in Series A funding led by Bain Capital Ventures, with continued participation from Accel and IA Ventures. Angel investors also participated, including the CFO of Mount Sinai. Bain Capital Ventures partner Alysaa Co praised the founding team’s mix of personal conviction and technical depth honed at Headway and Palantir, viewing Hera’s platform as one that learns what genuinely helps aging families rather than merely surfacing options. The capital will fund continued buildout of Hera’s AI platform and expansion into California, Florida, Maryland, Pennsylvania and Massachusetts, targeting more than 25 states by year-end after reaching 95% retention across over 1,000 families. (Link)
  7. Pathway Labs has raised an $8.5 million seed round led by AlleyCorp and Breyer Capital to deploy its FDA-cleared cardiology AI tool, alongside a partnership with OpenEvidence. Pathway Labs announced an $8.5 million seed round led by AlleyCorp and Breyer Capital to expand deployment across health systems, grow its clinical and commercial teams, and support ongoing R&D. The financing coincides with the launch of EchoNext, the first FDA-approved AI tool reading standard ECGs to flag structural heart disease. Breyer Capital’s Dr. Morgan Cheatham praised the company for surfacing imperceptible diagnostic signals from widely ordered tests, while AlleyCorp’s Dr. Alexi Nazem called the technology a pioneering new type of AI-enabled medicine. The capital will fund integration into real clinical workflows at national scale via the OpenEvidence platform. (Link)
  8. Upside has secured a $20 million Series A led by Aquiline, with participation from Flare Capital Partners and existing investors 645 Ventures, Freestyle Capital, Triple Impact Capital and Techstars. Upside banked a $20 million Series A to address the U.S. housing crisis through a healthcare lens. Aquiline led the round, with participation from Flare Capital Partners and support from existing investors 645 Ventures, Freestyle Capital, Triple Impact Capital and Techstars. Aquiline partner Dante La Ruffa framed housing instability as a persistent driver of avoidable healthcare spend and pointed to strategic connectivity across health plan, payer and broker channels. The funding will be deployed simultaneously across Medicaid, Medicare Advantage and employer-sponsored markets, funding leadership hires, operational depth and continued technology investment as Upside scales its housing stability platform. (Link)
  9. Anodyne Nanotech Closes $12.6 Million Series A Led by Velocity Partners VC to Advance ANN-101 — a Once-Weekly GLP-1 Transdermal Patch for Obesity Requiring No Injection or Cold Storage — into Phase I Clinical Trials Boston-based Anodyne Nanotech closed a $12.6 million Series A co-led by Velocity Partners VC and Evercurious VC, with major participation from Relativity Healthcare Partners, to advance ANN-101, its once-weekly GLP-1 patch for obesity, into Phase I clinical trials and scale manufacturing of its HeroPatch™ transdermal delivery platform capable of delivering multi-milligram weekly GLP-1 doses without an injection or cold storage. The financing also supports Anodyne’s pipeline including an apelin/GLP-1 combination patch designed to counter lean-muscle loss — a key side effect of current GLP-1 injectable therapies. (Link)
  10. Ladder Health has raised a $7 million seed round led by Nina Capital, with participation from Mairs & Power Venture Capital, South Dakota First Capital, 25madison Health, Hatteras Venture Partners, Create Health Ventures, Jumpstart Capital, White Oak Enterprises, Groove Capital and 7Rock Ventures. Ladder Health raised $7 million in an oversubscribed seed round led by Nina Capital to expand its virtual-first pediatric developmental care platform. Additional investors included Mairs & Power Venture Capital, South Dakota First Capital, 25madison Health, Hatteras Venture Partners, Create Health Ventures, Jumpstart Capital, White Oak Enterprises, Groove Capital and 7Rock Ventures. The diversified syndicate is backing a company addressing nationwide provider shortages and waitlists for pediatric therapy. The capital will support expansion across North Carolina, Massachusetts and Maryland, entry into additional markets, enhancement of its AI-enabled care platform, and deeper partnerships with pediatric practices and health systems. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Jun 22nd, 2026

LECO_Weekly-Healthcare-News_6-22-2026Download
  1. Apollo Global-Backed Thoreau Group Signs Definitive Agreement for Strategic Growth Investment in Ensemble Health Partners, the Nation’s Largest RCM Managed Services Provider, at an Approximately $12 Billion Valuation Thoreau Group — the healthcare investment platform founded by former New Mountain Capital executive Matt Holt and backed by Apollo Global Management — signed a definitive agreement on June 17–18, 2026 to make a strategic growth investment in Ensemble Health Partners at an estimated $12 billion valuation. Ensemble manages more than $55 billion in net patient revenue annually across 200+ hospitals and approximately 12,000 employees, serving major health systems through billing, payment, and AI-enabled RCM services — including an RCM-native large language model developed in partnership with Cohere — following a $4.75 billion dividend recapitalization completed in January 2026. Legacy investors Berkshire Partners, Warburg Pincus, and Bon Secours Mercy Health will continue as co-investors. The transaction positions Thoreau at the center of the scaled healthcare administrative outsourcing sector. (Link)
  2. Abry Partners has closed a $780 million single-asset continuation fund anchored by Neuberger Berman and Apollo S3 (NYSE: APO) to retain its investment in Centauri Health Solutions, while simultaneously divesting Centauri’s Provider Solutions business to Elevate, a portfolio company of Audax Private Equity and Parthenon Capital Partners. Boston-based private equity firm Abry Partners orchestrated a $780 million single-asset continuation fund to extend its ownership of Centauri Health Solutions — a healthcare technology company serving U.S. health plans and health systems — transferring the asset from Abry Fund IX into the new vehicle. The Continuation Fund was co-anchored by Neuberger Berman and Apollo S3 (NYSE: APO), with additional commitments from Abry’s existing LP base. Concurrently, Centauri’s Provider Solutions business was divested to Elevate, a portfolio company of Audax Private Equity and Parthenon Capital Partners, sharpening Centauri’s focus as a pure-play payer technology and data intelligence platform. Since Abry’s 2020 investment, Centauri’s payer business tripled revenue and quadrupled EBITDA. (Link)
  3. Altaris has agreed to acquire Simulations Plus (Nasdaq: SLP) for approximately $375 million in an all-cash transaction, representing a 26% premium to the company’s 60-day volume-weighted average price, with the deal expected to close in Q4 2026. New York-based Altaris, an investment firm managing over $9 billion in equity capital with an exclusive focus on healthcare, has entered into a definitive agreement to acquire Simulations Plus (Nasdaq: SLP) at $18.50 per share in cash. Altaris anticipates combining the target with Chemical Computing Group (CCG), an existing Altaris portfolio company focused on molecular design software, to create a more integrated AI-driven drug development platform. The all-cash transaction, unanimously approved by Simulations Plus’s board, is financed through committed equity and debt from Altaris-affiliated funds without a financing contingency. Simulations Plus co-founder Dr. Walter Woltosz has entered into a voting support agreement backing the deal. The transaction is expected to close in Q4 2026 subject to stockholder and regulatory approvals. (Link)
  4. Abarca Health and LucyRx Announce Strategic Combination to Create the Only Modern PBM Built for Commercial and Government Scale Abarca Health and LucyRx have announced a strategic combination to form a modern, independent pharmacy benefit manager (PBM) with the scale and technology to serve commercial and government clients nationwide. The combined entity, operating under the parent brand Healthcare Revolution Partners, will provide prescription services to more than 9 million members. Abarca contributes its Darwin Healthcare Intelligence platform — a cloud-native, configurable PBM technology stack — while LucyRx brings clinical capabilities and deep expertise serving employers and labor groups. Both brands will continue operating as subsidiaries with no disruption to clients or members. The combination arrives amid ongoing scrutiny of traditional PBM consolidation and demand for transparent, independent alternatives. (Link)
  5. Singlepoint Healthcare Acquires Healix, Expanding National Infusion Capabilities Singlepoint Healthcare has acquired Healix, a leading provider of outpatient infusion management services operating more than 220 physician-owned and ambulatory infusion centers nationwide. The deal enhances Singlepoint’s integrated care model for inflammatory diseases by adding specialized infusion services spanning infectious disease, gastroenterology, neurology, rheumatology, and related therapeutic areas. This marks Singlepoint’s third acquisition in the past year, reflecting an accelerated buy-and-build strategy in the outpatient infusion market — a high-growth segment driven by biosimilar adoption, site-of-care migration from hospitals to lower-cost settings, and increasing prevalence of chronic inflammatory conditions. Healix will continue its focus on optimizing patient care in outpatient settings following integration. (Link)
  6. Aldrich Capital Partners-backed Compliancy Group has acquired Healthicity, a leading provider of healthcare compliance and auditing software, to create the most comprehensive combined platform for healthcare compliance programs serving more than 3,000 healthcare organizations. Compliancy Group, the healthcare compliance SaaS platform backed by growth equity investor Aldrich Capital Partners, has acquired Healthicity, a provider of healthcare auditing and compliance software including Compliance Manager and Audit Manager+ solutions. The combination creates the first unified platform delivering end-to-end coverage of provider, coding, and documentation auditing alongside workforce compliance, risk assessment, and incident management for a combined customer base exceeding 3,000 U.S. healthcare organizations (Link)
  7. ChartSpan Acquires Validic, the Leading Personal Health Data Platform, Creating a Unified Clinical Care Management and Remote Patient Monitoring Platform for Health Systems, Payers, and Life Sciences Companies Greenville, SC-based ChartSpan, a leading care management services company, announced on June 22, 2026 the completed acquisition of Validic, the healthcare industry’s leading personal health data platform connecting wearable and clinical devices to health system workflows. The combined company unites ChartSpan’s clinical care teams and Chronic Care Management, Advanced Primary Care Management, and Remote Patient Monitoring services with Validic’s global IoT and health data API infrastructure, device logistics, and RPM software — enabling organizations to move from periodic observation to continuous patient understanding. (Link)
  8. Ohio-based Align Capital Partners’ portfolio company Premier Biotech (based in Cleveland, Ohio and Dallas, Texas) has acquired both NexScreen and TransMed, representing the firm’s seventh acquisition since partnering with ACP in November 2022. Cleveland, Ohio-based Align Capital Partners (ACP), a growth-oriented private equity firm managing $3.2 billion in committed capital, has executed two simultaneous bolt-on acquisitions through its drug and alcohol testing portfolio company Premier Biotech: NexScreen, a point-of-care diagnostic testing solutions provider operating across the U.S., Australia, and New Zealand; and TransMed, a broad-catalog drug testing and lab supply distributor with over 1,000 direct customer accounts and a global e-commerce platform. These transactions mark Premier Biotech’s sixth and seventh acquisitions under ACP’s ownership since November 2022, extending the company’s international footprint and product offering across healthcare, government, and workplace markets. (Link)
  9. Cleargate Capital Partners has made a strategic investment in Fellow Health Partners, a Bay Shore, New York-based provider of revenue cycle management services to more than 500 clinicians across approximately 50 healthcare organizations nationwide. Healthcare-focused private equity firm Cleargate Capital Partners, founded in 2025, has made an undisclosed strategic investment in Fellow Health Partners, a leading RCM services provider to physician groups, ambulatory surgery centers, and specialty healthcare organizations across the U.S. Cleargate’s investment is intended to fund growth across Fellow’s SAVi technology platform,capital to pursue add-on acquisitions. Fellow’s existing management team, led by CEO Michael N. Brown, will continue to lead the organization. The deal supports Cleargate’s thesis of backing founder-led, lower-middle-market healthcare businesses with partnerships. (Link)
  10. AI-Native Medicare Navigation Platform Connie Health Completes Acquisition of Clearlink’s Medicare Business — Its 10th Acquisition — Alongside a $40 Million Series B Led by HealthQuest Capital, Bringing Total Funding to $85 Million Boston-based Connie Health, the AI-native Medicare navigation platform, has completed its acquisition of Clearlink Insurance Agency’s Medicare business — its 10th acquisition — while closing a $40 million Series B led by HealthQuest Capital with participation from JSL Capital, Khosla Ventures, aMoon, and Pitango HealthTech. The round brings total funding to $85 million. The integration leverages Connie’s AI and automation platform to seamlessly absorb the large-scale book while maintaining personalized service through its network of local trusted agents. Capital will support continued national expansion, technology investment, and additional acquisitions as Connie deepens its role as a strategic partner for value-based care organizations and ACOs. (Link)
  11. Tredence Acquires KMK Consulting, a Morris Plains, NJ-Based Life Sciences Analytics Firm Serving 8 of the World’s Top 10 Pharmaceutical Companies, to Build a Scaled Healthcare and Life Sciences AI Platform Tredence, a global AI and data science solutions firm, has acquired KMK Consulting, a specialized analytics and consulting firm with deep expertise in pharmaceuticals and life sciences headquartered in Morris Plains, New Jersey. KMK partners with 8 of the world’s top 10 pharmaceutical companies and brings over two decades of domain expertise in commercial analytics, real-world evidence (RWE), and market research. The deal positions Tredence to expand its Healthcare & Life Sciences business by combining KMK’s domain depth with Tredence’s Agentic AI capabilities across the full molecule-to-market development journey. (Link)
  12. Interlock Equity-Backed VeloSource Simultaneously Acquires Quest Locum Tenens and Syncx LLC, Adding National Physician Staffing Scale and a Proprietary Vendor-Neutral Workforce Management Technology Platform St. Louis-based VeloSource LLC, a portfolio company of Interlock Equity, has acquired Quest Locum Tenens and Syncx LLC to build an enterprise healthcare workforce ecosystem. The deals expand VeloSource’s national clinical staffing capabilities and add Syncx’s proprietary vendor-neutral technology platform for workforce management, including a differentiated physician float pool model that digitizes scheduling and prioritizes internal resources before external placement. Quest brings additional nationwide placement expertise for physicians, nurse practitioners, physician assistants, and CRNAs. The combined platform aims to address clinician shortages and improve operational efficiency for healthcare organizations. (Link)
  13. Avista Healthcare Partners-backed EBI has acquired Xstim, a division of Precision Medical Products Inc., to expand its bone growth stimulation portfolio and reinforce its position as the only pure-play bone growth stimulation company. EBI, a portfolio company of New York-based Avista Healthcare Partners — which has invested over $10 billion across more than 50 healthcare businesses globally — has acquired Xstim, the bone healing division of Precision Medical Products Inc. Xstim’s next-generation, wearable, capacitively coupled electrical stimulation therapy for lumbar spinal fusion is highly complementary to EBI’s existing FDA-approved portfolio of implantable and non-invasive bone healing solutions, including the EBI® Bone Healing System, OrthoPak®, and SpinalPak®. The deal advances Avista’s strategy of building differentiated, growth-oriented healthcare product platforms with clear scale potential and broadens EBI’s total addressable market across spinal fusion, nonunion fracture, and joint fusion applications. (Link)
  14. HR HealthCare Acquires SteriGear LLC and Fig Leaf Brand, Expanding Urology Solutions Across the Care Continuum York, PA-based HR HealthCare has acquired SteriGear LLC, including the Fig Leaf brand of urinary drainage devices and related covers and drapes, to strengthen its bladder management portfolio across acute, post-acute, and home care settings. The Fig Leaf product emphasizes patient dignity with privacy features, while SteriGear’s solutions complement HR HealthCare’s TruCath line. The deal creates a more comprehensive urology platform accessible through a single source, consolidating procurement for hospital systems and post-acute care providers. The Fig Leaf brand will continue operating under its existing name, with the SteriGear brand transitioning into HR HealthCare’s portfolio over time. (Link)
  15. Michigan Ear Institute Partners with Align ENT & Allergy, Expanding Access to Specialized Ear, Hearing, and Balance Care Across Michigan and Ohio Under a Physician-Led MSO Model Michigan Ear Institute (MEI), headquartered in Farmington Hills, Michigan, has entered into a strategic partnership with Align ENT & Allergy, a physician-led management services organization. The transaction closed on March 25, 2026, and expands access to specialized ear, hearing, and balance care across Michigan and Ohio. MEI operates four locations and is recognized for advanced diagnostic and treatment options. The partnership aligns MEI with Align’s MSO model focused on operational support, billing, and practice management while preserving full clinical autonomy for its physicians. (Link)
  16. Brightstar Capital Partners Acquires Erdman, a Madison, WI-Based Architecture and Engineering Firm Specializing in Healthcare Facilities and Senior Living Communities, to Expand Its Architecture and Design Platform Brightstar Capital Partners has acquired Erdman, a Madison, Wisconsin-based architecture and engineering firm founded in 1951 specializing in healthcare facilities and senior living communities. Licensed in more than 45 states, Erdman joins KZF Design in Brightstar’s architecture and design platform and contributes its proprietary ZeroIn healthcare analytics platform — a data-driven tool for optimizing facility design and operational performance. The deal supports growing demand for healthcare and senior living construction driven by an aging population and expands Brightstar’s national footprint in healthcare facility design and development. (Link)
  17. PruittHealth Acquires Four Home Health Offices in South Georgia, Adding 36 Counties to Expand Its Statewide Service Area to 109 Counties Under the PruittHealth @ Home Brand PruittHealth has acquired four home health offices in South Georgia — Community Health Services of Georgia locations in Vidalia and Albany, and Georgia Home Health Services locations in Valdosta and Tifton — adding 36 counties to its service area for a total of 109 counties statewide. The acquired offices will operate under the PruittHealth @ Home brand and integrate into PruittHealth’s existing home health network. This expansion reinforces PruittHealth’s position as a leading provider of home health services across Georgia, continuing the organization’s strategy of geographic densification within its core market through targeted acquisitions of established home health agencies. (Link)
  18. Jennie Stuart Health Acquires Six Medical Practices Across Western Kentucky, Including Generations Primary Care, MDVIP, Hopkinsville Family Care, and Three Additional Clinics, Strengthening Regional Provider Coordination Jennie Stuart Health has acquired six medical practices — Generations Primary Care, MDVIP, Hopkinsville Family Care, Western Kentucky Pulmonary Clinic, Elkton Clinic, and Crofton Clinic — to expand access to primary and specialty care across western Kentucky. Patients will continue receiving care from the same providers at their current locations with no interruption in services, and MDVIP will maintain its existing direct primary care membership model. The acquisition strengthens provider coordination, improves specialist access, and supports the long-term stability of regional healthcare delivery in underserved rural and semi-rural Kentucky communities. (Link)
  19. Legend Senior Living Acquires Apple Blossom Senior Living in Moon Township, Pennsylvania, Expanding to 78 Residences Across Eight States as Part of Its Ongoing Pennsylvania Growth Strategy Legend Senior Living has acquired Apple Blossom Senior Living in Moon Township, Pennsylvania, as part of its ongoing Pennsylvania expansion. The community offers Independent Living cottages along with Personal Care and Memory Care options. With this addition, Legend now operates 78 senior living residences across eight states. The acquisition strengthens Legend’s presence in the greater Pittsburgh market and continues its family-led approach focused on personalized resident support, dignity, and quality of life. Legend’s acquisition strategy targets established communities in growing suburban markets where demand for senior living services is supported by favorable demographic trends. (Link)
  20. Imagen Dental Partners Adds Pineview Aesthetic & Family Dentistry in Bellevue, Washington, Expanding Its Pacific Northwest Presence with a Practice Founded in 2007 by Repeated Seattle Top Dentist Honoree Dr. Gannon Stahl Imagen Dental Partners has partnered with Pineview Aesthetic & Family Dentistry, a leading Bellevue, Washington practice founded in 2007 and led by Dr. Gannon Stahl, a University of Washington School of Dentistry graduate and repeated Seattle Top Dentist honoree. The practice offers comprehensive family, cosmetic, restorative, and implant dentistry using advanced clinical technology and a patient-first approach. Dr. Stahl will continue focusing on clinical excellence while gaining access to Imagen’s support infrastructure across recruiting, marketing, revenue cycle management, and operations — a structure consistent with the supported independence model common across dental service organization partnerships. (Link)
  21. New Jersey Medical Office Building and ASC Portfolio — Including Physician’s SurgiCenter — Sells for $13.6 Million; Two-Building Medical Portfolio in Toms River 99% Leased at Close A medical office building portfolio in Toms River, New Jersey, including Physician’s SurgiCenter, has sold for $13.6 million. The two-building Holiday City Medical Portfolio totals 55,680 square feet and was 99% leased at closing, with established tenants including Labcorp, University Radiology Group, Asetera Cancer Care, Premier Dermatology, Elite Podiatry, and several others. Horizon Equities sold the properties to an undisclosed buyer following strong investor interest, with nearly a dozen competing offers received. The transaction reflects continued investor appetite for stabilized, multi-tenant medical office and ambulatory surgery center assets in established suburban New Jersey healthcare markets. (Link)
  22. Group Benefit Services Acquires Integrity Administrators, a Sacramento, CA-Based Third-Party Administrator, Expanding Its Self-Funded Health Plan Administration Platform with Enhanced Nurse Navigator and Member Services Capabilities Group Benefit Services, Inc. (GBS) has acquired Integrity Administrators, Inc. (IAI), a third-party administrator based in Sacramento, California specializing in self-funded health plan administration. The combination enhances GBS’s platform with expanded resources, Nurse Navigator programs, and a high-touch service model focused on cost savings and member support. IAI clients will benefit from GBS’s broader infrastructure and national network while maintaining the personalized service approach that defines the IAI model. The transaction continues consolidation in the fragmented TPA market, where self-funded employers increasingly seek scaled administrators with clinical care coordination capabilities alongside traditional plan administration services. (Link)

Venture Deals and Other

  1. Samsung Electronics (KRX: 005930) has made a $175 million investment in Element Biosciences’ upsized Series E financing round, becoming the genomic and multiomic technology company’s largest shareholder, with an undisclosed amount from other co-investors also participating. Samsung Electronics (KRX: 005930) has committed $175 million into an upsized Series E financing round for Element Biosciences, a San Diego-based life sciences company specializing in DNA sequencing and multiomic technologies. Samsung, a longstanding investor in Element, will become its largest shareholder upon close, pending regulatory approvals. The investment reflects Samsung’s strategic confidence in Element’s growing product ecosystem — including AVITI, VITARI, and the forthcoming AVITI Dx and AVITI24 — and aligns with its broader precision medicine and life sciences innovation mandate. Proceeds will fund global commercialization, geographic expansion, and advancement of the company’s product roadmap across research, translational science, and diagnostic applications. (Link)
  2. Avataar Ventures has led a $28.5 million Series B round in Bengaluru-based deep-tech manufacturing startup Ethereal Machines, with participation from existing investor Peak XV Partners, to fund a new manufacturing facility, indigenous CNC technology development, and global market expansion. Bengaluru-based deep-tech firm Ethereal Machines has raised $28.5 million in a Series B round led by Avataar Ventures, with Peak XV Partners participating as a returning investor. The capital, arriving nearly two years after the company’s $13 million Series A, is earmarked to construct a new 300,000-square-foot automated manufacturing plant under an MOU with the Karnataka government, develop a proprietary multi-axis CNC controller, and expand into the U.S. and European markets. Ethereal Machines’ MaaS business has grown threefold year-on-year since its Series A and production capacity has expanded tenfold. The company targets sectors including aerospace, defense, semiconductor manufacturing, and consumer electronics. (Link)
  3. Echo Health Ventures and FMZ Ventures have co-led a $30 million Series C in InStride Health, with existing investors Valtruis, .406 Ventures, General Catalyst, and Mass General Brigham Ventures also participating, bringing the pediatric mental health company’s total raised to $86 million. InStride Health, a provider of insurance-based virtual specialty treatment for children, teens, and young adults with anxiety and OCD, has closed a $30 million Series C co-led by Echo Health Ventures — the strategic CVC arm of the Blue Cross Blue Shield collaborative network — and FMZ Ventures, a growth equity firm specializing in digitally enabled consumer marketplace companies. Existing investors Valtruis, .406 Ventures, General Catalyst, and Mass General Brigham Ventures also participated. The round brings InStride’s total capital raised to $86 million and will fund geographic expansion from 17 states to Midwest and Western markets and deepening of payer relationships with insurers including Aetna, Anthem, Cigna, and UnitedHealthcare. (Link)
  4. Index Ventures has led a $7 million seed round in Uncovr, with Seedcamp, Frst, No Labels Ventures, and Entrepreneurs First also participating, to fund the AI surgical documentation startup’s expansion across U.S. and European hospital systems. Uncovr, a surgical AI company that analyzes intraoperative video to automatically generate procedural coding and operative reports, has secured $7 million in seed funding led by Index Ventures, with Seedcamp, Frst, No Labels Ventures, and Entrepreneurs First among additional investors. Digital Surgery founder Jean Nehme, Color Health CEO Othman Laraki, and Meta board member Charlie Songhurst also contributed individually to the round. Uncovr, launched in 2025 and currently deployed across more than 400 operating rooms in the U.S. and Europe, has identified a 16% missed-billable-step rate and a ~10% reimbursement gap in procedures. The seed capital will be deployed to hire ML engineers and expand hospital partnerships. (Link)
  5. Bonfire Ventures, Supernode, Comma Capital, and individual investor Jacquelyn Kung have backed Vali Health with $6 million in funding as the San Francisco-based AI home care startup emerges from stealth. Vali Health, a San Francisco-based startup building AI infrastructure for the home care industry, has emerged from stealth with $6 million in funding from Bonfire Ventures, Supernode, Comma Capital, and individual investor Jacquelyn Kung. Founded by Serena Dang (CEO) and Jason Wu (CTO), Vali Health has built an AI-native 24/7 safety infrastructure designed to help mid-sized home care agencies automate workforce management and coordination, saving upwards of 20 hours per week. The startup has achieved 400% growth in just 12 months, now serving agencies across nearly 100 locations in 30 states. Capital will be used to expand operations and market reach. (Link)
  6. Vanna Health Raises $17 Million to Expand Evidence-Based Care for People Living with Serious Mental Illness Vanna Health, a value-based health technology company providing integrated mental and chronic health support through community-based coaching, has raised $17 million in funding co-led by a national healthcare insurer and AlleyCorp, with participation from Health Velocity Capital. The capital will support expansion of its clinical reach, technology infrastructure, and recovery-oriented care model for individuals with serious mental illness (SMI) such as schizophrenia and bipolar disorder. Vanna Health currently operates in four states and aims to scale its community-centered, technology-enabled approach nationwide. (Link)
  7. Khosla Ventures has led an $11 million seed round in Clair Health, with participation from a16z Speedrun, Brydge Club, Treehub, Cartan Capital, AGI House, Insiders VC, and Anne Wojcicki, to develop the first continuous, non-invasive wearable hormone monitor for women. Clair Health, a femtech startup co-founded by Stanford graduates Jenny Duan and Abhinav Agarwal, has raised $11 million in seed funding led by Khosla Ventures, with a16z Speedrun, Brydge Club, Treehub, Cartan Capital, AGI House, Insiders VC, and 23andMe co-founder Anne Wojcicki also contributing. The startup is building a wearable wristband leveraging a proprietary stack of 10 biosensors — including biomagnetic sensors not found in any competing consumer wearable — combined with AI models to continuously infer a woman’s hormonal cycle phase without blood draws or skin piercing. With a 25,000-person waitlist and a sold-out presale, Clair Health plans a November 2026 wellness product launch and subsequent pursuit of FDA clearance for applications across fertility, perimenopause, and hormone conditions. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Jun 15th, 2026

LECO_Weekly-Healthcare-News_6-15-2026Download

Healthcare Weekly News and Deals –June 15th, 2026

  1. Danaher Corporation (NYSE: DHR) has completed its acquisition of Masimo Corporation (NASD: MASI), a leading patient monitoring company, for a total enterprise value of approximately $9.9 billion in cash Danaher (NYSE: DHR) completed its acquisition of Masimo (NASDAQ: MASI) on June 10, 2026, paying $180 per share in cash — a deal valued at roughly $9.9 billion including assumed debt and net of acquired cash. The transaction, which represents approximately 18x estimated 2027 EBITDA, adds Masimo’s industry-leading pulse oximetry and specialty diagnostics portfolio to Danaher’s Diagnostics segment. Danaher expects the acquisition to generate more than $530 million in Masimo EBITDA in 2027 and has targeted over $125 million in annual cost synergies and $50 million in annual revenue synergies by the fifth post-close year, funded through cash on hand and debt proceeds. (Link)
  2. GSK plc (NYSE: GSK) has entered into a definitive agreement to acquire Nuvalent, Inc. (NASD: NUVL), a precision oncology biotech with two late-stage non-small cell lung cancer candidates currently under FDA review, for $10.6 billion in cash. GSK plc announced on June 9, 2026 a definitive agreement to acquire Cambridge, Massachusetts-based Nuvalent (NASDAQ: NUVL) for $124 per share in cash — a 40% premium to last close and aggregate equity consideration of $10.6 billion, or approximately $9.4 billion net of acquired cash. The acquisition centers on two late-stage assets under active FDA review: zidesamtinib (ROS1-positive NSCLC) and neladalkib (ALK-positive NSCLC), both of which could launch by year-end 2026 and are projected to generate combined revenues exceeding $800 million by 2029. (Link)
  3. Chiesi Group has completed its approximately $1.9 billion acquisition of KalVista Pharmaceuticals, Inc. (NASD: KALV), adding EKTERLY® (sebetralstat) — the first and only oral, on-demand treatment for hereditary angioedema — to its Rare Diseases business unit. Chiesi Group, the Parma, Italy-based research-focused biopharmaceutical group, completed its acquisition of KalVista Pharmaceuticals (NASDAQ: KALV) on June 11, 2026, paying $27.00 per share in cash following a tender offer in which approximately 77.8% of shares were validly tendered, for aggregate consideration of approximately $1.9 billion. With the closing, Chiesi assumes ownership of EKTERLY® (sebetralstat), a plasma kallikrein inhibitor approved in the U.S., EU, UK, and Japan for the treatment of acute hereditary angioedema (HAE) attacks in patients aged 12 and older. (Link)
  4. Novanta Inc. (NASD: NOVT) has entered into a definitive agreement to acquire Riverpoint Medical, a category leader in minimally invasive surgical consumables, from Arlington Capital Partners for $1.2 billion in upfront cash plus a $250 million milestone payment Novanta (NASDAQ: NOVT) struck a deal to acquire Riverpoint Medical from Arlington Capital Partners, a Washington D.C.-area private investment firm, for $1.2 billion upfront and up to $250 million in milestone payments due in Q1 2027 — implying a total potential consideration of $1.45 billion. The acquisition is priced at approximately 19x Riverpoint’s estimated 2026 Adjusted EBITDA and is expected to immediately accrete to Novanta’s 2026 adjusted EPS. Strategically, the deal doubles Novanta’s recurring medical consumables revenue to roughly $300 million and lifts medical end-market exposure to approximately 60% of total revenue, with Novanta financing the deal via cash on hand, a $300 million equity raise, and existing credit facilities. (Link)
  5. Humana Inc. (NYSE: HUM) has signed a definitive agreement to divest all or substantially all of its approximately 40% minority interest in Gentiva, the nation’s largest hospice and palliative care provider, to a consortium of investors for approximately $900 million. Humana (NYSE: HUM) announced on June 10, 2026 a definitive agreement to sell substantially all of its minority interest in Gentiva — the nation’s leading hospice and end-of-life services provider operating more than 430 locations across 35 states — to an undisclosed consortium of investors for approximately $900 million. Proceeds will be directed to general corporate purposes. Closing is expected in Q3 2026, subject to regulatory approvals and customary conditions. (Link)
  6. Medtronic plc (NYSE: MDT) has completed its acquisition of Scientia Vascular, a privately-held neurovascular access device maker, for $550 million with potential additional earn-out and milestone payments Medtronic (NYSE: MDT) completed its acquisition of Salt Lake City-based Scientia Vascular in June 2026 for $550 million — a deal originally signed in March 2026. Scientia’s portfolio of advanced guidewires and catheters is designed to improve physician navigation through complex cerebral vasculature, and will integrate seamlessly into Medtronic’s existing neurovascular product line to support full procedural workflows for stroke and neurovascular interventions. With approximately 310 employees, Scientia represents Medtronic’s latest strategic neurovascular investment, following similar sector consolidation plays by Boston Scientific and Stryker. (Link)
  7. Keenova Therapeutics plc has agreed to sell its Percocet and Endocet opioid prescription drug businesses to Par Health, Inc. for total consideration of approximately $250 million, fully exiting the opioid market upon close. Keenova Therapeutics plc announced on June 13, 2026 a purchase agreement with Par Health, Inc. to divest its Percocet (oxycodone HCl/acetaminophen) and Endocet branded prescription opioid businesses for total consideration of approximately $250 million — comprising a $25 million upfront payment, subject to customary adjustments, plus quarterly earnout payments based on the gross profit of the divested business over a five-year period post-close. The transaction is expected to close in Q3 2026, subject to HSR antitrust clearance and customary closing conditions. Following the completion of all related obligations, Keenova will no longer market, manufacture, or distribute opioid products, representing a full strategic exit from the category. The divestiture allows Keenova to refocus capital allocation on its core non-opioid pipeline priorities. (Link)
  8. Adial Pharmaceuticals, Inc. (NASD: ADIL) has acquired Azora Therapeutics, Inc. and its lead colon-targeted ulcerative colitis candidate AT177, concurrent with a private placement of up to $64 million led by Coastlands Capital. Adial Pharmaceuticals (NASDAQ: ADIL) announced on June 11, 2026 the acquisition of Azora Therapeutics in a stock exchange transaction, adding Azora’s lead asset AT177 — a proprietary oral, colon-targeted aryl hydrocarbon receptor (AhR) agonist in IND-enabling studies for ulcerative colitis — as the combined company’s primary pipeline focus. Concurrent with the acquisition, Adial entered into a private placement of up to $64 million: $32 million upfront, led by Coastlands Capital, with a potential additional $32 million tranche tied to clinical milestones. Following shareholder approval and securities conversion, former Azora shareholders are expected to own approximately 51% of the combined company, financing investors approximately 41.3%, and existing Adial shareholders approximately 7.7%. Adial shares rose approximately 35% on announcement. (Link)
  9. Sagility (NSE: SAGILITY) has acquired CareSeed, a Kansas City-based healthcare analytics company specializing in HEDIS quality reporting and Medicare Advantage performance, for up to approximately $30 million. Sagility, a tech-enabled healthcare operations company backed by institutional investors, acquired CareSeed in a deal valued at up to $30 million — comprising $17.5 million upfront and up to $12.5 million in earn-outs tied to performance. Founded in 2012 and based in Kansas City, Missouri, CareSeed serves 30 small and mid-sized U.S. payers through its cloud-native Forecast and Harvest platforms, generating $5.1 million in CY25 revenue at a 31.4% EBITDA margin. The acquisition is expected to be immediately EPS accretive to Sagility and adds 28 new Medicare Advantage health plan relationships, positioning Sagility to deliver an end-to-end quality operations continuum from HEDIS abstraction to prospective care gap closure. (Link)
  10. SK Capital Partners-backed Spectrum Vascular has acquired Piccolo Medical, developer of 510(k)-cleared proprietary blood-flow sensing catheter guidance technology, to deepen its vascular access platform and accelerate commercialization of the Nav+ Stylet. Spectrum Vascular, a White Plains, New York-based vascular access and medication management products company backed by SK Capital Partners, announced on June 11, 2026 the acquisition of Piccolo Medical, a developer of next-generation catheter guidance products more than a decade in development. Piccolo’s real-time catheter guidance uses proprietary blood-flow sensing technology to precisely guide catheter tip placement, eliminating the need for confirmatory chest X-rays — a standard and costly step in most vascular access procedures. Piccolo completed its first successful patient placements of the Nav+ Stylet in May 2026. Augustus Shanahan, CEO of Piccolo, will join Spectrum alongside his team to advance development and commercialization. (Link)
  11. Vizient has acquired Empierus, a healthcare-focused IT contracting and cost optimization advisory firm, to expand its indirect spend management capabilities across a sector spending more than $55 billion annually on information technology. Vizient, the Irving, Texas-based provider-driven healthcare performance improvement company with a $156 billion annual purchasing portfolio, announced on June 11, 2026 the acquisition of Empierus, a healthcare advisory firm specializing in IT contracting, healthcare technology management, and cost optimization. Through an existing partnership, Empierus delivered more than $36 million in savings for Vizient clients in 2025 alone; Empierus employees will join Vizient’s team of more than 250 indirect spend and purchased services experts. The acquisition addresses a rapidly growing, largely unmanaged category as healthcare organizations expand IT investments in cybersecurity, cloud, AI, and digital transformation. (Link)
  12. Capsa Healthcare, backed by Francisco Partners, has acquired The Harloff Company, a leading manufacturer of healthcare storage and mobility products, for undisclosed terms to deepen its clinical workflow solutions portfolio Canal Winchester, Ohio-based Capsa Healthcare — acquired by private equity firm Francisco Partners in April 2026 for approximately $500 million — has made its first add-on acquisition by purchasing The Harloff Company, a 75-year-old manufacturer of medical storage cabinets, procedure carts, medication storage systems, and endoscopic processing solutions. The combination integrates Harloff’s durable clinical infrastructure with Capsa’s tech-enabled pharmacy automation and point-of-care platforms, creating a more comprehensive healthcare equipment offering for hospitals, ambulatory surgery centers, and long-term care facilities. (Link)
  13. Grant Avenue Capital-backed PatientCare EMS Solutions has partnered with Superior Mobile Health, a Texas-based provider of non-emergency medical transportation services, expanding its geographic footprint into the Texas market PatientCare EMS Solutions, a New York-headquartered ground-based healthcare transportation platform backed by private equity firm Grant Avenue Capital, announced a strategic partnership with Superior Mobile Health, a San Antonio, Texas-based provider founded in 2011. Superior completed more than 80,000 patient transports in 2025 across a network of over 300 clinical staff, with strong existing relationships with Texas hospitals, municipalities, and nursing facilities. The partnership gives Superior access to PatientCare’s capital resources, operational infrastructure, fleet technology, and scale — and marks PatientCare’s entry into the Texas market under its buy-and-build strategy with Grant Avenue as sponsor. Terms were not disclosed. (Link)
  14. Alembic Therapeutics, LLC has acquired NUVESSA® (metronidazole vaginal gel 1.3%), an FDA-approved single-dose prescription treatment for bacterial vaginosis, from Exeltis USA, Inc. to expand its women’s health portfolio. Bedminster, New Jersey-based Alembic Therapeutics announced on June 9, 2026 the acquisition of NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc., assuming full U.S. commercialization and distribution responsibilities. NUVESSA is an FDA-approved, single-dose, pre-filled disposable applicator indicated for the treatment of bacterial vaginosis in females aged 12 and older — the most common vaginal infection in women of childbearing age, affecting an estimated 21 million U.S. women annually. (Link)
  15. Chambers Home Health & Hospice, a Northeast Texas home-based care provider founded in 2002, has partnered with Lucent Health Group. Chambers Home Health & Hospice, a Melissa Chambers-founded provider of skilled home health and hospice services across more than 20 counties in Northeast Texas operating through three agencies — Chambers Home Health, Chambers Hospice, and Healthcare Associates LLC — announced on June 10, 2026 a partnership with Lucent Health Group (LHG). The transaction positions Chambers to build on over two decades of regional growth while accessing LHG’s capital resources and healthcare operating expertise to support continued expansion across a growing home-based care market. Cross Keys Capital served as exclusive financial advisor to Chambers; Calhoun, Bhella & Sechrest provided legal counsel. (Link)
  16. Gemspring Capital ($5.1 billion AUM) has acquired Freedom Senior Services, a multi-state provider of culturally responsive home care, adult day, IDD, and VA services across Kentucky, Indiana, Ohio, Pennsylvania, and Tennessee Gemspring Capital Management, LP, a Westport, Connecticut-based middle market private equity firm with $5.1 billion of capital under management, acquired Freedom Senior Services, a provider of culturally responsive home care, adult day, intellectual and developmental disability (IDD), and VA services operating across Kentucky, Indiana, Ohio, Pennsylvania, and Tennessee. The transaction, announced in June 2026, was advised by Livingstone Partners on behalf of Gemspring. Freedom’s multilingual care delivery model and regional concentration in the Midwest and Appalachian markets positions it as a differentiated platform within a fragmented home- and community-based services sector facing strong demographic tailwinds. (Link)
  17. Apex Paramedics has been sold to Royal Ambulance, a California-based medical transportation provider, in a transaction advised by Helix Health Capital Advisors, marking Royal’s entry into the Colorado market. Helix Health Capital Advisors served as exclusive financial advisor to Apex Paramedics, a Denver-based provider of scheduled non-emergent interfacility transport (IFT) services, in its sale to Royal Ambulance announced June 9, 2026. Founded in 2015, Apex serves the Denver metro and Colorado Springs markets under multi-year service agreements with leading health systems. Royal Ambulance, a California-based provider of medical transportation and specialty transport services across the San Francisco Bay Area, expands its geographic footprint beyond Northern California through the acquisition and gains a scalable IFT platform in a high-growth Colorado market. (Link)
  18. 10x Genomics, Inc. (NASD: TXG) has acquired Proteintech Genomics, a division of Proteintech Group, to expand its proteomics and single-cell multiomic capabilities. 10x Genomics (NASDAQ: TXG) announced on June 9, 2026 the acquisition of Proteintech Genomics, a division within Proteintech Group, adding its Human Discovery Panel — the largest antibody-based single-cell protein panel currently available — designed to support integrated analysis of intracellular proteins, cell surface proteins, and transcriptomic profiles within sequencing-compatible workflows on 10x’s Chromium Flex chemistry. The acquisition is strategically timed to complement 10x’s April 2026 launch of the Atera whole-transcriptome single-cell platform, advancing the company’s multiomic vision by bridging proteomic and transcriptomic layers at single-cell resolution.  , and 10x Genomics stated the transaction will not meaningfully impact its near-term financial outlook. (Link)
  19. AMN Healthcare Services (NYSE: AMN) has acquired Jaide Health, a Boston-based AI-enabled medical interpretation and translation startup, for undisclosed terms to expand language access solutions across the patient journey AMN Healthcare Services (NYSE: AMN) acquired Jaide Health through its Language Services division in June 2026 to pair AI-assisted language tools with AMN’s existing human interpreter network. Jaide Health’s platform provides real-time, AI-enabled support for routine verbal exchanges and written translations — such as patient intake and discharge communications — addressing language access gaps for Limited English Proficiency (LEP) patients outside clinical encounters. The acquisition is consistent with AMN’s broader strategy of deploying technology solutions that reduce friction across the care continuum. (Link)
  20. PartsSource, a leading clinical technology performance platform, has acquired SkillNet, a healthcare workforce intelligence platform for hospital technology management teams, for undisclosed terms. Cleveland, Ohio-based PartsSource announced on June 9, 2026 the acquisition of SkillNet, a Workforce Intelligence platform purpose-built for healthcare technology management (HTM) departments. SkillNet provides hospitals and health systems with real-time visibility into technician competency compliance, skill-gap assessment, and team capability tracking — enabling HTM leaders to close critical technician deficiencies and expand care capacity. The acquisition extends PartsSource’s Enterprise Clinical Technology platform beyond parts procurement, service optimization, and asset performance management into the workforce intelligence layer, creating a more comprehensive operating system for hospital biomed and clinical engineering departments. (Link)
  21. Chinook Investment Partners has made a growth equity investment in PractiVet, a Scottsdale, Arizona-based veterinary infusion and syringe pump device company, with debt financing support from Mercantile Bank. Chinook Investment Partners, a Castle Pines, Colorado-based private equity firm focused on healthcare and business services, completed a growth investment in PractiVet in April 2026 through a transaction supported by Mercantile Bank. Founded in 2007 and headquartered in Scottsdale, Arizona, PractiVet is a leading branded supplier of infusion and syringe pump devices and IV infusion consumables serving thousands of veterinary hospitals and universities nationwide, with more than 30,000 devices deployed across specialty, emergency, and academic settings. The deal is consistent with Chinook’s strategy of backing profitable, growth-stage companies in recession-resilient healthcare end markets with revenues between $5 million and $100 million and EBITDA between $1 million and $10 million. (Link)

Venture Deals and Other

  1. Vida Ventures has led an oversubscribed $125 million Series B investment in SonoThera, with participation from ARK Invest, Leaps by Bayer, Otsuka Pharmaceutical, UCB Ventures SA, CureDuchenne Ventures, Vivo Capital, SymBiosis, and a roster of prominent existing investors to advance ultrasound-mediated nonviral genetic medicines. Vida Ventures led a highly syndicated $125 million Series B in South San Francisco-based SonoThera, joined by new investors ARK Invest (NYSE: ARKK), Leaps by Bayer, Otsuka Pharmaceutical, UCB Ventures, CureDuchenne Ventures, Vivo Capital, and SymBiosis, alongside returning backers including ARCH Venture Partners, Alexandria Venture Investments, Illumina Ventures, Johnson & Johnson Innovation – JJDC, RA Capital, Duquesne Family Office, Medical Excellence Capital, and Vertex Ventures HC. The oversubscribed round will advance SonoThera’s lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic, with the first DMD trial targeted for 2027. SonoThera’s proprietary RIPPLE™ ultrasound delivery and PORE™ payload engineering platforms represent a novel nonviral alternative to traditional gene therapy. (Link)
  2. Viking Global Investors has led an oversubscribed $100 million Series E financing in GT Medical Technologies, with participation from MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners, and FemHealth Ventures, to accelerate commercialization of its GammaTile brain tumor radiotherapy platform. Viking Global Investors — a global investment firm managing over $52 billion in assets — led an oversubscribed $100 million Series E in Tempe, Arizona-based GT Medical Technologies, joined by re-upping investors MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners, and FemHealth Ventures. The round follows compelling Phase 3 ROADS trial data presented at ASCO 2026 showing GammaTile — the company’s FDA-cleared bioresorbable radiation implant — reduced tumor recurrence risk by 93% and death risk by 41% at 12 months versus standard of care. Proceeds will fuel commercial and operational expansion and support the BRIDGES RCT in glioblastoma patients. This round follows a $53 million Series D completed in 2025. (Link)
  3. Atlas Venture and Medicxi Ventures have co-led a combined $101 million Series A and Series B financing in Ethyreal Bio, an ophthalmic biotech emerging from stealth to develop a first-in-class IGF-1R inhibitor for thyroid eye disease and Graves’ disease. Ethyreal Bio emerged from stealth on June 10, 2026 with $101 million in combined financing — a Series A co-led by Atlas Venture and Medicxi Ventures, alongside Nandi Life Sciences and Checkpoint Capital, followed by a Series B led by Avoro Capital with all Series A investors participating. The company’s lead asset, ETHY-001, is a first-in-human candidate targeting the insulin-like growth factor 1 receptor (IGF-1R) for thyroid eye disease (TED) and Graves’ disease, entering a market currently anchored by Amgen’s Tepezza (teprotumumab), which generated over $2 billion in peak annual sales. Proceeds will fund ETHY-001 into Phase 1, planned for later in 2026, with a differentiated mechanism targeting potential improvements in tolerability versus the current standard of care. (Link)
  4. Prime Radiant Partners has invested $50 million in Cellares, the first Integrated Development and Manufacturing Organization (IDMO) for cell therapy, growing its Series D to $327 million and bringing total capital raised to $739 million. Cellares, the South San Francisco-based IDMO pioneering automated cell therapy manufacturing, announced on June 15, 2026 a $50 million investment from Prime Radiant Partners, growing its Series D financing — originally anchored by BlackRock and Eclipse — to $327 million total, with total capital raised reaching $739 million. The new capital supports Cellares’ global Smart Factory buildout spanning South San Francisco, Bridgewater (NJ), Leiden (Netherlands), and Kashiwa City (Japan), targeting commercial-scale production in 2027. Cellares has manufactured and delivered the first GMP doses of Cabaletta Bio’s investigational CAR-T therapy on its Cell Shuttle® platform, signed a 10-year supply agreement with Cabaletta, and secured a $380 M global manufacturing agreement with Bristol Myers Squibb for commercial-scale cell therapy capacity. (Link)
  5. Caffeinated Capital has led an oversubscribed $23 million Series A investment in Neion Bio, with participation from Basis Set Ventures and other new investors, to advance the company’s egg-based biologics manufacturing platform. Caffeinated Capital, an early-stage technology-focused fund and original seed backer of Neion Bio, led the New York-based biotech’s oversubscribed $23 million Series A, with new investors including Basis Set Ventures, Clocktower Ventures, and Hawktail also joining the round. Neion Bio deploys frontier genetic engineering to convert chicken eggs into highly efficient biological manufacturing vessels for complex, glycosylated proteins — positioning the company as an infrastructure-layer alternative to traditional cell culture-based biologic production. The financing follows Neion’s March 2026 emergence from stealth and its announcement of a commercial co-development and supply agreement with a major pharmaceutical company for a multi-product biosimilars collaboration. (Link)
  6. Tau Ventures, Upstream Ventures, Proofpoint Capital, Draper Associates, Wicklow Capital, and 29 additional investors have co-invested in a $24 million Series A round in Klinic Inc., a Texas-based specialty healthcare provider-enablement platform. Klinic Inc., a Frisco, Texas-based healthcare technology company, closed a $24 million equity financing round backed by 34 investors — including Tau Ventures, Upstream Ventures, Proofpoint Capital, Draper Associates, and Wicklow Capital. Founded in 2021 by Avish Bhama and Dan Cheung, Klinic operates as a Shopify-like infrastructure layer for independent specialty practices across 12 medical disciplines including oncology, cardiology, and rare diseases, providing unified tools for patient acquisition, EHR, RCM, prior authorization tracking, and care coordination. The company’s first round sale closed in January 2026 per an SEC Form D filing, and proceeds are expected to fund aggressive platform expansion across North American specialty markets. (Link)
  7. Shore Search Partners has led a Series A growth investment in Aton Health, a Kansas City-based healthcare company embedding research infrastructure into routine specialty care to generate real-world evidence at scale. Aton Health, based in Kansas City, Missouri, announced on June 12, 2026 the closing of a Series A growth investment led by Shore Search Partners, the healthcare-focused venture arm of Shore Capital Partners — which closed $850 million across two new funds in 2025. Aton integrates its TrialSight™ and CareSight™ data collection platforms directly into existing specialty practices, enabling providers to participate in non-interventional research programs — beginning in gastroenterology and expanding into additional specialties — without disrupting clinical workflows. The model connects pharmaceutical sponsors with high-quality, real-world patient populations at the point of care, addressing structural limitations of traditional clinical trial site access. Investment amount was not disclosed. (Link)
  8. Index Ventures has led a €6 million ($7 million) seed round in Uncovr, a Paris- and New York-based surgical AI startup, with participation from Seedcamp, Frst, No Label Ventures, Entrepreneurs First, and notable healthcare angels, to build AI infrastructure that converts surgical video into clinical records. Index Ventures — one of Europe’s most active technology venture funds — led the debut seed round in Uncovr, joined by institutional backers Seedcamp, Frst, No Label Ventures, and Entrepreneurs First, as well as angel investors including Digital Surgery founder Jean Nehme (whose prior company was acquired by Medtronic (NYSE: MDT)), Color Health CEO Othman Laraki, and Meta board member Charlie Songhurst. Uncovr’s AI platform analyzes real-time surgical and endoscopic video to automatically generate operative reports and procedural billing codes, addressing a structural documentation gap affecting more than 400 million surgeries annually. The company plans to use the capital to scale its AI platform and expand into U.S. hospital systems. (Link)
  9. NVENTRIC, a South Korean medical device company specializing in vascular intervention, has closed a ₩34.5 billion (~$22.6 million) pre-IPO financing round from 14 institutional investors, including Loftyrock Investment, Moneyball Ventures, Shinhan Capital, IPS Ventures, and LB Investment, to fund global expansion and a planned KOSDAQ listing. NVENTRIC attracted 14 new institutional backers to its pre-IPO round, with Shinhan Capital, IPS Ventures, Quad Asset Management, and Heungkuk Securities participating as follow-on investors from prior rounds alongside new commitments from Loftyrock Investment, Moneyball Ventures, Moneyball Partners, Scale-up Partners, AJU IB Investment, HB Investment, Pacific Capital, Flexus Partners, and Heungkuk Securities. The company has achieved a 52.9% CAGR in cumulative revenue over the past four years, posting approximately $3.9 million in total revenues through the period. Proceeds from the round will fund global commercial expansion and accelerate NVENTRIC’s preparations for a KOSDAQ IPO. (Link)
  10. Institutional healthcare investors and company insiders have participated in a $10.5 million private placement financing in CervoMed Inc. (NASD: CRVO), a clinical-stage biotech developing treatments for age-related neurological disorders. CervoMed (NASDAQ: CRVO) raised $10.5 million in a private placement led by institutional healthcare investors, with meaningful insider co-investment from board chairman Joshua S. Boger, Ph.D. — founder of Vertex Pharmaceuticals (NASDAQ: VRTX) — alongside trusts affiliated with CEO Dr. John Alam and board member Sylvie Grégoire. The company sold 3,360,377 units at $3.14 per unit, with Series B and C warrants that could generate an additional $21.7 million in gross proceeds if fully exercised. Proceeds will fund ongoing development of neflamapimod, an oral neuroinflammation inhibitor being advanced toward Phase 3 for dementia with Lewy bodies, while supporting pursuit of a strategic partnership, and are expected to extend CervoMed’s cash runway into Q2 2027. (Link)
  11. Arcadia Biosciences (NASD: RKDA) has raised $4 million through an at-the-market private placement of common stock and preferred investment options under Nasdaq rules to fund working capital and general corporate purposes. Arcadia Biosciences (NASDAQ: RKDA), a Dallas-based producer and marketer of wellness products including its Zola coconut water brand, completed a $4 million private placement priced at $1.03 per share on June 12, 2026, issuing 3,883,496 common shares with accompanying Series A-1 and A-2 preferred investment options exercisable at $0.91 per share. Investors attracted to RKDA’s at-the-market structure, which bypasses shareholder approval requirements under Nasdaq Rule 7.1 provisions, drove a notable 18%+ single-day stock price surge on the announcement. Proceeds will be directed toward working capital needs and general corporate operations as the company continues executing on its consumer wellness portfolio strategy. (Link)
  12. Institutional investors have participated in an $8.5 million private placement in Bluejay Diagnostics (NASD: BJDX), a Massachusetts-based near-patient testing company, with total potential proceeds of up to $23.7 million if warrants are fully exercised. Bluejay Diagnostics (NASDAQ: BJDX), headquartered in Acton, Massachusetts, closed an $8.5 million private placement on June 5, 2026, issuing 3,655,917 shares at $2.325 per share alongside two series of warrants — Series G (exercisable for five years) and Series H (short-term) — each covering up to 3,655,917 additional shares at a $2.075 exercise price. If warrants are fully exercised, total gross proceeds could reach approximately $23.7 million, which BJDX estimates would extend its cash runway well beyond its anticipated FDA approval and first full year of commercialization. Near-term proceeds are targeted toward clinical studies supporting regulatory clearance and R&D activities. (Link)
  13. New and existing institutional and sophisticated investors have collectively committed A$30 million to Vitrafy Life Sciences (ASX: VFY) through a non-underwritten institutional placement to fund manufacturing expansion and accelerate U.S. market entry for its Guardion cryopreservation devices. Vitrafy Life Sciences (ASX: VFY), an Australian life sciences company focused on smart cryopreservation solutions, secured firm commitments for a A$30 million (~US$19.5 million) institutional placement on June 10, 2026, issuing approximately 11.54 million new shares at A$2.60 per share — a 31.6% discount to its last closing price. The capital raise is directed toward three key uses: A$15 million for Guardion device fleet inventory build, A$8 million for U.S. sales and operational scaling, and A$5.2 million for working capital. The placement, backed by both new and existing institutional backers, supports Vitrafy’s positioning ahead of the 2027 blood industry replacement cycle in the U.S., where the company has partnered with Vitalant for frozen red blood cell preservation solutions. (Link)

Market Rumors

  1. Matt Holt’s Thoreau Group, backed by Apollo Global Management, is reported to be in advanced talks to acquire Ensemble Health Partners, a leading revenue cycle management company, in a deal valuing the business at approximately $12 billion. Bloomberg reported on June 12, 2026 that Thoreau Group — the healthcare technology platform created by former New Mountain Capital managing director and president Matt Holt, backed by Apollo Global Management — is in advanced talks to acquire Ensemble Health Partners and that a deal could be signed imminently. Cincinnati-based Ensemble Health Partners is one of the largest revenue cycle management companies in the U.S., generating approximately $2.7 billion in annual revenues serving major health systems. Thoreau Group is expected to become the controlling shareholder of Ensemble. The reported valuation of approximately $12 billion would represent one of the largest healthcare services transactions of 2026. No parties have confirmed the report. This item is based solely on Bloomberg reporting and should be treated as unconfirmed pending an official announcement. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Jun 8th, 2026

LECO_Weekly-Healthcare-News_6-8-2026Download

Healthcare Weekly News and Deals –June 8th, 2026

  1. New Brunswick, NJ-based Johnson & Johnson (NYSE: JNJ) agreed to acquire Firefly Bio, Inc. for $1 billion in cash to add its Firelink™ degrader antibody conjugate (DAC) platform targeting KRAS-driven and other hard-to-treat solid tumors, expanding J&J’s next-generation oncology pipeline Johnson & Johnson (NYSE: JNJ) announced on June 8, 2026 a definitive agreement to acquire Firefly Bio, Inc., a biotechnology company developing its proprietary Firelink™ degrader antibody conjugate (DAC) platform, for $1 billion in cash. The Firelink™ platform delivers a highly selective protein degrader to tumor cells while avoiding healthy cells, targeting KRAS-driven solid tumors — among the most prevalent and historically hard-to-treat oncology targets. The acquisition adds preclinical candidates and a novel modality complementing J&J’s existing antibody engineering expertise across monoclonal antibodies, bispecifics, and ADCs. Closing is expected later in 2026, subject to regulatory approvals and customary conditions. (Link)
  2. Wilmington, Delaware-based Incyte Corporation (NASD: INCY) agreed to acquire Vega Therapeutics — a wholly owned subsidiary of Star Therapeutics — for $1.25 billion upfront plus up to $750 million in sales milestones (up to $2.0 billion total), adding VGA039, a Phase 3-ready first-in-class monoclonal antibody for von Willebrand disease Incyte Corporation (NASD: INCY) announced on June 8, 2026 a definitive agreement to acquire Vega Therapeutics, Inc. from Star Therapeutics, LLC for $1.25 billion upfront plus up to $750 million in sales milestone payments, totaling up to $2.0 billion. Vega’s lead candidate, VGA039, is a first-in-class investigational monoclonal antibody modulating Protein S to improve hemostasis in von Willebrand disease (VWD) — the most common inherited bleeding disorder, affecting approximately 135,000 diagnosed U.S. patients. VGA039 is in Phase 3 pivotal development as a potentially first-ever subcutaneous prophylactic therapy for VWD patients who currently require frequent IV infusions; it holds FDA Breakthrough Therapy and Orphan Drug designations. Closing is expected in Q3 2026, subject to antitrust clearance. (Link)
  3. Nashville-based Ascension health system finalized its $3.9 billion acquisition of ASC operator AMSURG — adding 250 ambulatory surgery centers across 34 states — after the FTC required divestitures of seven surgery centers, creating one of the largest nonprofit health system-owned ambulatory surgery portfolios in the country Ascension, one of the largest nonprofit health systems in the United States, closed its $3.9 billion acquisition of AMSURG following an FTC consent order requiring divestiture of seven ASCs in five metropolitan markets to SCA Health — a subsidiary of UnitedHealth Group’s (NYSE: UNH) Optum — and one additional ASC. The acquisition adds 250 ASCs across 34 states to Ascension’s existing portfolio of 58 wholly owned surgical centers, dramatically expanding its outpatient surgery footprint. Industry observers view the deal as a catalyst for broader ASC sector consolidation. (Link)
  4. Joplin, Missouri-based Freeman Health System completed the $110 million acquisition of Northwest Health from Community Health Systems (NYSE: CYH), adding four Arkansas hospital facilities and marking Freeman’s first expansion into the state Freeman Health System finalized the $110 million purchase of Northwest Health from Community Health Systems (NYSE: CYH). The transaction included substantially all assets of four hospitals — Northwest Medical Center Bentonville, Northwest Medical Center Springdale, Willow Creek Women’s Hospital in Johnson, and Siloam Springs Regional Hospital — plus associated outpatient centers and practices, bringing approximately 2,200 employees into the Freeman organization. The deal marks Freeman Health’s inaugural geographic expansion into Arkansas, adding significant hospital density in the rapidly growing Northwest Arkansas market. (Link)
  5. Aveanna Healthcare Holdings (NASD: AVAH) has completed the acquisition of Family First Homecare for $175.5 million, adding 27 pediatric home care locations across seven states to its national platform. Atlanta-based Aveanna Healthcare Holdings (NASD: AVAH), a diversified home care platform serving medically complex patient populations, has closed its $175.5 million all-cash acquisition of Family First Homecare, a scaled multi-state provider of pediatric private duty nursing services. Funded entirely from cash on hand, the transaction adds 27 locations across Florida, Illinois, Iowa, North Carolina, Pennsylvania, South Dakota, and Texas to Aveanna’s portfolio. The deal lifts Aveanna’s full-year 2026 revenue guidance by $70 million to a range of $2.63–$2.65 billion, and increases its Adjusted EBITDA guidance by $10 million to a range of $338–$342 million, reflecting immediate financial accretion from the deal. (Link)
  6. Parsippany, NJ-based Med-Metrix (PE: Harvest Partners and A&M Capital Partners) entered into a definitive agreement to acquire Vitalware from Health Catalyst (NASD: HCAT) for $147 million in cash, strengthening its mid-revenue cycle technology platform PE-backed Med-Metrix, supported by Harvest Partners (~$20 billion AUM) and A&M Capital Partners, signed a definitive agreement to acquire Vitalware from Health Catalyst (NASD: HCAT) for $147 million in cash. Vitalware is a Best-in-KLAS mid-revenue cycle software business generating approximately $37 million in FY2025 revenue; its cloud-based chargemaster management, revenue integrity, and coding optimization tools strategically expand Med-Metrix’s platform. For Health Catalyst, the divestiture proceeds retire its ~$160 million senior secured term loan, sharpening the company’s strategic focus. Vitalware was founded in 2011 and acquired by Health Catalyst in 2020. (Link)
  7. New Haven, CT-based Rallybio Corporation (NASD: RLYB) and San Diego-based Avenzo Therapeutics announced a definitive merger agreement — combined company to operate as Avenzo Therapeutics advancing next-generation oncology small molecules and ADCs Rallybio Corporation (NASD: RLYB) and Avenzo Therapeutics announced on June 1, 2026 a definitive merger under which Rallybio acquires Avenzo, with the combined company operating as Avenzo Therapeutics. A concurrent oversubscribed $215 million private placement from healthcare institutional investors and mutual funds funds operations into late 2028 and supports advancement through multiple clinical milestones across next-generation oncology small molecules and ADCs. Pre-transaction Rallybio stockholders will own approximately 2.8% of the combined company; Rallybio intends to distribute substantially all pre-closing net cash to existing stockholders. Closing expected Q4 2026, subject to stockholder approval. (Link)
  8. Murfreesboro, Tennessee-based National HealthCare Corporation (NYSE American: NHC) completed the $50.5 million acquisition of five skilled nursing facilities, converting decades-long management agreements into full ownership across 566 operating beds National HealthCare Corporation (NYSE American: NHC) announced on June 4, 2026 the closing of the $50.5 million purchase of five skilled nursing facilities — four in Tennessee and one in South Carolina, totaling 566 operating beds — from National Health Corporation (an ESOP entity). NHC subsidiaries have managed these facilities since 1988; the acquisition gives NHC full ownership of both operations and real estate. CEO Steve Flatt noted the transition is invisible to patients and partners and will be immediately accretive to cash flow and earnings. (Link)
  9. Westlake Village, California-based LTC Properties (NYSE: LTC) announced a $54 million SHOP acquisition of a 104-unit assisted living and memory care community in Phoenix, Arizona — welcoming MorningStar Senior Living as its eleventh SHOP operator and ninth new partner since the platform’s May 2025 launch LTC Properties, Inc. (NYSE: LTC) announced on June 2, 2026 a $54 million SHOP acquisition of a 104-unit assisted living and memory care community in Phoenix, Arizona, at a 6.75% cap rate with an expected unlevered IRR in the low-to-mid teens. The community will continue to be managed by MorningStar Senior Living — new to LTC and its eleventh SHOP operating partner. Since its SHOP launch, LTC has completed $524 million in SHOP acquisitions, including $171 million in 2026, with SHOP now representing approximately 28% of annualized NOI and 32% of gross investments. LTC targets an additional $285 million in SHOP acquisitions closing by end of Q3 2026. (Link)
  10. New York-based Strata Critical Medical (NASD: SRTA) completed the all-cash acquisition of Louisville Perfusion Services, Inc., a regional perfusion and blood management provider serving cardiac surgery programs in Kentucky, for up to $20 million — adding a Midwest and Southern stronghold to its 275+ hospital national perfusion platform Strata Critical Medical (NASD: SRTA) announced on June 2, 2026 the completed acquisition of Louisville Perfusion Services, Inc. (LPS), a regional provider of perfusion and blood management services to cardiac surgery programs in Kentucky. The transaction consists of approximately $16 million upfront plus up to $4 million in performance-based consideration. LPS is expected to generate approximately $10 million in revenue and $3 million in Adjusted EBITDA for 2026. The deal expands Strata’s cardiac perfusion platform into the Midwest and Southern U.S., adds ECMO support and organ transplant capabilities, and is consistent with Strata’s strategy of bolt-on acquisitions at mid-single digit Adjusted EBITDA multiples. (Link)
  11. Frisco, Texas-based Soleo Health (PE: Court Square Capital Partners and WindRose Health Investors) acquired Realo Specialty Care Pharmacy and BluHaven Management from Realo Drugs, adding a specialty pharmacy and ambulatory infusion center in North Carolina and bringing its national portfolio to 28 specialty pharmacies and 30+ infusion suites Soleo Health, a portfolio company of Court Square Capital Partners and WindRose Health Investors, acquired both Realo Specialty Care Pharmacy and BluHaven Management from Realo Drugs. The dual acquisition adds a specialty pharmacy in Morrisville, N.C., and an ambulatory infusion center in Raleigh, N.C., deepening Soleo’s presence in North Carolina, South Carolina, Virginia, and Maryland. The deal brings Soleo’s national portfolio to 28 specialty pharmacies and over 30 ambulatory infusion suites. (Link)
  12. Salt Lake City-based Bristol Hospice acquired Hope Hospice and Palliative Care, expanding its presence into the greater Memphis, Tennessee market Bristol Hospice, one of the largest hospice providers in the United States, announced on June 1, 2026 the acquisition of Hope Hospice and Palliative Care, bringing compassionate end-of-life services into the greater Memphis community. The acquisition honors Hope Hospice’s legacy of patient-centered care while integrating it into Bristol’s national network and clinical infrastructure. Bristol operates dozens of locations nationwide. (Link)
  13. Southlake, Texas-based Alliance Clinical Network (PE: Amulet Capital Partners and BPOC) completed a strategic merger with Atlas Clinical Research, creating an expanded national clinical trial site network across seven states with nearly 50 years of combined clinical research experience Alliance Clinical Network and Atlas Clinical Research announced on June 2, 2026 the closing of their strategic merger, combining nearly 50 years of collective clinical research experience across sites in Arizona, California, Florida, Nevada, New York, Pennsylvania, and Texas. The combined organization serves sponsors across CNS disorders, internal medicine, women’s health, metabolic diseases, dermatology, gastroenterology, pain management, and vaccines. Alliance is backed by Amulet Capital Partners and BPOC; Anthony Milonas serves as CEO. The merger was originally announced May 13, 2026. (Link)
  14. Marietta, Georgia-based Wellstar Health System finalized an agreement to acquire Mountain Lakes Medical Center, a 25-bed critical access hospital and Level IV Trauma Center in Clayton, Georgia, expanding its hospital portfolio from 11 to 12 facilities Wellstar Health System announced a definitive agreement to acquire Mountain Lakes Medical Center (MLMC), a 25-bed critical access hospital and Level IV Trauma Center in Clayton, Ga., serving Rabun County and surrounding northeast Georgia and western North Carolina. The acquisition is expected to close August 1 pending regulatory approvals. Wellstar’s strategic rationale centers on connecting MLMC patients to expanded specialty resources, digital health capabilities, and advanced clinical programs across its growing Georgia footprint. (Link)
  15. New York-based National Healthcare Properties (NASD: NHP), a senior housing REIT, announced approximately $279 million in signed purchase agreements and letters of intent for SHOP acquisitions expected to add 1,214 units to its existing 3,615-unit portfolio National Healthcare Properties (NASD: NHP) announced on June 1, 2026 signed purchase and sale agreements or non-binding letters of intent for approximately $279 million of SHOP acquisitions, with estimated weighted average year-one and year-three cap rates of 8.0% and 9.7%, respectively. The pipeline is expected to add 1,214 units to NHP’s existing 3,615 needs-based senior housing units. NHP also announced its Class A common stock will be added to the Russell 2000 and 3000 Indexes effective after market close on June 26, 2026, following its April 2026 NASD listing. (Link)
  16. Irvine, California-based Discovery Behavioral Health announced an agreement with lender HPS Investment Partners to transfer majority ownership in exchange for a substantial reduction of its $280 million debt obligations, following a December 2025 lender seizure of the company; regulatory approval pending Discovery Behavioral Health — one of the largest behavioral health platforms in the country, formerly backed by Webster Equity Partners — announced on June 2, 2026 an agreement with HPS Investment Partners to transfer majority ownership in exchange for a substantial reduction of its $280 million debt burden. HPS and Capital One originally seized Discovery’s assets in December 2025 after repeated covenant defaults on debt agreements originally entered in June 2021. Discovery briefly contested the takeover in New York state court before abandoning the effort. The announcement formalizes the ownership transfer structure pending regulatory approvals; a CEO change was also announced simultaneously. (Link)
  17. Radnor, Pennsylvania-based Hidden River Strategic Capital invested debt and convertible preferred equity into Redding, California-based Northstar Senior Living to support its merger with North Palm Beach, Florida-based Alta Senior Living, creating a scaled national senior living management platform Hidden River Strategic Capital announced on June 2, 2026 an investment in Northstar Senior Living in connection with its merger with Alta Senior Living. The combined company will operate as Northstar Senior Living, managing assisted living, memory care, and independent living communities under long-term contracts with community owners across the U.S. Hidden River’s investment consisted of debt and convertible preferred equity. Northstar’s executive team will run day-to-day operations; Alta CEO Doug Brawn will serve as Board Chair. Blueprint CRE facilitated the capital partner search and merger. (Link)
  18. San Francisco-based Clarify Health completed the acquisition of Loyal Health Holdings to create healthcare’s first closed-loop network intelligence and patient activation platform, combining referral analytics with AI-powered patient engagement tools across nearly 500 hospitals Clarify Health completed the acquisition of Loyal Health Holdings, Inc., a healthcare-specific patient activation platform, creating what the combined company describes as the industry’s first closed-loop network intelligence engine spanning referral intelligence, patient activation, and outcomes measurement. Loyal’s Care Activation Platform manages over 80,000 provider and location profiles and serves nearly 500 hospitals nationwide. The merged entity pairs Clarify’s Meridian® machine learning platform with Loyal’s AI-powered scheduling, chat, and predictive propensity engines. Clarify CEO Todd Gottula leads the combined company. (Link)
  19. San Juan Capistrano-based The Ensign Group (NASD: ENSG) acquired the real estate and operations of Woodland Health and Rehabilitation, a 62-bed skilled nursing facility in Mount Pleasant, Iowa The Ensign Group (NASD: ENSG) acquired the real estate and operations of Woodland Health and Rehabilitation, a 62-bed skilled nursing facility in Mount Pleasant, Iowa, effective June 1, 2026, through a Standard Bearer Healthcare REIT, Inc. subsidiary. The facility will be operated by an Ensign-affiliated tenant. The acquisition brings Ensign’s total portfolio to 396 healthcare operations across 17 states. (Link)
  20. The Ensign Group (NASD: ENSG) acquired the real estate of Memory Care of Contra Costa, a 46-unit memory care facility in Pleasant Hill, California, effective June 1, 2026, through its Standard Bearer Healthcare REIT subsidiary — to be leased to a third-party operator under a long-term triple net lease Through a subsidiary of Standard Bearer Healthcare REIT, The Ensign Group (NASD: ENSG) acquired the real estate of Memory Care of Contra Costa, a 46-unit memory care facility in Pleasant Hill, California, effective June 1, 2026. The facility will be operated by an experienced third-party operator under a long-term triple net lease. CEO Barry Port called the acquisition a ‘home run’ for the Standard Bearer portfolio. Ensign’s real estate subsidiaries now own 181 real estate assets across its national portfolio. (Link)
  21. Poway, California-based Diazyme Laboratories, Inc. (a General Atomics subsidiary) acquired Carolina Liquid Chemistries Corporation, a Greensboro, North Carolina-based FDA-registered manufacturer and value-added reseller of chemistry systems and reagents Diazyme Laboratories, Inc. announced on June 1, 2026 the acquisition of Carolina Liquid Chemistries Corporation (CLC), an FDA-registered manufacturer and value-added reseller of chemistry systems and reagents founded in 1994 in Greensboro, North Carolina. CLC’s cost-effective reagent products will complement Diazyme’s proprietary enzyme and immunoassay technologies, creating synergies for clinical and reference laboratories of all sizes. CLC’s business will be fully integrated into Diazyme’s operations. Diazyme is a cGMP and ISO 13485 certified medical device manufacturer. (Link)
  22. Bridgepoint has acquired Obagi Medical from Waldencast (NASD: WALD) in a transaction valued at up to $460 million, securing a dermatology and aesthetics skincare business European PE firm Bridgepoint has agreed to acquire Obagi Medical from publicly traded beauty holding company Waldencast (NASD: WALD) in a deal worth up to $460 million. Waldencast originally acquired Obagi Medical in 2022 before expanding it into injectable aesthetics through a bolt-on acquisition. The divestiture allows Waldencast to deleverage its balance sheet and redirect investment exclusively toward Milk Makeup. Bridgepoint’s acquisition provides Obagi Medical with focused, dedicated ownership to advance its position in the rapidly growing physician-dispensed dermatology and aesthetics market, which had expanded to include the FDA-approved Obagi Saypha® MagIQ™ dermal filler range prior to the transaction. (Link)
  23. Geneva, Switzerland-based SGS (SIX: SGSN), the world’s leading testing, inspection and certification company, acquired CMIC, INC., a Chicago, Illinois-based specialized bioanalytical testing services provider — its second U.S. bioanalytical acquisition in two months SGS announced on June 3, 2026 the acquisition of CMIC, INC., a Chicago, Illinois-based provider of bioanalytical testing services established in 2010. CMIC’s 27,000-square-foot GLP-compliant facility delivers bioanalysis across pre-clinical and clinical phases for pharmaceutical and biotech manufacturers developing biologics and complex therapies. CMIC, INC. is a group company of CMIC HOLDINGS Co., Ltd., which will continue collaborating with SGS through its pharmaceutical arm. The deal advances SGS’s Strategy 27 objective to double North American sales between 2023 and 2027. SGS operates over 2,500 laboratories across 115 countries.  (Link)
  24. Guildford, UK-based Venture Life Group (AIM: VLG) agreed to acquire two U.S. women’s health consumer brands — FemiClear and CUROXEN — from Austin, Texas-based OrganiCare Nature’s Sciences for up to $28 million, expanding its intimate health portfolio into Walmart, Walgreens, CVS, and Target Venture Life Group plc (AIM: VLG) announced on June 4, 2026 an agreement to acquire the FemiClear and CUROXEN consumer healthcare brands from OrganiCare Nature’s Sciences for up to $28 million — $23 million upfront and up to $5 million in deferred consideration tied to 2026 trading performance, funded from existing cash. FemiClear addresses gynaecological conditions including bacterial vaginosis, genital herpes, thrush, and UTIs (~98% of combined revenues); CUROXEN provides infection prevention for wounds and mouth sores. Combined net revenues were $12.1 million in the 12 months to March 31, 2026, up 29.1% year-on-year. Distribution spans Walmart, Walgreens, CVS, and Target. Venture Life shares rose approximately 9–10% on announcement. (Link)
  25. Suresnes, France-based Servier agreed to acquire the muscular dystrophy business of Boulder, Colorado-based Edgewise Therapeutics (NASD: EWTX) for up to $2.65 billion — $1.55 billion upfront plus up to $1.1 billion in milestones — to advance sevasemten, a first-in-class oral fast skeletal myosin inhibitor for Duchenne and Becker muscular dystrophy French pharmaceutical firm Servier announced on June 1, 2026 a definitive agreement to acquire Edgewise Therapeutics’ (NASD: EWTX) muscular dystrophy business for up to $2.65 billion — $1.55 billion upfront plus up to $1.1 billion in regulatory and commercial milestones. The deal secures sevasemten, a first-in-class oral fast skeletal myosin inhibitor in pivotal testing for Becker muscular dystrophy and mid-stage studies for Duchenne. Edgewise retains its cardiovascular pipeline (EDG-7500 for HCM, EDG-15400 for HFpEF) and becomes a cardiovascular-focused company post-close. All Edgewise employees supporting the muscular dystrophy business will receive comparable offers from Servier. Closing is expected in Q3 2026. (Link)

Venture Deals and Other

  1. Charlottesville, Virginia-based Contraline, Inc. closed a $92.5 million Series B co-led by BVF Partners and RA Capital Management — with GV (Google Ventures), Lumira Ventures, and Invus participating — to advance NES/T Gel, a first-in-class daily hormonal male contraceptive, into late-stage development Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, announced on June 2, 2026 the closing of a $92.5 million Series B co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. Proceeds support late-stage development of NES/T Gel — an investigational, daily, topical, hormonal, reversible male contraceptive with first-in-class potential — and advancement of ADAM, a non-hormonal hydrogel implant in clinical trials. BVF’s Iris van Alderwerelt van Rosenburgh joined the Board. No male contraceptive pill or equivalent has been approved in the U.S.; NES/T Gel addresses a massive unmet need in men’s reproductive health. (Link)
  2. Founders Fund has led a $435 million Series C in NewLimit alongside Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins, Abstract, Valor Equity Partners, Eli Lilly Ventures, Human Capital, and others to fund the first human clinical trial of an aging reprogramming medicine. Founders Fund led NewLimit’s $435 million Series C, joined by new investors Thrive Capital, Greenoaks, and Quiet Capital, and returning backers including Kleiner Perkins, Abstract, Nat Friedman and Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, and Human Capital. Founded in 2021 by Coinbase (NASD: COIN) CEO Brian Armstrong alongside Blake Byers and CEO Jacob Kimmel, NewLimit is developing epigenetic reprogramming medicines to reverse cellular aging. The raise will fund the company’s lead liver reprogramming therapy into human clinical trials — a timeline dramatically accelerated by a recent prototype breakthrough that demonstrated age reversal in old human liver cells. The company’s long-term vision is to treat aging itself as a clinically addressable condition. (Link)
  3. Felicis, Bain Capital Ventures, Optum Ventures, Sunflower Capital, Conviction, BoxGroup, Dorm Room Fund, and Constellation have co-invested in a $50 million Series A for Adaptive Innovations, an AI-native home health provider based in New York and Dallas. Felicis led a $50 million Series A in Adaptive Innovations, the first AI-native homecare provider, with significant participation from Bain Capital Ventures, Optum Ventures, Sunflower Capital, Conviction, BoxGroup, Dorm Room Fund, and Constellation, along with prominent angels from healthcare and frontier AI. The round brings Adaptive’s total funding to $60 million, including a previously undisclosed $10 million Seed. Since its 2025 launch, Adaptive has achieved an industry-leading sub-5% rehospitalization rate versus an 11% industry average, reduced clinician documentation time by 80%, and delivered over 100,000 visits across partnerships with more than 500 healthcare organizations including every major Texas hospital system. Proceeds will fund platform scaling and clinical workforce expansion into new states. (Link)
  4. General Catalyst and Chemistry led a $35 million Series A in Yuzu Health — with Anthropic’s Anthology Fund, Bain Future Back Ventures, Lachy Groom, and Neo — to modernize health insurance TPA infrastructure with AI-automated claims processing Yuzu Health secured $35 million in Series A funding led by General Catalyst and Chemistry, with participation from Anthropic’s Anthology Fund, Bain Future Back Ventures, Timeless Ventures, Lachy Groom, and Neo. Founded in 2022, Yuzu Health is a vertically integrated third-party administrator (TPA) powering claims processing, payments, and member administration for health plans, with a unified data architecture offered as a white-labeled solution. The company automates historically manual workflows including claims adjudication, stop-loss submissions, reconciliation, and downstream reporting, enabling more customizable plan designs including direct contracts and dynamic copays. (Link)
  5. San Francisco-based Lassie raised $35 million in Series A led by Andreessen Horowitz (a16z) — with Night Capital and fintech founders from Superhuman, Plaid, and Wise — to build AI autonomous systems for small healthcare businesses Lassie raised $35 million in Series A led by Andreessen Horowitz (a16z), with Night Capital and prominent fintech founders from Superhuman, Plaid, and Wise participating. a16z’s Alex Rampell joined the board. Lassie’s platform currently operates in more than 700 dental and doctor practices across 49 states, automating front-office, scheduling, billing, and operational workflows so small healthcare practices can run themselves with reduced administrative overhead. (Link)
  6. New York-based Novellia raised $18 million in Series A led by Spark Capital — with Khosla Ventures, Acrew Capital, Bling Capital, and TMV — to scale its patient-controlled real-world data platform providing anonymized health records for drug R&D Novellia, the only real-world data company built entirely on patient-contributed information, announced an $18 million Series A led by Spark Capital with participation from Khosla Ventures, Acrew Capital, Bling Capital, and TMV, bringing total funding to $28 million. Alongside the raise, Novellia launched its patient-facing mobile app allowing individuals to securely access and contribute their complete health history. Novellia provides structured real-world datasets to top-10 pharma companies for drug development — addressing what the company calls a $50 billion gap in research-grade patient data. Announced June 2, 2026. (Link)
  7. San Diego-based Rejuvenate Bio (a George Church / Harvard Wyss Institute spinout) announced $6 million in financing and a strategic R&D collaboration with Merck Animal Health to advance gene therapies targeting age-related chronic diseases in animals and humans Rejuvenate Bio, a gene therapy company co-founded by Harvard professor George Church as a spinout from the Harvard Wyss Institute, announced on June 8, 2026 a $6 million financing round and a strategic R&D collaboration with Merck Animal Health. Rejuvenate Bio develops gene therapies targeting the root causes of age-related diseases — including heart failure, kidney failure, Type 2 diabetes, and obesity — in both humans and dogs, using its dual-species strategy to build clinical evidence through companion animal studies while advancing toward human therapeutics. Rejuvenate Bio has previously raised over $10 million in its Series A. (Link)
  8. Houston, Texas-based Goldenrod Therapeutics, Inc. completed the initial closing of a $6.5 million Series Seed round led by Ataxia Ventures and Fannin Partners to advance 11h — a brain-penetrant PDE4 inhibitor — into Phase I clinical trials for Friedreich’s Ataxia and other neurodegenerative diseases Goldenrod Therapeutics, Inc., a Fannin Innovation-founded precision therapeutics company, announced the initial closing of a $6.5 million Series Seed round led by Ataxia Ventures and an affiliate of Fannin Partners. Proceeds fund manufacturing, formulation optimization, IND-enabling studies, and a Phase I trial in Friedreich’s Ataxia (FA) — a rare and progressive neurodegenerative disease — with pharmacodynamic biomarkers of PDE4 pathway modulation. Goldenrod’s lead candidate, 11h, is a next-generation, orally bioavailable, brain-penetrant PDE4 inhibitor designed at the University of Nebraska Medical Center (UNMC) to overcome emesis limitations of earlier inhibitors. Development has been supported by NIH and Department of Defense grants. (Link)
  9. Aurora Forge, Jackson Healthcare, Peg’s Foundation, and family offices co-invested a $3 million Seed round in Columbus, Ohio-based Radley Health — alongside existing investor CareSource — to fund expansion of its peer-driven mental health platform into Georgia Aurora Forge, Jackson Healthcare, Peg’s Foundation, and prominent family offices participated in a $3 million Seed round for Radley Health, joining existing investor CareSource, a nonprofit health plan headquartered in Dayton, Ohio. Radley Health has built one of the largest peer support networks in Ohio, with over 450 certified peer support specialists in more than 70 counties across a state where 75 of 88 counties face Mental Health Professional Shortage Area designations. Proceeds support peer workforce growth, healthcare provider partnerships, technology enhancements, and a Georgia market launch where the company has already recruited 50 peer support specialists through partnership with the Georgia Mental Health Consumer Network. (Link)
  10. Enable Ventures, Florida Opportunity Fund, Castellan Group, DeepWork Capital, Sawmill Angels, and Black Opal have jointly invested $5.75 million in Kalogon, a Melbourne, Florida-based smart seating solutions company. Enable Ventures — the first venture fund dedicated to closing the disability wealth gap — led a $5.75 million funding round in Melbourne, Fla.-based Kalogon, a smart seating technology company specializing in seated health solutions for wheelchair users, commercial aviation, and other extended-sitting use cases. Participating investors include Florida Opportunity Fund, Castellan Group, and returning backers DeepWork Capital, Sawmill Angels, and Black Opal. The investment follows a strong year for Kalogon, during which the company more than tripled its medical revenue year-over-year and moved into a dedicated manufacturing facility. Kalogon’s technology is currently being tested to reduce fatigue for U.S. Air Force B-52 and E-4B aircrew on extended missions. Proceeds will fund engineering, R&D, and international expansion. (Link)